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Abstract
The research presented in this thesis describes the production and application of 
antibodies against morphine-3-glucuromde and parathion, an organophosphate 
pesticide
A variety of morphine-3-glucuronide-protein conjugates were produced and used to 
generate and characterise polyclonal antibodies These polyclonal antibodies were 
used in the development of immunoassays in a competitive ELISA format and on the 
BIAcore (a surface plasmon resonance based optical biosensor capable of monitoring 
biomolecular interactions in ‘real-time’)
Combinatorial single chain Fv (scFv) antibody phage display libraries were also 
generated to morphine-3-glucuromde Splenomic mRNA from mice pre-immunised 
with a morphine-3-glucuronide-BSA conjugate was used in the amplification of 
antibody genes followed by cloning into vectors from a well-established phage display 
system Two positive clones were isolated in the first two rounds of panning One 
clone (E3) was selected and re-cloned into a plasmid for soluble scFv antibody 
expression The soluble scFv antibody was purified and used in the development of a 
competitive ELISA-based assay Further analysis of the E3 clone was carried out in 
the development of an inhibition BIAcore assay for morphine-3-glucuromde in 
biological matrices Affinity determinations of the scFv antibody to morphine-3- 
glucuromde were carried out using ‘real-time’ biomolecular interaction analysis
Polyclonal antibodies to the organophosphate pesticide, parathion, were also produced 
and characterised They were used to generate competitive ELISA and BIAcore-based 
inhibition immunoassays However, when analysed on the BIAcore, the parathion 
polyclonal antibody displayed no inhibition
XXV
Chapter 1 
Introduction
1
1 1 The Immune System
The mammalian immune system has evolved a diverse range of defence mechanisms 
to identify and remove foreign materials such as viruses, bacteria, fungi, parasites and 
foreign cells The immune system is broken up into two mechanisms of defence, 
innate immunity (non-adaptive immunity) and adaptive immunity Innate immunity 
acts as the first line of defence against infectious agents This type of immunity 
consists of a series of physical and physiological barriers Some of the physiological 
factors include pH, temperature and the presence of degradative chemical substances 
which protect the body Cell-mediated non-specific response to foreign cells is also 
part of this type of immunity and includes such internal systems as phagocytosis by 
macrophages and cell lysis by natural killer (NK) cells Phagocytic cells are derived 
from bone marrow stem cells and their function is to engulf foreign particles present 
in the body, internalise them and destroy them As the innate immune response is 
non-specific these cells are located in areas of the body most likely to encounter 
foreign bodies Natural killer cells have the ability to recognise surface changes in 
cells, which are infected They bind to the infected cells and destroy them The body 
has also developed other external barriers such as the skin, which prevents the 
penetration of infectious agents into the body and the mucous membranes that prove 
effective against the majority of infectious agents (Roitt et a l, 1998)
The adaptive immune response is divided into the humoral and cell-mediated immune 
response The adaptive immune system produces a specific reaction to the infectious 
agent and has the ability to produce memory cells to prevent future infection (Roitt et 
al, 1998)
111  The Lymphoid system
The cells involved in the immune response are organised into tissues and organs in 
order to perform their function These are collectively referred to as the lymphoid 
system This system consists of primary and secondary lymphoid organs (Male et a l, 
1996) The primary lymphoid organs comprise of the thymus and bone marrow
2
which are responsible for the antigen-independent differentiation of progenitor cells 
from the bone marrow into T-lymphocytes and the development of antibody- 
producing B-lymphocytes, respectively There are various classes of T-cell, which 
possess the ability to recognise foreign antigens present in the organism, and so these 
cells are considered part of the adaptive immune response The primary lymphoid 
organs gain their repertoire of specific antigenic receptors in order to cope with the 
various antigens an individual would come in contact with throughout life Another 
important feature of the primary lymphoid system is that lymphocytes gain the ability 
to recognise the difference between self and foreign antigens 
Secondary lymphoid organs include the lymph nodes, spleen, and mucous-associated 
lymphoid tissues (MALT), including the tonsils and Peyer’s patches of the gut The 
lymph nodes are scattered throughout the body and are connected to each other and 
the spleen by a network of lymphatic vessels These organs create the environment in 
which lymphocytes can interact with one another at high concentrations to produce T- 
cell-dependent B-cell activation (Male et a l , 1996)
1 1 2  The Humoral immune response
The humoral immune response is mediated by antibodies produced by B-lymphocytes 
(Roitt et a l, 1998) For the generation of a strong immune response, the interaction 
between B- and T-cells is of critical importance for the production of antigen-specific 
antibodies (Figure 1 1) There are two types of T-cells, T Helper (Th) and T 
cytotoxic (Tc) cells There are two subsets in the Th cells, ThI and Th2, which are 
primarily different due to the cytokines they produce TH1 cells produce interferon 
gamma (IFN-y) and tumour necrosis factor (TNF-p) which are mainly responsible for 
the activation of T cytotoxic cells TH2 cells mainly secrete interlukins and their main 
function is the activation of B-cells Tc cells are responsible for destroying cells of 
the body displaying antigen on the surface Following exposure to an antigen, 
macrophages engulf, process and present the antigen on the surface of the cell in 
conjunction with MHC (Major Histocompatability Complex) Class II These cells 
are known as antigen presenting cells (APC) T helper (TH) cells recognise antigen in
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the form of MHC class II-antigen complex via their T-cell receptors The T-cell 
receptor is a heterodimer comprised of a- and p-chains which consist of variable and 
constant regions, which form the binding site Contact between the T-cell and the 
antigen presenting cell activates the T-cell, which proliferates and forms a clone of 
Th cells specific to the antigen resulting in the release of interlukin-1 (IL-1) The TH 
cell then selectively stimulates B cells that have already encountered the particular 
antigen to proliferate by the release of IL-2 In similar fashion, antigens are also 
processed by B-cells When antigens bind to antigen receptors on a B-cell, the B-cell 
internalises the antigen and presents the antigen fragment bound to MHC class II on 
the surface of the cell However, in this case, the processing and presentation of 
antigen on the surface of B-cells is specific to a particular antigen Th cells receptors 
bind to the antigen-MHC complex on the surface of the B-cells, causing the B-cells to 
synthesise a receptor for IL-4 which is synthesised by the activated Th cells This 
leads to the production of IL-5 by B-cells which results in B-cell differentiation into 
memory and plasma cells Plasma cells secrete antibody at an approximate rate of 
2000 per second for the 4 to 5 day lifetime of the cells These specific antibodies 
help eliminate the foreign invader Memory B-cells, express membrane bound 
antibody and remain in the body for long periods of time primed for secondary 
exposure to the antigen (Roitt et a l, 1998)
Once the humoral immune response has been activated, centroblasts now undergo a 
process known as affinity maturation, which involves somatic hypermutation of the 
amino acid sequence of the variable heavy and light chains This produces high 
affinity selected antibodies and occurs late in the primary response to a T-dependent 
antigen Most of the mutations which occur produce lower affinity antibodies 
Selection of the higher-affinity antibodies for proliferation is explained as higher- 
affinity antibodies bind more efficiently to antigen complexes on the surface of the 
follicular dendritic cells The binding interaction inhibits the apoptosis of these high- 
affinity binding antibodies However, B-cells producing antibodies with lower 
affinities, which do not bind to the antigen-complexes, undergo apoptosis This 
process ensures that only higher affinity antibodies are selected
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Figure 1.1. Diagrammatic representation of the interaction between an antigen presenting 
T-cell and B-cell leading to T- and B-cell activation in a primary response» The antigen is 
initially phagocytosed into an antigen presenting cell and processed and presented on the 
surface of the cell as MHC class II-antigen complex, TH cells bind to this complex through 
the T-cell receptor resulting in proliferation and differentiation. Expression of cytokine 
receptors by the B-cell and production of cytokines by the TH cell drives the proliferation of 
the B-cells. As B-cells can also bind and process antigen, they are also stimulated when Th 
cells interact with the displayed fragment B-cells differentiate into plasma cells with the 
ability to produce large quantities of antibody and memory cells, which circulate the body 
in order to elicit a strong antibody response to subsequent secondary infections.
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Another important part of the B-cell differentiation process is class switching Class 
switching occurs during the differentiation process and is triggered to form different 
isotypes as a result of the type of cytokine present B-cells expressing IgM/D 
antibody on the surface of the cell may switch to the synthesis of IgG, IgA or IgE 
molecules within this process Once this has occurred, subsequent rounds of 
antigenic challenge will produce a much stronger immune response involving the 
higher affinity memory B-cells which are principally of an IgG class (Roitt et a l, 
1998)
1 2 Antibody Structure
Antibodies or immunoglobulins are a group of glycoproteins present in the serum of 
all mammals Rodney Porter (Porter et a l , 1966) in 1966 proposed the basic four 
polypeptide chain model for antibodies The structure of antibodies varies depending 
on their isotype, however, antibody structure is generally represented by the IgG 
antibody as shown in Figure 1 2
The antibody is composed of four polypeptide chains, with two identical heavy 
chains (H) and two identical light chains (L) (called k  (kappa) or X (lambda)) 
(Hanmgan, 2000) The light chain has a molecular weight of approximately 25 kDa, 
whereas the heavy chain has a molecular weight of approximately 50 kDa The two 
heavy chains are held together by interchain disulphide bonds while various antibody 
chains are held together by intracham disulphide bonds The amino terminal end of 
the antibody is characterised by variability (V) of the sequences in both the heavy (H) 
and light (L) chains which are known as the Vh and VL regions The remainder of the 
molecule is constructed of constant regions (Ch and Cl) These constant regions are 
broken up into three distinct regions ChI, Ch2 and Ch3 A hinge region is also 
present, which is found between the ChI and Ch2 domains, allowing conformational 
changes to occur in the antibody resulting in flexibility of between 60-180° This 
flexibility allows the two binding sites to work independently from one another 
The binding site of an antibody to an antigen is located within the variable region of 
the antibody The properties of antigenic recognition, specificity and affinity are
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comprised of approximately 110 amino acid residues located in the variable region 
These are referred to as hypervariable regions forming a region complementary in 
structure to the antigen epitope Hypervariable regions are also referred to as 
complementarity determining regions (CDRs) and the intervening peptide segments 
which are approximately 10 amino acid residues long are known as framework 
regions (FR) The CDR regions in both light and heavy chain V regions are sub­
divided into three CDRs (CDR1 , CDR2, CDR3) The light and heavy chain CDRs 
form the six hypervariable loop structures producing a three-dimensional structure, 
which acts as the antigen-binding pocket
There are five distinct classes of antibody, IgA, IgM, IgD, IgE and IgG which have 
been determined by the difference in the structure of their heavy chains IgA 
represents 15-20% of total antibody concentration and may be present as a monomer 
or a dimer, and is found predominantly in seromucous secretions such as saliva, milk 
and tracheobronchial secretions IgM accounts for approximately 10% of total 
antibody concentration and has a pentameric structure and is predominantly the early 
antibody seen in the immune response to primary infections IgD accounts for less 
than 1% of total antibody present but is known to be present in large quantities on the 
membranes of many B-cells, and may have a role in lymphocyte differentiation IgE 
is found in trace amounts in the body and plays a role in immunity to helminthic 
parasites Hypersensitivity conditions such as hay fever is also associated with this 
antibody
Finally, IgG is the major antibody present and accounts for 70-75% of the total 
antibody concentration It is divided into four subclasses called IgGi, IgG2, IgG3, and 
IgG4 which are based on the type of heavy chain present (Roitt et a l, 1998)
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Figure 1.2. Diagrammatic representation of an immunoglobulin molecule. The amino 
terminal end of the antibody is characterised by variability (V) of the sequences in both the 
heavy (H) and light (L) chains, which are known as the VH and VL regions, respectively. 
The remainder of the molecule is constructed of constant regions (CH and CO. These 
constant regions are broken up into three distinct regions: CH1, CH2 and CH3. There is 
also a hinge region which is found between the ChI and Ch2 domains which allows 
conformational changes to occur in the antibody resulting in the flexibility of between 60- 
18(f. The CDR regions confer the specificity of the antibody to a particular antigen and 
this is known as the antigen binding site. The two heavy chains are held together by 
interchain disulphide bonds while various antibody chains are held together by intrachain 
disulphide bonds.
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1 3 Genetics of antibody diversity
Antibodies are extremely diverse and possess the charactenstic to generate numerous 
varied structures possessing the ability to bind to antigen As antibodies are 
composed of heavy and light chains and since any light chain may combine with any 
heavy chain, the number of possible variant sites is a product of the number of heavy 
and light chains This ability is located in the CDR regions as they are directly 
responsible for antigen binding The body produces more different forms of antibody 
than the number of genes in the genome This diversity is generated by the gene 
organisation
Heavy and light chain variable regions of an antibody encode for antibody diversity 
and this is as a direct result of the genetic nature of the antibody light and heavy chain 
germline genes (Tizard, 1995) Variable light chain regions are composed of V 
(variable) and J (joining) loci, whilst heavy chain gene sequences are composed of V 
(variable), D (diversity) and J (joining) loci The recombination between these three 
regions directly contributes to antibody variability As a result of B-cell maturation, 
recombination of the various VDJ sequences on the heavy chain and the VJ 
sequences on the light chain takes place resulting in the formation of a functional 
gene During recombination, the D region is placed adjacent to the V region through 
a process known as looping-out, in which the intervening heptamenc and nonamenc 
complementary sequences forming stem-loop structures are removed (Figure 1 3) 
(Roitt et a l, 1998) This process is random, with the possibility of any region 
recombining with another
Further diversity may be achieved by the insertion of small sets of nucleotides 
between the VJ and DJ sequences resulting in changed sequences Somatic mutation 
also causes single base changes allowing additional diversity (Benjanimi et a l, 1996) 
The main function of this type is to increase the binding affinity of the antibody to 
their antigen This allows the immune system to improve the affinity of its antibodies 
after the initial immunisation Junctional site diversity may also occur during the 
recombination of various VJ and VDJ sequences as a result of the imprecise joining
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ends of various sequences and this changes the amino acid sequence which directly 
alters the binding site of the antibody.
Class switching is determined as a result of antigenic stimulation of B-cells. Constant 
H regions are found downstream of the variable region genes, in the specific order of 
|i, 8, y, 8, and a. Each of these constant gene sequences, except for the 8 gene, has at 
the 5' end a repeating base sequence called the switch region. At this region 
recombination of any VDJ sequences with Ch regions may occur. Depending on the 
individual environmental conditions to which the B-cell is exposed will determine the 
type of antibody produced by the cell. The heavy and light chain sequences are then 
translated and assembled into an intact antibody molecule (Roitt et al., 1998).
Germline DNA
Constant
Vh Genes Dj- Di2 regions Jj-J6 regions region
Functional B cell heavy chain gene
Figure 1.3. Diagrammatic representation of heavy chain gene recombination. There are 
two separate processes involved in the recombination of the gene. Heavy chain gene 
segments are composed of multiple VD and J regions and a constant region, which 
encodes for the class of the antibody. The first recombination step is the combining of the 
D and J segments present on the germline DNA which occurs through looping of 
intervening DNA by recombinase enzymes. This introduces further variability at the point 
of cleavage. The second step combines the V region with the DJ sequence resulting in the 
fixing of specificity of the antibody. This results in the formation of a functional B-cell 
variable heavy chain gene.
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1 4 Antibody affinity
The generation of an immune response to a particular antigen results in the 
production of antibodies The interaction formed when an antibody comes in contact 
with its specific antigen is determined by a combination of different physical forces, 
hydrophobic interactions, hydrogen bonds, electrostatic binding and van der Waals 
forces (Tijssen, 1985)
Hydrophobic interactions involve the association of non-polar residues in aqueous 
environments Electrostatic binding is the result of attraction between oppositely 
charged groups on the two interactants, the effects of which may be greatly enhanced 
due to the removal of water molecules as a result of hydrophobic interactions 
Hydrogen bonds are also formed when hydrogen atoms are shared between two other 
atoms Van der Waals forces are as a result of the interactions between the electron 
clouds of adjacent non-polar groups on the neighbouring molecules This results in 
the induction of oscillating dipoles between the two molecules producing a net 
attractive force The strength of these forces are only effective over a small distance, 
resulting in the epitope on the antigen and the binding site on the antibody becoming 
the defining factor for the strength of the interaction
The term affinity is defined as the sum of the attractive and repulsive forces for a 
single antibody-antigen bond and may be described in terms of reaction kinetics At 
equilibrium, the formation of an antibody-antigen complex may be expressed as
JCaEqua tion  1 1  Ab + A g <-------» Ah Ag
kd
Where Ab is antibody and Ag is antigen and Ab Ag is the antibody-antigen complex 
and ka and kd are the association and dissociation rate constants, respectively
Equation 1 2 I v  k a
K d
Ab Ag
Ab \A g
The affinity of the antibody for the antigen is given by the equilibrium association 
constant Ka
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\ kdEquation 1 3 A d  = — - =  — -  =
K a Ka
The affinity of the antibody-antigen interaction may also be stated as the equilibrium 
dissociation constant, KD, which is a reciprocal of the Ka value
1 5 Monoclonal antibody technology
Monoclonal antibody technology was first reported by Kohler and Milstein, (1975) 
Before this, all antibodies produced were of a polyclonal nature Although polyclonal 
antibodies were useful in many areas, their heterogeneous nature also limited their 
application However, the homologous nature of monoclonal antibodies allows the 
generation of antibodies with differing characteristics such as higher specificity and 
affinity
For the production of monoclonal antibodies (Figure 1 4) by somatic cell fusion, an 
initial immunisation of the host animal with the antigen is required This primes the 
animal for the production of specific antibodies to the antigen of interest Production 
of antibody to the specific antigen is monitored closely until the titre is sufficient to 
perform a fusion The spleen is removed from the animal and the splenocytes 
harvested in order to perform the procedure The other fusion partner in this 
procedure is a mouse myeloma cell line (i e X63-Ag8 653 and Sp2/0-agl4) 
Myeloma cells are tumorigemc B-lymphocytes, which may be cultured in vitro 
These cells lack the enzyme called hypoxanthine guanidine phosphoribosyl 
transferase (HGPRT) and are unable to proliferate in the presence of HAT 
(Hypoxanthine, Aminoptenn and Thymidine) medium Aminopterin blocks the de 
novo biosynthesis of purines and pyrimidines needed for the production of DNA 
One of the characteristics of HGPRT cells is that they cannot utilise the salvage 
pathways for DNA synthesis as they do not possess the required enzyme systems 
However, splenocytes carry the required enzymes to produce DNA through the 
salvage pathway but are unable to proliferate outside the body and die off naturally 
Fused cells, however, will proliferate in HAT medium as the characteristic to use the 
salvage pathway to produce DNA will come from the spleen cell and the
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characteristic to be immortal comes from the myeloma cell, resulting in an immortal 
hybridoma cell capable of antibody production
Splenocytes from the immunised animal are fused with myeloma cells by the addition 
of polyethylene glycol (PEG), which promotes membrane bridging, cell fusion and 
transfer of nuclei (Hurrell, 1985) Once hybidomas have been selected, using HAT 
medium, the culture supernatants are screened for hybridomas producing specific 
antibodies to the antigen Eventually, hybridomas from a single cell are produced 
using a procedure known as cloning by limiting dilution where cultures are recloned 
until they eventually come from a single cell (Goding, 1996)
Monoclonal antibodies may also be produced by in vitro immunisation (Borrebaeck 
et a l , 1983) For the production of monoclonal antibodies using this method (Figure 
1 5), spleen cells are harvested from naive mice and incubated with the antigen of 
interest for a period of 5-9 days, before the somatic cell fusion procedure Antibodies 
produced using in vitro immunisation are as a result of a primary response and are 
generally IgM antibody molecules with low quantities of IgGs The production of 
IgM antibodies is a disadvantage of this system as in general these antibodies have a 
lower affinity than IgG antibodies However, this system reduces the immunisation 
time required for in vivo immunisation and also the amount of antigen required for 
the procedure Bonwick et al (1996) has demonstrated the ability of this method to
produce antibodies by generating antibodies to flucofluron and sulcofiiron However,
\
the lack of papers in the literature suggests that there has been very little success in 
the development of assays using antibodies produced by in vitro technology 
The use of monoclonal antibodies as a therapeutic agent in humans, has been severely 
limited due to the fact that most of the monoclonal antibodies produced having been 
of murine origin The use of these antibodies in humans elicits an anti-murine 
antibody response, limiting the number of times the antibody may be used in any 
single individual Production of human monoclonal antibodies is limited with respect 
to the fact that human immunisation is difficult and relies on accidental immunisation 
through disease or infection There has also been little success in attempts to produce 
human monoclonal antibodies using hybridoma technology as there are few suitable
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myeloma fusion partners of human origin However, using the Epstein-Barr virus 
transformation (James and bell, 1987) of human lymphocytes, there has been some 
success (Burton, 1991) This procedure can produce cell lines, which are unstable or 
produce low levels of antibody However, this is still desirable as human antibodies 
are being produced and can be used in the treatment of humans (Sims et a l, 1993) 
Protein engineering techniques have also been developed as alternatives in the 
production of human monoclonal antibodies (Co and Queen, 1991, Hurle and Gross, 
1994)
15 1 Humanised/Chimeric antibodies
Since the advent of monoclonal antibody technology by Kohler and Milstein, this 
technique has been used in a wide variety of processes Although murine monoclonal 
antibodies have been widely applied in clinical diagnostics, there has been limited 
success in the application of these antibodies to human therapy (Clark, 2000) 
Therapeutic use of murine monoclonal antibodies was found to have two major 
problems Firstly, murine monoclonal antibodies did not trigger the appropriate 
human effector systems (Clark et a l, 1983) Secondly, even when murine antibodies 
did work in vivo, the patients immune system would recognise these antibodies as 
foreign and elicit a human anti-murine-antibody (HAMA) immune response, cutting 
short the time in which the antibodies had to work (Schroff, et a l, 1985) The 
HAMA response may be potentially reduced by production of mouse-human 
chimeric antibodies The development of chimeric mouse-human antibodies provides 
a double benefit of reduced immunogenicity and the ability to recruit human Fc 
effector functions Such antibodies are produced by combining the entire variable 
(V) or binding domain of a mouse antibody with a human antibody constant (C) or Fc 
domain (Co and Queen, 1991) However, in some cases such as the murine antibody 
OKT3 used in the prevention of organ rejection, much of the antibody response is 
directed against the V region rather than the C region (Jaffers et a l, 1986) This 
result suggests that chimeric antibodies that possess a murine V region may still 
result in an immunogenic effect To inhibit this immunogenic response, V-region
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humanisation was required This involved changing some of the FR residues of the 
V-region on the murine antibody to sequences more similar to human sequences, 
while also retaining the ability to bind to antigen (Riechmann et a l, 1988)
Two further strategies have been developed for the production of ‘fully human 
antibodies’ Firstly, recombinant antibody technology may be used as human 
antibody V-regions can be selected from recombinant phage display libraries by 
affinity selection strategies (Winter et a l, 1994) Secondly, the creation of transgenic 
mice whereby the mice immunoglobulin genes have been replaced with human 
immunoglobulin genes which allow the production of human antibodies upon 
immunisation (Mendez et a l, 1997)
One further technique developed involves reconstituting severe combined 
immunodeficient (SCID) mice with human penferal blood lymphocytes, followed by 
the immunisation of these animals with antigen and rescuing the immune B-cells by 
fusion with myeloma cells However, antibodies produced by this procedure are 
found to contain unique ldiotypes which may induce an immunogenic response 
(Clark, 2000)
Humanised antibodies have been produced for the clinical treatment of patients with 
cancer One such example is described by Nakamura et al (2000) as they used a 
mouse-human chimeric monoclonal antibody (Mab) KM966, which was specific for 
the cell-surface tumour antigen ganglioside GM2, to produce a humanised antibody 
This antibody was produced to improve the antibodies potential in clinical settings by 
reducing the antibodies immunogenicity The humanised antibody developed 
KM8969 was found to inhibit the growth of GM2 positive tumour cells due to 
apoptosis induction Further clinical studies carried out by Parajuh et al (2001) 
demonstrated that both the humanised antibody (KM8969) and the mouse-chimeric 
antibody (KM966) promoted the lysis of lung cancer cells by blood mononuclear 
cells (MNC) of lung cancer patients
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1 5  2 Applications of monoclonal antibodies
Monoclonal antibodies have been used for diagnostic and therapeutic applications 
(Voigt and Zintl, 1999) since their discovery Detection systems for a variety of
target molecules ranging from pesticides to illicit drug residues have also been
developed with the use of monoclonal antibodies (Fitzpatrick et a l, 2000)
The use of monoclonal antibodies as therapeutic agents is also gaming in importance 
in the treatment of a number of conditions such as cancer, cardiovascular diseases and 
viral infections Monoclonal antibodies were initially thought to be of great 
importance for the treatment of cancer and a twofold strategy for treatment was 
envisaged Initially, monoclonal antibodies locate and bind to tumour-specific
antigens and this is followed by the triggering of a lethal attack against neoplastic
cells In recent years much of the work has been carried out by academic researches 
(Funaro et a l, 2000) as much of the early expectations about the applications of 
monoclonal antibodies did not unfold
One area for the use of monoclonal antibodies for therapeutic application is B-cell 
lymphomas which are suited to therapy using monoclonal antibodies due to the 
accessibility of malignant cells in the blood, spleen, bone marrow and lymph nodes 
Production of monoclonal antibodies to the surface expressed CD20 on malignant 
human B-cells may be used for anti-tumour use by altering the normal signal 
pathways (Maloney et a l, 1996, Shan e ta l} 1998)
Agonistic monoclonal antibodies have also been studied which possess the ability to 
mimic natural ligands and may also be useful in the treatment of solid tumours by 
targeting antigens which are involved in the signalling pathways (Gibbs, 2000) The 
HER2 signalling pathway is one of the best studied and it has been found that an anti- 
HER2 monoclonal antibody caused changes in the signal pathways within the cell 
resulting in an inhibition of this type of breast cancer cell (Pietras et a l, 1999)
The use of monoclonal antibodies for the production of bispecific antibodies are 
continuously under investigation, enabling the potential signalling ability of these 
antibodies to recruit specific effector molecules to tumour cells (Hudson, 1999, Segal 
etal, 1999)
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Shu et al (2001) recently produced a monoclonal antibody for the development of a 
direct ELISA to differentiate between infection and vaccination of the Japanese 
encephalitis (JE) virus Monoclonal antibodies have also been produced against 
Salmonella enteritidis hpopolysaccharide (LPS) (Iankov et a l, 2001) for the 
differentiation of various strains of the virus
1 6 Antibody Engineering
Antibody engineering can be defined as the construction of designer antibodies and is 
one of the fastest growing fields in molecular biology Over the last fifteen years, 
genetic and molecular techniques have been used as a means of generating 
monoclonal antibodies and antibody fragments (Smith, 1985) Recombinant antibody 
display technology is utilised in the generation of antibody fragments from several 
species including human, rabbit, mouse and sheep This has resulted in the 
engineering of antibody fragments (Figure 1 6), which include the antigen-binding 
(Fab) and single chain variable fragment's (scFv) This truncated Fab fragment 
consists of one V l domain and one V H domain The Fv fragment is the smallest part 
of the antibody required for antigen binding The Fv fragment can be very unstable 
for use in therapeutics or immunoanalysis because it lacks the inter-chain disulphide 
bond, which is present m the Fab fragment (Killard et a l, 1995) Protein engineering 
has allowed for the development of a more stable Fv fragment A synthetic peptide 
linker (or in some cases the insertion of cysteine residues to form a disulphide bridge) 
can be incorporated into the Fv fragment to produce a more stable single chain Fv 
(scFv) fragment A single chain Fv fragment is composed of a heavy chain variable 
region joined to a light chain variable region by a flexible 15 amino-acid linker 
Smaller antibody fragments may also be engineered capable of binding to antigen 
These include the Fd region which consists of one V h, one C h I domain from the 
heavy chain, and the complementary determining region (CDR), which is the smallest 
antibody fragment with the ability to bind to antigen
The DNA with the genes required to code for antibody fragments is available from a 
number of sources, which include the genetic material from non-immunised or
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immunised animals or humans and genes from a repertoire of naive, semi-synthetic or 
synthetic genes (Ditzel et a l, 1993) Messenger RNA may also be used from 
hybndomas expressing specific functional antibodies to a specific antigen and used to 
provide the raw material for cloning the antibody variable gene segments (Winter and 
Milstein, 1991)
Due to the advent of antibody phage display technology, isolation of antibodies with 
higher affinities has become possible while simultaneously reducing the size of the 
antibody (De Haard et a l, 1998)
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Figure 1.6. Illustration of an antibody and antibody fragments. The fragments illustrated 
above may be produced by genetic or enzymatic and chemical manipulation. The whole 
antibody may be initially broken up into either Fab (antigen-binding fragment) or F(abf)2 
(two antigen-binding fragments linked) and Fc (crystalline fragments) regions. Fab 
fragments may be further broken up into Fv (variable fragments), scFv (single chain Fv) 
and individual CDR regions which are all capable of antigen-binding.
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16  1 Combinatorial Phage Display Libraries
All the techniques used so far have relied on the use of spleen cells or hybridomas as 
the starting material This changed with the development of a technique known as 
Combinatonal Phage Display (Barbas et a l, 1991) This system allowed the 
possibility of producing recombinant monoclonal antibodies from cloning light and 
heavy chain antibody genes, and expressing them in E coh using phage vectors 
Huse et al (1989) have used this phage display system to express a combinatonal 
library of Fab fragments of a mouse antibody repertoire in Escherichia coh They 
used the Lamda (X) phage system to express their libraries Initially using genes 
amplified by PCR, the heavy and light chains were cloned into AHc2 and A,Lcl 
vectors, respectively The oligonucleotide sequences used in the construction of 
these vectors contained segments for the construction, expression, and secretion of 
Fab fragments The heavy and light chains were randomly combined at the two 
£coRI sites, which were present in each vector However, results proved that this 
system was capable of producing only relatively small libraries (106) This resulted 
in work being carried out on systems based on filamentous phage display to try to 
improve the size of the libraries
However, work continued using the X phage system (Caton and Koprowski, 1990, 
Persson et al, 1991) Caton and Koprowski produced a combinatonal library to 
Influenza-virus hemagglutinin which was generated by using mRNA obtained from 
an immunised donor mouse A combinatonal library which contained 2 5 x 107 
phage particles was generated From this, ten strong positive phage were identified 
and re-infected into bacteria which was co-infected by helper phage to excise a 
plasmid containing the heavy and light chain expression sequences It was found by 
taking supernatants from these bacteria that there were Fab fragments present that 
were HA-specific From this, results showed that the isolated antibodies had similar 
characteristics in relation to the immune status of the donor mouse This result was 
significant with respect to assessing the human immune responses to different 
pathogenic agents, as libraries may be generated from human peripheral blood 
lymphocytes
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Persson et al (1991) also used this X phage display to produce monoclonal antibodies 
against tentanus toxoid He produced a combinatorial library which contained 1 x 105 
members from untreated cells and 6 x 106 from stimulated cells From these 
experiments, results showed that the libraries generated were too small (106) Caton 
also found this, indicating the need for different techniques to produce a library with 
a sufficient yield One such technique was the use of filamentous phage systems 
These systems allowed foreign peptide sequences to be expressed on the surface of an 
infectious phage There are a number of advantages in using this method, the first 
one being that a large number of phage can be screened at the same time The second 
advantage was that since each phage encodes a random sequence expressed on its 
surface, if a phage is recovered with a low yield, amplification of phage is possible by 
re-infection in bacteria
It was not until 1990 when Scott and Smith (Scott and Smith, 1990) used filamentous 
bacteriophage vectors into which foreign antigenic determinants were cloned into the 
phage gene III and shown as part of the gene III protein (pill) which was placed at the 
tip of the virion Gene III is the part of the phage which encodes the coat protein pill 
which is located at one end of the virion The carboxyl-terminal is half buried in the 
virion and takes part in morphogenesis while the amino-terminal half of pill binds to 
the F pilus during infection Smith, (1985) showed that it was possible to insert 
foreign sequences between the two domains without effecting pIIFs function 
Results showed that the foreign sequences were expressed on the surface of the 
phage Scott and Smith produced a library, which expressed six random residue 
sequences on the pin fusion protein Once expressed on the surface of phage, it 
became possible to select specific phage with the required characteristics 
Devlin et al (1990) constructed a larger library of phage which expressed 15 random 
residue peptide sequences as the gene III fusion proteins He constructed a new 
vector, by introducing enzyme sites into gene III and by placing a P-lactamase gene 
in the polylinker 3' of the lac promoter to produce the M13LP67 vector This 
allowed the production of a mature pin protein with the predicted sequence
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McCafferty et a l, (1990) was the first to clone and express an antibody Fv domain in 
filamentous phage using VH and VL fragment genes from a murine anti-lysozyme 
antibody
Filamentous phage displaying systems for the selection and screening of antibodies 
were found to be easier to work with, and future work concentrated on developing 
these systems
16 2 Construction of combinatorial phage display libraries
The continued progress in the use and application of recombinant DNA technology 
has enabled the possibility of producing specific antibodies by use of phage 
displaying recombinant antibody libraries
The first step in the production of a recombinant antibody library (Figure 1 7) using 
phage display is the isolation of mRNA from sources such as peripheral blood, spleen 
cells or bone marrow The isolated mRNA should contain the full repertoire of 
antigen specificities and may be used in the production of complementary DNA 
(cDNA) using reverse transcription The technology behind the use of phage display 
as a tool to produce antibodies is the use of this cDNA in the polymerase chain 
reaction (PCR) Utilising suitable primers, PCR may be applied for the amplification 
of heavy and light chain genes for antibody production These amplified gene 
fragments are then joined together and cloned into a suitable phage expression vector 
Once this occurs the antibody may be displayed on the surface of the phage allowing 
the antibody on the surface to be treated exactly like an antibody for selection and 
affinity studies (Hoogenboom et a l, 1998)
Other characteristics encoded on the phage vector include, an antibiotic resistance 
marker, the phage coat protein, an origin of replication, a promoter, and a tag to aid in 
scFv purification
The lacZ promoter is present to produce strain-dependent lac promoter expression 
Under control of the lacZ promoter expression of the vector can be induced using 
isopropyl-P-D-galactopyranoside (IPTG) and suppressed in the presence of glucose 
Helper phage is used for the packaging of phagemid DNA into a virion This allows
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the expression of recombinant antibodies on the surface of the phage Screening for 
specific antibodies is carried out by propagation of E coli resulting in the excretion 
of virions into the supernatant The antibody fragments are usually linked to one of 
two phage coat proteins (pill or pVIII) on the surface of phage particles (Figure 1 8) 
Following the isolation of the specific antibodies required, the DNA from these 
clones are sub-cloned into plasmids with the characteristic for soluble expression of 
antibody
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Figure 1.7. Diagrammatic illustration of a generic model for the production of a 
combinatorial antibody phage display library. Messenger RNA was initially isolated from 
a suitable source as listed above. The mRNA undergoes reverse transcription and PCR 
amplification of antibody heavy and light chain genes using families of variable 5r primers 
and constant 39 primers. Light and heavy chain genes are joined together and ligated into 
a plasmid followed by transformation into E. coli. Phage expression is brought about by 
infection with helper phage, and affinity selection takes place against the desired antigen 
immobilised to a solid support When specific clones have been isolated, soluble antibody 
may be expressed by religating specific light and heavy chain genes into a vector for 
soluble expression.
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vector contained within the phage and the phage is ready for infection into E.colL
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16  3 Selection and screening of specific phage antibodies
Selection processes that remove clones producing specific antibodies are of vital 
importance in obtaining antibodies that are required The most popular selection 
methods include affinity selection (also known as biopanning) of phage displaying 
antibodies by use of immobilising antigen onto solid supports and columns or 
alternatively, the use of the BIAcore biosensor for 'real-time' analysis of antibody 
binding to antigen immobilised onto the surface of a chip followed by selection of the 
specific antibodies
The biopanning process (Figure 1 9) for specific antibodies from combinatorial phage 
display libraries may be achieved by multiple rounds of phage binding to antigen, 
followed by washing to remove non-specific phage and elution to retrieve specific 
phage This may be achieved with the use of immunoassay plates or immunotubes to 
which hapten-protein-conjugates are absorbed onto the surface or use of the BIAcore 
biosensor with conjugate immobilised onto a chip (Clackson et a l, 1991, Marks et 
a l, 1991, Griffiths et a l, 1994, Malmborg et a l, 1996) The higher the ratio of 
hapten bound to the protein, the higher the chance of phage antibodies binding to the 
hapten rather than the conjugate However, conjugates which possess a high hapten 
to protein ratio may cause difficulties As many haptens are hydrophobic, the more 
haptens present on the protein will result in insoluble complexes, which will inhibit 
the absorption of the conjugate onto the surface of the immunoplate or immunotube 
Haptens covalently immobilised on the surface of immunoplates may also be used in 
the selection process for specific antibodies This will decrease the possibility of 
selection of non-specific antibodies as the carrier-protein is no longer present in the 
selection process However, immobilisation may depend on the availability of the 
functional groups on the hapten and is not suitable for all haptens 
Following selection of recombinant antibodies using the biopanning process, it may 
be necessary to screen large numbers of clones for selection of antibodies with the 
required characteristics This is achieved with the use of a simple ELISA (Marks et 
a l, 1991) with coated antigen on the surface The polyclonal phage mixture is added 
to the wells of the plate and the binding allowed to come to equilibrium, followed by
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the use of enzyme-labelled secondary antibodies and chromogemc substrate for 
detection
The problems associated with using a selection system such as the biopanning 
process and the screening assays are that these systems are required to reach a state of 
equilibrium Using these procedures results in the selection of high affinity 
interactions over lower affinity interactions (Kretzchmar et a l, 1995) which may not 
be desirable in some assay configurations such as the BIAcore biosensor The 
BIAcore has the ability to perform 'real-time' analysis of biomolecular interactions 
but requires antibodies with relatively high dissociation rates for the repeated 
regeneration of the sensor chip surface However, due to the nature of the ELISA 
screening technique, the antibodies isolated have low dissociation rates and would 
require more severe regeneration conditions to dissociate the antibody-antigen 
complex This problem may be solved using the BIAcore biosensor for selection of 
positive antibody displaying phage with different affinities (Malmborg et a l, 1996) 
This development has become very important as the use of antibody and antibody 
fragments on biosensors is becoming more prevalent (Turner, 1997) Antibodies 
selected using the BIAcore biosensor possess the characteristics for use on this sensor 
and so may be applied to the development of BIAcore biosensor assays 
By using the BIAcore biosensor for screening, it is possible to monitor the entire 
binding pattern of an antibody mixture Unpunfied antibody mixtures such as 
supernatant may be directly injected over a surface with the antigen of interest 
immobilised and antibodies may be screened on the basis of their dissociation rate 
constants as described by Marks et al (1992) In this paper, antibody fragments were 
screened using the BIAcore biosensor and results showed the selected antibodies 
exhibited affinities improved by 300 times compared to conventional selection 
techniques
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Figure 1.9. Illustration of affmity-selection panning process. Phage libraries are 
subjected to several rounds of panning which include the capture of phage by binding to 
antigen on a solid support. Specifically bound phage is then eluted from the antigen and 
used for re-infection into E. coli for screening offurther rounds ofpanning.
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1.6.4. Expression of recombinant scFv antibodies
Bacterial expression systems are a popular method for the production of all functional 
antibody fragments (Fv, Fab, F(ab') 2, and scFv). Bacterial fermentation is both rapid 
and inexpensive, and genetic manipulation of bacteria can lead to high level 
production making it a perfect expression system for scFv antibodies. Unlike 
complex whole antibodies, which require post-translational modifications like 
glycosylation, scFv’s can be produced in bacteria as fully functional antigen binding 
molecules. E. coli is the preferred bacterial expression system due to its ease of 
manipulation. Figure 1.10 shows the structure of the bacterium and the different 
spaces within it where scFv antibodies can be produced.
Flagellum
(C) Soluble scFv in 
supernatant
Figure 1.10. Diagrammatic representation of an E.coli bacterium illustrating the various 
locations of expression of scFv antibodies. (A) Insoluble inclusion bodies (containing 
antibody) in the cytoplasm. (B) Soluble expression of antibody in the periplasm. (C) 
Soluble expression of antibody in the supernatant
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ScFv’s may be expressed without a signal sequence to specifically direct it to the 
periplasm resulting in the formation of insoluble inclusion bodies in the cytoplasm 
followed by a refolding procedure (Kipnyanov et a l, 1997, Cho et a l, 2000) This 
refolding step may be problematic and may be avoided by manipulating the E cob so 
that it mimics the secretory pathway in eucaryotic cells using a specific signal 
sequence that directs the scFv to the periplasmic space This signal sequence is 
cleaved during transport through the membrane allowing the correct folding of the 
antibody for expression
16 5 Purification of recombinant scFv antibodies
Several methods for scFv purification are available These include antigen affinity 
chromatography (Owen et a l, 1992, Casey et a l, 1995, Cho et a l, 2000), protein A 
chromatography (Mahler et a l, 1997), cation exchange chromatography
(Kretzschmar et a l, 1996), size exclusion chromatography (Kretzschmar et a l, 
1996), human constant light chain tagging (Ridder e ta l, 1995, Longstaff et a l, 1998) 
and immobilised metal affinity chromatography (IMLAC) (Kipnyanov et a l, 1997, 
Freyreeta l, 2000)
IMAC has gained attention due to its many advantages over the more traditional 
antigen-affinity chromatography including higher ligand stability, higher protein 
loading, milder elution conditions, lower cost and complete recovery of ligand 
following regeneration (Arnold, 1991) IMAC involves the insertion of genes coding 
for a histidine (His) tag, containing 4-6 histidine residues, into the scFv sequence 
Insertion at the N or C terminus ensures that the antigen binding site is not effected 
(Casey et a l, 1995) The column consists of transition metals such as Ni2+, Co2+, 
Zn2+ and Cu2+, chelated by mtrotnacetic acid (NTA), iminodiacetic acid (IDA) or tns 
(carboxymethyl) ethylenediamine (TED) (Arnold, 1991, Muller et a l, 1998) His
tagged proteins bind to a metal-chelate solid support, while impurities are eluted 
Specifically bound protein may be eluted using low pH, which confers a positive 
charge on the His residues so they are incapable of binding metal ions, or by addition 
of imidazole, which competes with His for metal binding The advantage of the latter
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system being that it does not denature the protein (Janknecht et a l, 1991) Janknecht 
et al (1991) has used this system to purify human serum response factor to greater 
than 95% purity Subsequently, Casey et al (1995) has utilised Cu2+-IDA chelated 
IMAC to purify a His tagged protein to 90% purity, with higher yield than that of 
antigen affinity chromatography (10mg/l as opposed to 2 2mg/l) Kipnyanov et al 
(1997) have shown that IMAC can also be used to successfully purify scFv’s from E 
coh penplasmic extracts
16 6 Applications of recombinant scFv antibodies to proteomics
Proteomics may be defined as the study of protein properties such as expression 
levels, post-translational modification, interactions etc with respect to obtaining a 
global, integrated view of disease processes, cellular processes and networks at the 
protein level (Blackstock and Weir, 1999) The use of recombinant antibody phage 
displaying libraries for the production of recombinant antibodies are becoming 
increasing important in the field of proteomics This is mainly due to recent 
advances, which include the development of larger combinatorial antibody phage 
displaying libraries which contain high-affimty binders to target antigens These 
larger libraries and new advances in screening technologies which use high-density 
antibody arrays to identify differentially expressed proteins, may be used in 
proteomic research (Holt et a l, 2000)
The selection procedures used in the application of antibody phage display 
technology to the study of proteomics are of great importance There are three main 
selection strategies and these are, selection on complex antigen, conventional but 
highly parallel selection and use of a library of antibodies selected against a library of 
antigens (Holt et a l, 2000)
The first strategy, selection on complex antigen simultaneously selects many 
antibodies against antigens such as cells, cellular extracts or tissue sections The 
characteristics of this selection method would indicate the selection of large numbers 
of specific antibodies, however, due to the inherent biases in phage selection, a small 
number of antibodies are selected toward the most abundant proteins present
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(Hoogenboom et a l, 1999) The next selection strategy concentrates on selecting 
antibodies against individual proteins, expressed cDNAs or peptides, performed in 
parallel This method has the potential for high-throughput, however, it needs the use 
of robotics which are expensive and problems exist when selected antibodies against 
protein fragments may not recognise the parent protein The third strategy for 
selection is to select a library of antibodies against a library of antigens allowing the 
production of vast quantities of antibody-antigen binding pairs (Fields and Song, 
1989, Visintin e ta l, 1999)
The ProAb™ approach (Pennington and Dunn, 2001), applying phage antibodies to 
functional genomics is also being utilised This approach takes interesting pieces of 
DNA from databases of ESTs (‘expressed sequence tags’) and translates them into 
proteins Peptides are synthesised chemically to represent the protein sequence and 
used as antigens to which phage antibodies are selected The antibodies which are 
selected using this approach can then be used as detection reagents in 
immunocytochemistry, thereby revealing the distribution and abundance of the gene 
product in normal and diseased tissues
The ProxiMol™ selection technique (Pennington and Dunn, 2001) is also used in 
proteomics Within this method, catalysed reporter deposition (Bobrow et al, 
1989,1992) has been utilised to allow the isolation of phage antibodies binding in 
close proximity to a biotinylated guide molecule (Osborne et a l, 1998) When 
utilising phage display technology to screen for antibodies to a cell surface antigen, a 
guide molecule, such as a biotinylated target ligand, or a HRP-conjugated antibody, is 
added to intact cells, together with phage from a >10n human antibody library 
Following this, biotin-tyramine reagent is added resulting in bound phage being 
labelled with biotin These biotin labelled phage antibodies are then recovered using 
streptavidm-coated magnetic beads
Both the ProAb™ strategy and ProxiMol™ method may be applied to work in 
conjunction with one another as the selected phage antibodies from the ProAb™ 
strategy can be applied as guide molecules in the ProxiMol™ method selections 
Screening of positive antibodies is of vital importance in proteomics Traditional 
ELISA techniques have proved adequate for such a purpose However, such a
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technique only allows a small percentage of the positive clones to be screened Other 
methods have been developed for screening One method of particular importance is 
the use of antibody arrays which have the ability to increase throughput up to several 
hundred times (Ekins et a l, 1990) Antibody arrays for high-throughput screening of 
antibody-antigen interactions have been developed by De Wilde et al (2000) This 
technique uses high robotic picking and high density gndding of bacteria containing 
antibody genes followed by filter-based enzyme-linked immunosorbent assay 
(ELISA) screening to identify clones that express binding antibody fragments This 
method had the ability to screen up to 18,342 different antibody clones at a time 
against 15 different antigens This method proves that new and improved screening 
methods are essential for the continued progress of phage display in the study of 
proteomics
16 7 Applications of recombinant scFv antibody fragments for use in residue 
analysis
Over recent years, information on recombinant DNA techniques, combined with 
immunoglobulin structure and function, have lead to the development of recombinant 
single chain variable fragment (scFv) antibody technology These antibodies have 
been produced in bacteria (Krebber et a l, 1997) Such recombinant antibodies may 
be used for the analysis and detection of various antigens There are many 
advantages in using recombinant technology compared to traditional detection 
methods such as the ability to modify properties through mutagenesis, speed of 
production of antibodies and the possibility of generating rare and novel 
functionalities Selection from phage antibody libraries provides a new tool for the 
isolation of novel self antigens, such as disease-associated antigens (Hoogenboom et 
a l, 1998) This application has been used for probing lymphocyte cell surfaces, 
yielding antibodies to known antigens and a number of promising uncloned new cell- 
type specific antigens (De Kruif et a l, 1995) Recombinant antibodies with a specific 
range of affinities are required for small antigens, however, although the literature
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may suggest that obtaining such antibodies through recombinant phage display 
technologies is straightforward, this is not the case
Many of the detection methods using recombinant antibody technology to date have 
been ELISA based Garrett et al (1997) produced a scFv, specific for the 
organophosphate pesticide parathion using DNA obtained from a hybndoma cell line 
secreting an anti-parathion monoclonal antibody (Mab) An ELISA was developed 
and the limits of detection for the scFv and Mab were 2 3 and 1 6 ng/well 
respectively
Further work was carried out on the detection of organophosphate pesticides by 
Alcocer et al (2000) when a comparison was carried out between polyclonal, 
monoclonal and recombinant antibodies to chlorpyrifos-ethyl Polyclonal antiserum 
and two murine monoclonal antibodies recognising chlorpyrifos-ethyl were produced 
The hybndoma cell lines DNA was used in the production of scFv’s The two scFv’s 
limit of detection in ELISA were either similar or improved compared to the 
monoclonal antibody Cross reactivity studies were also earned out which showed all 
the antibodies to be specific to the chlorinated aromatic ring
Functional scFvs have also been produced against the herbicides paraquat (Graham et 
a l, 1995), atrazine (Byrne et a l, 1996) and tnazine (Kramer and Hock, 1996)
Single chain Fv fragments have also been used in the detection of potato viruses 
Leafroll luteovirus (Harper et a l, 1997) was detected using a scFv with alkaline 
phosphatase attached Alkaline phosphatase removes the need for the use of a 
secondary enzyme-labelled antibody and decreases the time needed for the assay 
Potato virus Y potyvirus (Boonham et a l, 1998) was detected using scFv antibodies 
in ELISA at concentrations of 50 ng/ml in plant sap Results indicated that the scFv 
antibodies displayed similar detection charactensties to commercially available 
monoclonal antibodies
Detection of environmental toxins has become increasingly important, and scFv 
antibodies are now being used for their detection They have been produced against 
the mycotoxins zearalenone (Yuan et a l, 1997) and aflatoxin Bi (Daly et a l, 2001)
ScFv antibodies produced against aflatoxin Bi were applied for use in the BIAcore 
biosensor and could detect levels of aflatoxin Bi as low as 3 ng/ml McElhiney et al
ii
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(2000) also developed an ELISA for the detection of the cyanobacterial hepatotoxin 
microcystin-LR An scFv antibody isolated from a naive human phage display 
library was used in the assay The most sensitive antibody clone isolated, detected 
free microcystin-LR with an IC50 value of 4 |iM
These case studies of detection systems using antibody phage display technology 
highlight the potential of the technology for the selection of antigen specific 
antibodies with detection characteristics equivalent or better than traditional 
technologies
1 7 Immunoassays
17 1 Design of immunoassays
This section focuses on the design of enzyme-based immunoassays The first assay 
formats of interest are non-competitive, soiid-phase enzyme immunoassays These 
assays may be sub-divided according to the immunoreactant immobilised on the solid 
phase One commonly used method is the immobilisation of antigen on solid phase 
for detection of antibodies with the use of enzyme labelled anti-antibody molecules 
The possibility of immobilising antigen followed by detection with labelled specific 
antibody is also a commonly used method This method yields higher specificity, but 
suffers from high background values Another general approach associated with this 
type of immunoassay is the detection of antigens with the use of an antibody 
sandwich assay In this assay format primary antibody is immobilised on solid phase 
followed by the addition of antigen, which results in specific antibody capturing the 
relative antigen This is followed by the addition of a second antigen-specific 
enzyme-labelled antibody resulting in the formation of a sandwich assay The final 
method in this class of assay is known as the class-capture technique useful in the 
diagnosis of infectious agents This method works on the principal that infections 
inducing a secondary immune response can be detected by monitoring the different 
antibodies produced at each stage of infection
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Non-competitive homogenous (homogeneous assays do not require the separation of 
free and antibody-bound fractions of the analyte) enzyme immunoassays are further 
types of immunoassays which are performed without the involvement and attachment 
to a solid phase and they do not require the separation of free and bound label This 
method of analysis may be achieved by labelling two monoclonal antibodies directed 
against different epitopes of the antigen with two enzymes selected so that one 
produces the substrate for the other
Competitive homogenous enzyme immunoassays have several general formats The 
detection of hapten is carried out with the use of enzyme-hapten conjugates used as 
antigen The activity of the conjugated enzyme is modulated by the reaction of 
hapten-specific antibodies with the haptenated enzyme The presence of competing 
free hapten will decrease this modulation resulting in a detectable difference Other 
methods within this group can include the use of substrate conjugated to hapten 
instead of enzyme The antigen-specific antibody reacting with the antigen-substrate 
conjugate then prevents the substrate being acted upon by the enzyme In the 
presence of free antigen, the reaction of antibody with substrate-bound antigen is 
prevented
Finally, competitive, solid-phase enzyme immunoassays are the last group of interest 
Within this assay format the antibody is immobilised on the solid phase and the 
antigen is labelled with the enzyme Binding of antigen-enzyme conjugate to 
immobilised antibody is inhibited by the addition of free antigen, which results in the 
production of a standard curve for the detection of hapten (Tijssen 1985)
17 2 Immunoassays-experimental
The increased need for systems with the ability to monitor, detect and quantify 
various molecules has led to the growth of immunoassays Immunoassays (Price and 
Newman, 1997) are bioanalytical methods in which the detection and quantification 
of a molecule is dependent on the binding of the molecule to a specific antibody 
Enzyme-Linked Immunosorbent Assay (ELISA) (Gosling, 1990, Crowther, 1995) is 
the most commonly used technique for measuring hapten-antibody interactions and is
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a solid-phase heterogeneous technique used for the detection of a wide range of 
analytes ELISA may have a number of formats However, two assay formats, 
indirect ELISA and competitive ELISA, were primarily used in the development of 
assays in relation to the work in this thesis
A schematic representation of a competitive ELISA technique is shown in Figure 
111 As direct immobilisation of small haptens onto an immunoplate may prove 
difficult, the hapten is coupled to protein through various coupling chemistries and 
added to the wells of a 96 well immunoplate, which is known as coating Proteins 
bind primarily to the surface of the wells of y-irradiated 96-well immunoplates by 
hydrophobic interactions After a suitable incubation period, the wells are washed to 
remove any loosely bound conjugate A suitable blocking solution (1 e 2% marvel) is 
then added to the wells to ‘block’ any unreacted sites on the plate that may result m 
non-specific binding of either primary or secondary antibodies Solutions are then 
prepared with a constant amount of antibody present with varying concentrations of 
free hapten After washing the blocked immunoplate, these antibody-hapten mixtures 
are added to the wells of the plate and incubated During this incubation period, 
competition occurs between the hapten bound on the surface of the well and free 
hapten in solution for the antibody Again following washing, a suitable secondary 
antibody (e g horseradish peroxidase-labelled goat anti-rabbit antibody) is added to 
the wells of the plate followed by chromogemc substrate for detection purposes The 
intensity of the colour produced by the enzyme-substrate reaction is monitored 
spectrophotometrically at the appropnate wavelength With this type of assay, the 
colour intensity is inversely proportional to the amount of free hapten in solution (i e 
the higher the concentration of free hapten the weaker the colour intensity) The 
results from such assays may be used to construct standard curves, from which the 
concentration of hapten in unknown solutions may be determined 
Figure 1 12 represents the format for an indirect ELISA This type of ELISA is 
mainly used for the determination of antibody titres in purified and unpunfied 
samples The format of this ELISA is similar to the format of the competitive 
ELISA However, dilutions of primary antibody are added to the wells of the 
immunoplate instead of the antibody-hapten mixtures
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When analysing both indirect and competitive ELISA formats, it is evident that the 
sensitivity of both assays depends solely on the affinity of the antibody for the 
hapten
The BIAcore biosensor is also used in the development of inhibitive immunoassays in 
this thesis As discussed in section 4 1 1 1, the BIAcore works on the principle of 
surface plasmon resonance and may be used to develop immunoassays to various 
metabolites With this system, either hapten or antibody may be immobilised onto 
the surface of the chip Immobilisation of hapten may prove difficult depending on 
the functional groups available This is why most assays developed immobilise 
protein-hapten conjugates onto the surface Standards of free hapten are prepared and 
premixed with antibody and after a suitable incubation time, passed over the surface 
of the chip with protein-hapten conjugate immobilised The hapten in solution 
inhibits the binding of antibody to the surface and the amount of antibody that binds 
to the surface is inversely proportional to the amount of free hapten in solution The 
results of this immunoassay may be used in the construction of a standard curve and 
unknown concentrations determined from such a curve
17 3 Immunoassay optimisation
Assay design requires the selection of reagents and a protocol whereby the main 
objective of the assay which is the most accurate measurement of analyte 
concentration is achieved There is little doubt that the ability of an assay to detect 
hapten is directly related to the affinity and selectivity of the antibody for the 
particular hapten When analysing a competitive assay, the main function of enzyme 
conjugates and free hapten is to compete for a limited number of binding sites present 
on the specific antibodies, according to a reversible antibody-hapten equilibrium 
competition with an antibody-enzyme conjugate Lower affinity of the antibody for 
the competitor, compared with the hapten, will shift the equilibrium conditions in 
favour of the formation of an antibody-hapten complex Association of the antibody 
with the labelled-antigen is then inhibited, hence the structure of the labelled 
competitor has a key role to play in the sensitivity of the immunoassay
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Dose-response curves are a common feature of such assay systems As fixed 
amounts of antibody and enzyme conjugates are present, the enzyme activity 
determined by absorption readings is related to the hapten concentration by a dose 
response curve When response is plotted against the logarithm of the hapten 
concentration, the curve produced is of a sigmoidal nature with a relatively linear 
portion near the point of half inhibition, which is known as the IC50 The change in 
the absorbance reading in this curve correlate to the hapten concentrations used in the 
assay
Characterisation of these assays requires the determination of the limit of detection 
and the limit of quantification The limit of detection (LOD) is defined as the1
smallest concentration of hapten which results in a change in signal enabling accurate 
differentiation between it and the signal from the zero concentration of hapten 
Although there are several methods of determining sensitivity, the one most favoured 
for use is selection of the dose which inhibits 10% of the binding of the antibody with 
the enzyme label at 90% However, the limit of quantification is the level above 
which the quantitative results can be obtained with a reasonable degree of accuracy 
and precision In the case of many assays with sigmoidal curves, the accuracy of the 
assay decreases as the curve approaches the asymptotes at both the higher 
concentrations of free hapten and the lower concentrations
Assays require high levels of precision and reproducibility The precision of an assay 
is defined as the way in which replicate analysis of sample agree with one another 
The reproducibility of the assay may be defined as the assays ability to provide the 
same result when used on different days or by different users With respect to a 
normal sigmoidal curve we find that the variability is not uniform and that the errors 
increase as the ranges move to the asymptotes of the curve at the highest and lowest 
concentrations of sample In the case of many assays the highest precision is 
obtained for concentrations close to the I C 5 0
The accuracy of an assay is defined as the closeness of agreement of the measured 
test results with the expected true reference value Depending on the type of assay 
required low accuracy values may be acceptable if the assay is a confirmatory assay
41
However, if the assays function is to determine exact concentration of hapten high 
accuracy values are required
The specificity of the assay is the ability of the assay to produce a signal representing 
a measurement of the hapten being analysed Quantitative determinations of hapten 
concentration are reliable only if there is no cross-reactivity Cross reactivity with 
other haptens will produce false results within the assay However, various antigens 
may possess similar epitopes resulting in the production of antibodies with cross- 
reactivity to these antigens This results in the need to fully understand and 
determine the antibodies cross-reactivity
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Figure 1.11. Schematic diagram of a typical competitive ELISA. (1) Wells of an 
immunoplate are coated with a protein-hapten conjugate. (2) Wells are blocked with a 
suitable blocking solution (e.g. 2% marvel). (3) The antibody-hapten solutions are then 
added to the wells of the plate and allowed to incubate. (4) Wells are washed to remove 
unbound antibody and hapten, the bound antibody remains on the surface of the well. (5) 
A species specific secondary enzyme-labelled antibody is added to the wells and allowed to 
incubate. (6) With the addition of substrate, in the presence of the enzyme on the 
secondary antibody, a colour is produced and detected spectrophotometrically at the 
appropriate wavelength.
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Figure 1.12. Schematic diagram of a typical indirect ELISA mainly used for the 
determination of purified and unpurified antibody titre. (1) Wells of an immunoplate are 
coated with a protein-hapten conjugate. (2) Wells are blocked with a suitable blocking 
solution (e.g. 2% marvel). (3) Dilutions of antibody are prepared and added to the wells of 
the plate. (4) A species specific secondary enzyme-labelled antibody is added to the wells 
and allowed to incubate. (5) With the addition of substrate, in the presence of the enzyme 
on the secondary antibody, a colour is produced and detected spectrophotometrically at the 
appropriate wavelength.
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Figure 1.13. Schematic representation of the BIAcore inhibitive immunoassay format for 
quantitative determination of hapten. Standards of free hapten were prepared and 
premixed with antibody and after a suitable incubation time, passed over the surface of the 
chip with protein-hapten conjugate immobilised. The excess antibody in the mixtures 
binds to the sensor chip surface and the amount of antibody, which binds, is inversely 
proportional to the amount of free hapten in solution.
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1 8 Aims of Research
The aim of this project was to develop antibodies to morphine-3-glucuromde and 
parathion for use in the development of competitive ELISA immunoassays and rapid 
and sensitive BIAcore inhibition immunoassays for the analysis of these compounds
Chapter 3 describes the production and characterisation of drug-protein conjugates to 
morphine-3-glucuromde used for the production of two polyclonal antibodies to 
morphine-3-glucuromde in rabbits Both affinity purified polyclonal antibodies were 
used to develop competitive ELISA immunoassays for morphine-3-glucuromde in 
urine
In chapter 4, the polyclonal antibodies were used in the development of BIAcore- 
based inhibition immunoassays for the detection of morphine-3-glucuromde in urine 
Studies were carried out on the suitability of these antibodies for application on the 
BIAcore biosensor and results displayed good reproducibility with low CVs
Chapter 5 describes the development of combinatorial phage display libraries using 
the Krebber system for the production of single chain Fv (scFvs) antibodies that 
detect morphine-3-gIucuromde Competitive ELISA and BIAcore inhibition 
immunoassays were developed for the detection of morphine-3-glucuromde using an 
affinity selected scFv antibody
Chapter 6 describes the denvatisation of parathion to amino-parathion and following 
characterisation, was used in the production and characterisation of drug-protein 
conjugates to the organophosphate pesticide parathion The drug-protein conjugates 
were then used for the production of a polyclonal antibody to parathion, it’s 
purification and use in a competitive ELISA immunoassay Studies were also earned 
out on the applicability of this antibody for the development of a BIAcore-based 
immunoassay
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Chapter 2 
Materials & Methods
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2 1 Materials
All standard laboratory reagents were purchased from Sigma Chemical C o , Poole, 
Dorset, England unless stated otherwise
Reagent Supplier
Acetic acid 
Hydrochloric acid 
Sodium chloride 
Tween 20 
Parathion
Riedel de-Haen AG, Wunstorfer, Strabe 40, D- 
30926, Hannover, Germany
Bacteriological Agar 
Tryptone 
Yeast Extract 
PBS tablets
Oxoid, Basingstoke, Hampshire, RG24 8PW, 
England
Bicinchonmic acid assay (BCA) kit Pierce and Wamner (UK) Ltd, Chester, England
DNA ligase Boehnnger-Mannheim L td, East Sussex, England
CM-Dextran Fluka Chemicals, Gillingham, Dorset, England
Hepes
Tnzol
Gibro BRL, Renfew Rd, Paisley PA49RF, Scotland
HPLC-grade solvents Lab-Scan, Stillorgan, Co Dublin, Ireland
Hydrogen peroxide BDH Chemicals L td, Poole, Dorset, England
PCR Optimizer Kit 
ProBond™ Resin
Invitrogen, 9704-CH-Gromngen, Netherlands
PCR Primers Sigma-Genosys Ltd, Cambridge CB2, England
Sfil enzyme New England Biolabs, Hitchin, Herts, England
VCSM13 Helper Phage Stratagene, North Torrey Pines Rd La Jolla, USA
Wizard Plus Mini-prep kit and PCR 
prep DNA purification kit 
PCR-related Reverse-Transcnption 
System
Promega Corporation, 2800 Wood Hollow Rd, 
Madison, WI 53711-5399, USA
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2 2 Equipment
Equipment Supplier
Atto dual mini slab AE-6450 
Atto AE-6100
Atto Corp, Bunhyo-Kui, Tokyo 113, Japan
BIAcore 1000™ 
BIAcore 3000™ 
CM5 chips
Pharmacia Biosensor AB, Uppsala, Sweden
Eppendorf tubes 
Sterile universal containers
Sarstedt, Wexford, Ireland
Heraeus Christ Labofiige 6000 
Biofuge A Microcentrifuge
Heraeus Instruments Inc, 111-a Corporate 
Boelevard, South Plainfield, New Jersey, USA
Titretek Twinreader Plus Medical Supply Company, Damastown, 
Mulhuddart, Dublin 12, Ireland
Image Master VDS Pharmacia Biotech, San Francisco, CA , USA
IR Spectrophotometer The Nicolet Instrument Corp, Madison, USA
NMR Spectrometer, 400MHz AC400 Brucker, Coventry, CV4 9GH, England
NUNC Maxisorb plates NUNC, Kamstrup DK, Roskilde, Denmark
3015 pH meter Jenway L td, Essex, England
Orbital incubator Gallenkamp, Leicester, England
RM6 Lauda waterbath 
T-Gradient BIOMETRA-PCR 
Millipore Filtration Apparatus
AGB Scientific L td, Dublin Industrial Estate, 
Glasnevin, Dublin 9, Ireland
SB1 Blood tube rotator Stuart Scientific, London, England
Sorvall RC-5B refrigerated centrifuge Du Pont instruments, Newtown, Connecticut, USA
Sterile cell culture lab-wear Brownes, Foxrock, Dublin, Ireland
Stuart Platform Shaker STR6 Lennox, Naas R d, Dublin, Ireland
Ultrafiltration cell 8400 Amicon Inc Beverly, Massachusetts 01915, USA
UV-160A spectrophotometer Shimadzu Corp, Kyoto, Japan
UVP ImageStore 7500 gel 
documentation system
Ultra Violet Products, Upland, CA, USA
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2 3 Methods
2 3 1 General formulations
2 3 1 1  Culture media formulations
2 x Tryptone and yeast extract (TY) medium Tryptone 
Yeast Extract 
NaCl
16 g(X 
10g/l 
5g/l
Luna broth (LB) medium Tryptone 16 g/1
Yeast Extract 10 g/1
NaCl 5 g/l
Bacteriological agar 15 g/1
Non-expression medium (NE) Tryptone 
Yeast Extract 
NaCl 
Glucose
16 g/1 
10 g/1
5 g/1
1%, v/v
Chloramphenicol 25 jag/ml
Low expression medium (LE) Tryptone 16 g/1
Yeast Extract 10 g/l
NaCl 5 g/1
Glucose 1%, v/v
Chloramphenicol 25 |xg/ml
IPTG 05mM
Expression Medium (EM) for soluble scFv 2 x TY medium
antibodies Chloramphenicol 25 |ig/ml
Super optimal catabohtes (SOC) medium Tryptone 20 g/1
Yeast Extract 5g/l
NaCl 0 5 g/1
KC1 2 5 mM
MgCl2 20 mM
Glucose 20 mM
pH 70
Tryptone and yeast extract (TYE) medium 2 x TY medium
Bactenological agar 15 g/1
2 3 12  Buffer formulations
Phosphate buffered saline (PBS)
One tablet (Oxoid) was dissolved per 100 mis of distilled water according to 
manufacturer’s instructions When dissolved, the tablets prepare Dulbecco’s A PBS 
which contains 0 15 M NaCl, 2 5 mM potassium chloride, 10 mM disodium hydrogen 
phosphate and 18 mM sodium dihydrogen phosphate, pH 7 4 This buffer will be 
referred to throughout as PBS
Tns buffered saline (TBS)
Tns buffered saline containing 1 mM CaCk, 0 05 M Tns, 0 15 M NaCl, pH 7 4, was 
prepared as the dilution buffer for the monoclonal anti-FLAG antibody for western 
blotting and ELISA analysis of soluble scFv’s
Tris-acetic acid-EDTA buffer (TAE)
A stock solution of 50 X TAE buffer was prepared in a final volume of 1 1 by 
dissolving 242 g Tns, and addition of 57 1 ml glacial acetic acid followed by 100 ml 
of 0 5 M EDTA, pH 8 0 All gels were ran in 1 X TAE
Hepes Buffered Saline (HBS)
Hepes buffered saline (BIACORE running buffer) containing 50 mM NaCl, 10 mM 
HEPES, 3 4 mM EDTA and 0 05% (v/v) Tween-20 was prepared by dissolving 8 76 
g of NaCl, 2 56 g of HEPES, 1 27 g of EDTA and 500 jal of Tween 20 in 800 ml of 
distilled water The pH of the solution was then adjusted to pH 7 4, by the addition of 
2 M NaOH The final volume was then made up to 1,000 ml in a volumetric flask 
The solution was filtered through a 0 2 |im filter and degassed prior to use
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2 3 2 Production of drug-protein conjugates
2 3 2 1  P ro d u ctio n  o f  protein conjugates to m o rp h w e -3 -g lu cu ro m d e
A 50 mg/ml solution of morphine-3-glucuromde (M3G) was prepared in 50 mM HC1 
and made up to a final volume of 5 ml with 0 2 M borate buffer, pH 8 5 
Concentrations of EDC (N-ethyl-N-(dimethyl-aminopropyl) carbodnmide 
hydrochloride) and NHS (N-hydroxysuccinimide) were then added to give a final 
molarity of 0 4 and 0 1 M, respectively, in the solution and incubated at room 
temperature without agitation for 10 min Protein (BSA, OVA, THY) was prepared 
at a molar ratio of 1 100 to M3G in 5 ml of 0 2 M borate buffer, pH 8 5, and added 
dropwise to the M3G solution This solution was then incubated at room temperature 
for 2 h with stirring The solution was dialysed against 50 volumes of PBS overnight 
at 4°C
2 3 2 2 P ro d u ctio n  o f  pa rath io n  conjugates
Production of parathion conjugates was performed according to Ercegovich et al 
(1981)
2 3 2 2 1 P reparation  o f  red uced  p arathion
Parathion (150 mg) was dissolved in 6 ml of diethyl ether and extracted with cold 1% 
(w/v) sodium carbonate (Na2C03) in distilled water (4 x 50 ml) to remove any phenol 
impurities 5 ml of 9 1 acetic acid-concentrated HC1 and 0 5 g of zinc power were 
added to the phenol free ether solution The yellow reaction mixture was stirred 
under reflux for 45 min The solids were then filtered from the colourless solution 
and subsequently washed with 10 ml of carbon tetrachloride (CCU) The combined 
organic phase was then washed with 5 ml of distilled water and dried over 0 5 g of 
anhydrous sodium sulphate The solvent was subsequently removed under reduced
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pressure Characterisation of the product was earned out by NMR and IR 
spectroscopy
2 3 2 2 2 Preparation of parathion conjugates
Reduced parathion (10 mg) was dissolved in 5 ml of distilled water containing 2 mM 
HC1 The solution was cooled on an ice bath, and a chilled 0 1 M sodium nitrite 
(NaN02) solution was added dropwise until a positive starch-iodide paper test was 
observed The mixture was stirred for 30 min and the excess nitrous acid was 
decomposed with urea The reaction mixture was added to 50 mg of OVA dissolved 
in 10 ml of 0 2 M borate buffer, pH 9, and stirred in an ice bath for 2 h A bright 
orange colour was then observed The conjugation mixture was dialysed against 2 
changes of 5 L of distilled water daily for 5 days at 4°C The dialysed product was 
then stored at -20°C The same procedure was earned out for the production of BSA, 
THY and dextran conjugates
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2.3 3 Characterisation of protein-drug conjugates
2 3 3 1  Ultraviolet spectroscopy
Conjugates were prepared at a concentration of 1 mg/ml in PBS, and their UV spectra 
analysed from 200-400 nm UV spectra of similar concentrations of control protein 
were also prepared and recorded Comparison of the two spectra gave putative 
confirmation of the conjugation of parathion to protein carrier molecules
2 3 3 2 Im m u n isatio n
Mice were immunised as described in section 2 3 5 3 with preparations of M3G- 
protein conjugates as described in section 2 3 2 1 Blood was taken from the mice as 
described in section 2 3 6 2 after 10 days and analysed for production of antibodies 
to the specific drug as described in section 2 3 8 1
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2 3 4 Production of lmmunoaflflnity matrices
An lmmunoaffimty matrix was prepared by the chemical coupling of parathion-BSA 
to sepharose-4B The lmmunoaffimty matrix was then used for the affinity- 
punfication of polyclonal antibodies to parathion from ammonium sulphate 
precipitated-rabbit immunoglobulin fractions
2 3 4 1 Preparation o f parathion-BSA Sepharose column
Parathion-BSA was coupled to CNBr-activated sepharose 4B according to the 
manufacturer’s instructions 1 5 g of CNBr-activated sepharose 4B was weighed out 
and swollen in 250 ml of 1 mM HC1 for 1 h, giving approximately 5 ml of wet gel 
The gel was sucked dry on a Buckner funnel with a filter of pore size 0 2 jam, and 
washed twice with 100 ml of PBS 50 mg of parathion-BSA was dissolved in 10 ml 
of coupling buffer (0 1 M NaHCCb, pH 8 3, with 0 5 M NaCl) The coupling 
solution was then added dropwise to the gel, under gentle rotation, and the mixture 
rotated overnight at 4°C The gel was then washed successively with 50 ml each of, 
0 1 M sodium bicarbonate, pH 8 5, PBS and PBS containing 1 0 M NaCl to remove 
any non-chemically bound parathion-BSA The gel was then mixed with 10 ml of 1 0 
M ethanolamine for 2 h under gentle rotation to block the excess active amine groups 
The gel was then washed with 0 1 M acetate buffer, pH 4 0, containing 0 5 M NaCl 
and with coupling buffer, and stored in PBS with azide (0 05%, v/v) at 4°C
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2 3 5 Antibody production
2 3 51 Licensing fo r drug and animal use
The possession and use of morphine-3-glucuromde for analytical purposes is licensed 
by the Department of Health All processes involving the use of live animals is also 
licensed Extreme care was taken to minimise stress to the animals involved
2 3 5 2 Immunisation procedure for the production o f rabbit antiserum to 
morphine-3-glucuromde andparathion
A 1 mg/ml solution of conjugate was prepared (M3G-BSA, parathion-OVA) in PBS 
and added to an equal volume of Freund’s Complete adjuvant This solution was 
then vortexed until an emulsion was present New Zealand White female rabbits 
were injected subcutaneously at a number of sites with 1 ml of the emulsion The 
immunisation was repeated 21 days later with Freund’s Incomplete adjuvant Bleeds 
were taken from the marginal ear vein of the animals between 10 and 15 days after 
immunisation, and the cycle of reboosting and bleeding procedure was repeated until 
an adequate titre of no less than 1/200,000 was obtained Once a sufficient titre was 
obtained the animals were sacrificed with an overdose of anaesthetic and the serum 
removed as described in section 2 3 6 1
2 3 5 3 Immunisation procedure o f BALB/c mice fo r  the production o f single 
change Fv antibodies to morphine-3-glucuromde
A 1 mg/ml solution of M3G-BSA was prepared in PBS and added to an equal volume 
of Freund’s Complete adjuvant This solution was vortexed until an emulsion was 
present 5-10 week old BALB/c mice were immunised subcutaneously with a total 
volume of 250 |il over several sites Further intraperitoneal immunisations were 
carried out after 21 days using Freunds Incomplete adjuvant The mice were bled 7 
days later and the antibody titre against the specific drug determined The reboosting
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and bleeding procedure was repeated until an adequate titre of no less than 1/1,000 
was obtained The animals were then immunised intravenously through the tail vein 
with 250 (il of 1 mg/ml M3G-BSA in PBS 3-4 days prior to sacrifice This was 
followed by sacrifice by cervical dislocation and removal of the spleen
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2 3 6 Preparation of serum
2 3 6 1 Preparation o f rabbit serum
1 ml blood samples from the marginal ear vein were collected for estimation of 
specific antibody titre in rabbit serum Blood was allowed to clot for 2 h at room 
temperature, followed by overnight at 4°C, thus allowing the clot to tighten It was 
then centrifuged at 4,000 rpm for 20 min and serum removed and stored at -20°C 
For collection of polyclonal antisera, the rabbit was anaesthetised and sacrificed by 
cardiac puncture and blood removed from the heart with a syringe The whole blood 
was treated as described above
2 3 6 2 Preparation o f mouse serum fo r estimation o f titre
10-20 |uil of blood was removed from the tail of the mouse for estimation of specific 
antibody titre in the sample of blood Blood was allowed to clot at room temperature 
for 30 min, followed by centrifugation at 14,000 rpm for 2 min The serum was 
removed and stored at -20°C until further analysis
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2 3 7 Antibody purification and characterisation
2 3 7 1 Purification ofpolyclonal antibody from whole serum
Purification of polyclonal antibody from rabbit serum was initially carried out by 
precipitation with saturated ammonium sulphate This was followed by affinity 
purification using a protein G column or immunoaffinity matrices consisting of a 
parathion-BSA sepharose column
2 3 7 2 Saturated ammonium sulphate precipitation
The ammonium sulphate precipitation of antibody from rabbit serum was carried out 
according to the method of Hudson & Hay, (1980) Saturated ammonium sulphate 
(SAS) was prepared by dissolving 500 g of ammonium sulphate in 500 ml distilled 
water at 50°C, leaving the solution overnight at 4°C and adjusting the pH to 7 2 10
ml of cold saturated ammonium sulphate (100%, w/v) was added dropwise to an 
equal volume of rabbit serum on ice with stirring The mixture was allowed to stir at 
room temperature for 30 min, followed by centrifugation at 3,000 rpm for 20 min 
The supernatant was discarded and the precipitate washed twice in 10 ml of 45% 
(w/v) ammonium sulphate The washed pellet was dissolved in 5 ml of PBS and 
dialysed in 5 L of PBS overnight at 4°C to remove residual ammonium sulphate
2 3 7 3 Protein G affinity chromatography
A 2 ml protein G-sepharose column was poured and equilibrated with 50 ml of PBS, 
pH 7 4, containing 0 3 M NaCl (running buffer) 2 ml of the dialysed ammonium 
sulphate rabbit immunoglobulin fraction was applied to the column and the flow rate 
adjusted to 1 ml/min The sample was then re-applied to the column twice followed 
by washing the column with 20 ml of PBS, pH 7 4, containing 0 5 M NaCl and 
0 05% (w/v) Tween (wash buffer) Affinity captured-antibody was eluted with 0 1 M 
glycme/HCl, pH 2 2 1 ml fractions were collected and immediately neutralised to
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pH 7 0 by addition of 100 \x\ of 1 5 M Tris/HCl, pH 8 7, to each fraction, in order to 
prevent denaturation of antibody The optical density of each fraction was recorded 
at 280 nm, and those fractions containing protein were pooled and dialysed overnight 
in PBS at 4°C, and sodium azide was added to 0 05% (v/v) The sample was 
aliquotted (0 5 ml fractions) and stored at -20°C
2 3 7 4 Affinity purification o f polyclonal anti-parathion antibodies using a 
parathion-BSA sepharose column
Purification of the anti-parathion polyclonal antibody was carried out as described in 
section 2 3 7 3, except that a 5 ml parathion-BSA sepharose column was used
2 3 7 5 Bicinchommc acid (BCA) protein assay
Standard protein solutions with concentrations between 0-2 mg/ml were prepared in 
PBS using either bovine serum albumin (BSA) or for immunoglobulin concentration 
determination IgG 10 jul of protein sample or standard was placed in wells of a 96 
well microtitre plate 190 [i\ of BCA working reagent (50 parts reagent A to 1 part 
reagent B) was added The plate was incubated at 37°C for 30 mm after gentle 
mixing The absorbance of the wells was determined at 562 nm on a Titretek 
Twinreader Plus plate reader A standard curve of known protein concentration 
versus absorbance was constructed from which unknown sample protein 
concentrations were determined
2 3 7 6 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed to assess antibody purity The compositions of gels, electrophoresis buffer 
and sample buffer are shown in Table 2 1 Samples and protein markers were 
prepared in sample loading buffer (4 1, sample buffer) and boiled for 5 min Samples 
were run at 50 mA per gel on an Atto AE-6450 minigel gel until samples had reached
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the base of the stacking gel, and then at 20 mA per gel until the dye had reached the 
base of the resolving gel Coomassie blue was used to stain the gel or the gel was 
used for western blotting
2 3 7 7. Coomassie blue staining fo r SDS-PAGE gel
Coomassie blue staining solution (0 2% (w/v) Coomassie blue R250 in 30 10 60 
(v/v/v) methanol acetic acid watei) was prepared and gels were stained for 30 min 
and destained overnight at 4°C (in destaming solution 10 7 53 (v/v/v)
methanol acetic acid water)
2 3 7 8 Western blotting o f scFv antibodies
Proteins were transferred from acrylamide gels to nitrocellulose using a BioRad wet 
blotter for 90 minutes at 72 V, in electrophoresis buffer containing 20% (v/v) 
methanol Blocking of the membrane was carried out with blocking solution (5% 
(w/v) non-fat milk powder, 0 01% (v/v) antifoam A, 0 02% (v/v) sodium azide in Tns 
Buffered Saline (TBS) (50 mM Tns-HCl, 150 mM NaCl, pH 7 4) for 2 h at room 
temperature or overnight at 4°C Monoclonal anti-FLAG antibody (1/500 dilution) 
was added in blocking solution containing 1 mM calcium chloride (CaCl2) for 1 5 h 
at room temperature This was followed by washing the nitrocellulose three times in 
TBS containing 1 mM CaCl2 for 10 min each time Alkaline phosphatase-labelled 
anti-mouse IgG prepared in 5% (w/v) fat free milk powder in TBS containing 1 mM 
calcium chloride was added to the nitrocellulose filter for 1 5 h shaking at room 
temperature Final washing consisting of four 10 min washings in TBS containing 1 
mM CaCl2 The western blot was developed with one-step 5-bromo-4-chloro-3’- 
mdolyphosphate/mtro blue tetrazohum chloride (BCIP/NBT) reagent (Promega) 
Colour development was stopped by the addition of 2 mM EDTA in PBS
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Table 2 1 Composition of stacking gel, resolving gel, electrophoresis buffer and 
sample loading buffer for SDS-PAGE
Stacking gel 5% (w/v) acrylamide 
0 13% (w/v) bis-acrylamide 
125 mM Tns (pH 6 8)
0 1% (w/v) SDS
0 15% (w/v) ammonium persulphate 
0 25% (v/v) TEMED
Resolving gel 10% (w/v) acrylamide 
0 27% (w/v) bis-acrylamide 
375 mM Tns (pH 6 8)
0 1% (w/v) SDS
0 08% (w/v) ammonium persulphate 
0 08% (v/v) TEMED
Electrophoresis buffer 25 mM Tns (pH 8 8) 
192 mM glycine 
0 1% (w/v) SDS <
Sample loading buffer 60 mM Tns (pH 6 8)
25% (v/v) glycerol 
2% (w/v) SDS 
14 4 mM 2-mercaptoethanol 
0 1% (w/v) bromophenol blue
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2 3 7 9 Agarose gel electrophoresis
Samples from 10 to 20 |il were prepared in 6 X loading buffer (0 25% (w/v) 
bromophenol blue, 40% (w/v) sucrose) Samples were loaded into the wells of 
agarose gels, typically between 0 8 and 1 2% Gels were prepared using TAE and 
Type 1-A agarose Ethidium bromide was added to gels at 0 5 |ig/ml Samples were 
electrophoresed at 80 V per gel for 2 h
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2 3 8 General enzyme immunoassay protocol using polyclonal antibodies
2 3 8 1 Non-competitive ELISA fo r determination o f polyclonal antibody titre and 
optimal concentration o f protein conjugates
Ranges of protein drug conjugates of appropriate type (M3G-THY, M3G-OVA, 
parathion-BSA, parathion-OVA, cephalexin-BSA) were coated onto microtitre 
(Nunc) plates and incubated overnight at 4°C Plates were washed three times with 
PBS containing 0 05% (v/v) Tween (PBST) and three times with PBS The plates 
were then blocked with 2% (w/v) marvel in PBS for 1 h at 37°C Serial dilutions of 
polyclonal antibody in PBS were added to the wells of each conjugate concentration 
on the plate and allowed to bind at 37°C for 1 h This was followed by addition of a 1 
in 5000 dilution in PBS of HRP-labelled goat anti-rabbit antibody and incubation for
1 h at 37°C Plates were again washed and chromogenic substrate (0 4 mg/ml o- 
phenylenediamine (o-PD), in 0 05 M phosphate citrate buffer, pH 5 0, and 0 4 mg/ml 
of urea hydrogen peroxidase) was added and incubated for 30 min at 37°C 
Absorbance was read at 492 nm
2 3 8 2 Competitive ELISA for polyclonal antibody
Competitive immunoassay was performed using this polyclonal antibody as described 
in section 2 3 8 1 However, standards of free analyte were mixed with antibody and 
added to the wells following coating and blocking
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2 3 9 Production of murine scFv antibody libraries to morphine-3-glucuronide
2 3 91 Isolation o f total RNA from the spleen o f BALB/c mice
The spleen was remove using aseptic technique The weight of the spleen was 
recorded and 1 ml of Trizol Reagent was added per 40 mg of spleen present This 
solution was then homogenised and incubated at room temperature for 5 min The 
mixture was centrifuged at 14,000 rpm for 15 min The upper aqueous phase 
(represents approx 40% of total volume) was removed and precipitation of the RNA 
was carried out by adding 0 5 ml isopropanol/ml of trizol The solution was 
incubated for 10 min at room temperature, followed by centrifugation at 14,000 rpm 
for 10 min Removal of excess salt from the mixture is essential as this will interfere 
with cDNA synthesis and PCR The mixture was washed with 1 ml of EtOH/ml of 
trizol reagent The pellet was dislodged by inverting the eppendorf tubes several 
times Following centrifugation at 10,000 rpm for 5 min, the EtOH was removed and 
the pellet allowed to dry at 37°C for 10 min The final pellet was dissolved in 30 fil 
of ultrapure water at 4°C overnight
2 3 9 2 Reverse transcription o f mouse spleen mRNA
Reverse transcription was carried out by using a Promega PCR-related Reverse 
Transcription System cDNA was synthesised by using random hexamer primers 
(Promega) A mixture of MgCl2, 10X buffer, dNTP (dATP, dCTP, dGTP, dTTP 
mix) and ultrapure water was prepared The required volume of enzyme was added 
followed by the appropriate concentration of mRNA The reaction was incubated at 
room temperature for 10 min, 42°C for 2 h and then finally stored at -20°C
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2 3 9 2 1. Reverse transcription components for cDNA synthesis
Component Stock concentration Concentration in 20ul
MgCl2 25 mM 5 mM
10X Buffer 10X 1 X
dNTP mix 10 mM 1 mM
RNase Inhibitor 40 1 U/rxn
Random Primer 0 5 jag/jLil 0 2 fig/rxn
AMVRT 25 U/jml 15 U/rxn
Ultrapure water to 20 |il including RNA
RNA 7-10 jig/rxn
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2 3 9 3 Amplification of antibody light and heavy chain genes using polymerase 
chain reaction
2 3 9 3 1 PCR Primers
The listed PCR primers were obtained from Sigma-Genosys Ltd The primers were 
used for assembling mouse scFv fragments which are compatible with the pAK vector 
system as performed by Krebber et a l, 1997
Variable light chain back primers
LB 1 5'gccatggcggactacaaaGAY ATCCAGCTGACTCAGCC3'
LB2 5 'gccatggcggactacaaaGAY ATTGTTCTCWCCCAGTC3 '
LB3 5 'gccatggcggactacaaaGAY ATTGT GMTMACT C AGTC3 '
LB4 5 ' gccatggcggactacaaaGAY ATTGT GYTRAC AC AGTC3 '
LB5 5 'gccatggcggactacaaaGAY ATTGTRAT GACMC AGTC3 '
LB6 5 ' gccatggcggactacaaaGAYATTMAGATRAMCCAGTC3 '
LB7 5'gccatggcggactacaaaGAY ATTCAGATGAYDCAGTC3'
LB8 5'gccatggcggactacaaaGAY ATYCAGATGACACAGAC3'
LB9 5'gccatggcggactacaaaGAY ATTGTTCTCAWCC AGTC3 '
LB10 5'gccatggcggactacaaaGAYATTGWGCTSACCCAATC3'
LB 11 5'gccatggcggactacaaaGAY ATTSTRATGACCC ARTC3 '
LB12 5 ' gccatggcggactacaaaGAYRTTKTGATGACCC AR A C3 '
LB13 5'gccatggcggactacaaaGAY ATTGTGATGACBCAGKC3'
LB 14 5'gccatggcggactacaaaGAYATTGTGATAACYCAGGA3'
LB 15 5'gccatggcggactacaaaGAY ATTGTGATGACCCAGWT3'
LB 16 5 'gccatggcggactacaaaGAYATTGTGATGACACAACC3 '
LB 17 5'gccatggcggactacaaaGAYATTTTGCTGACTCAGTC3'
LB A. 5 'gccatggcggactacaaaGAJGCT GTTGTG ACTC AGG AATC3 '
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Variable light chain primers for
LF1 5'ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTGATTTCCAGCTTGG3' 
LF2 5'ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAGCTTGG3' 
LF4 5'ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAACTTTG3' 
LF5 5'ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTCAGCTCCAGCTTGG3' 
LFX. 5'ggagccgccgccgcc(agaaccaccaccacc)2ACCTAGGACAGTCAGTTTGG3'
Variable heavy chain back primers
HB 1 5'ggcggcggcggctccggtggtggtggatccGAKGTRMAGCTTCAGGAGTTC3' 
HB2 5 'ggcggcggcggctccggtggtggtggatccGAGGT BC AGCTBC AGC AGTC3' 
HB3 5 'ggcggcggcggctccggtggtggtggatccC AGGTGC AGCT G AAGS AST C3' 
HB4 5'ggcggcggcggctccggtggtggtggatccGAGGTCCARCTGCAACARTC3' 
HB5 5'ggcggcggcggctccggtggtggtggatccCAGGTYCAGCTBCAGCARTC3' 
HB6 5'ggcggcggcggctccggtggtggtggatccCAGGTYCARCTGCAGCAGTC3' 
HB7 5'ggcggcggcggctccggtggtggtggatccCAGGTCCACGTGAAGCAGTC3' 
HB8 5 'ggcggcggcggctccggtggtggtggatccGAGGT GAASST GGT GGAAT C3' 
HB9 5 'ggcggcggcggctccggtggtggtggatccGAVGTG A WGYT GGT GG AGT C3' 
HB 10 5'ggcggcggcggctccggtggtggtggatccGAGGTGCAGSKGGTGGAGTC3' 
HB 11 5 'ggcggcggcggctccggtggtggtggatccGAKGT GCAMCTGGTGGAGTC3' 
HB12 5'ggcggcggcggctccggtggtggtggatccGAGGTGAAGCTGATGGARTC3' 
HB 13 5 'ggcggcggcggctccggtggtggtggatccGAGGTGC ARCTTGTTGAGTC3'
HB 14 5 'ggcggcggcggctccggtggtggtggatccGARGTRAAGCTTCTCGAGTC3'
HB 15 5'ggcggcggcggctccggtggtggtggatccGAAGTGAARSTTGAGGAGTC3' 
HB16 5 'ggcggcggcggctccggtggtggtggatccCAGGTTACTCTRAAAGWGTSTG3' 
HB 17 5 'ggcggcggcggctccggtggtggtggatccC AGGTCC AACT VC AGC ARCC3'
HB 18 5 'ggcggcggcggctccggtggtggtggatccGATGTGAACTTGGAAGTGTC3' 
HB19 5 'ggcggcggcggctccggtggtggtggatccGAGGTGAAGGTCATCGAGTC3'
68
Variable heavy chain for primers
HF 1 5 'ggaattcggcccccgaggcCG AGG A A ACGGT GACCGT GGT3'
HF2 5' ggaattcggcccccgaggcCG AGG AG ACT GT G AG AGT GGT3'
HF3 5 'ggaattcggcccccgaggcCGC AG AG AC AGT G ACC AG AGT3'
HF4 5' ggaattcggcccccgaggcCG AGGAGACGGT GACTGAGGT3'
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2 3 9 3 2 Components o f PCR reaction fo r  amplification o f  antibody light and 
heavy chain genes
The concentration of stock primers varied However, 0 1 nmol concentration of the 
forward and reverse primers were used per reaction
Component Stock concentration Concentration in 50 ul
Forward Primers varied 0 1 nmol each primer/rxn
Reverse Primers varied 0 1 nmol each primer/rxn
10X Buffer 10 X 1 X
MgCl2 25 mM 1 0 mM
dNTP 20 mM 0 4 mM
Ultrapure water to 50 |il including Taq and DNA
cDNA 6-8 jiig of cDNA per 50 \x\ rxn
Taq polymerase 5 U/|il 5 U/rxn (multiplex)
2 3 9 3 3 PCR conditions for amplification o f antibody light and heavy chain 
genes
Typical thermal cycling conditions were as follows
94°C X 5 min ‘Hot-Start*
94°C X 1 min 
63°C X 30 sec 
58°C X 50 sec 
72°C X 1 min 
repeat X 7 cycles
94°C X 1 mm 
63°C X 30 sec 
72°C X 1 mm
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repeat X 24 cycles 
72°C X 10 nun
All ramping rates were at 4°C/sec 
2 3 9 4 Purification of PCR reaction products
PCR purification was performed using the Wizard PCR prep DNA purification kit 
(Promega) An Atto AE-6100 gel electrophoresis system was used The PCR 
product was run on a 0 5% (w/v) low melt agarose gel containing 0 5 |ig/ml 
ethidium bromide for 2 h at 50 V until the 400 base pair (bp) fragment was separated 
from the unincorporated primer The 400 bp fragment was cut from the gel with a 
sterile scalpel and the DNA purified from the low melt agarose as follows The 
sample was incubated at 70°C in a waterbath/heating block causing the agarose to 
melt within 5 min 1 ml of resin was immediately added and mixed thoroughly by 
pipetting for 15 sec For each PCR preparation a plunger from a 5 ml syringe was 
attached to a Wizard Mini column and the resin was slowly pushed through The 
column was then washed with 2 ml of 80% (v/v) isopropanol The column was 
centrifuged for 2 min at 14,000 rpm to remove any residual buffers The minicolumn 
was placed in a new 1 5 ml eppendorf tube and 20 |il of autoclaved ultrapure water 
was applied to the mimcolumn and allowed to incubate for 1 mm The column was 
centrifuged at 14,000 rpm for 20 sec to elute the DNA fragment and stored at -20°C 
until required
2 3 9 5 Quantification o f purified PCR products
After purification the fragments were re-electrophoresed on an agarose gel with a 
quantitative Molecular Weight Marker (Promega, 100 bp Molecular Weight 
Markers), as the concentration must be determined prior to splice by overlap 
extension PCR (SOE-PCR) The 500 bp fragment of this marker was used as a
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reference for densiometric quantitation as 5 \i\ contains 150 ng of the 500 bp 
fragment and 50 ng of the other molecular weight fragments
2 3 9 6 Components o f Splice by overlap extension (SOE) PCR
Gel purified light and heavy chains were joined and amplified together to produce a 
800 bp fragment using SOE PCR
2 3 9 6 1 PCR Primers 
SOE Primers
Single chain back 5'ttactcgcggcccagccggccatggcggactaccccG3'
Single chain forward 5'ggaattcggcccccgag3'
2 3 9 6 2 SOE PCR components for amplification o f joined antibody light and 
heavy chain genes
Component Stock concentration Concentration in 50 ul
10 X buffer 10X 1 X
MgCl2 25 mM 1 0 mM
dNTP 20 mM 0 4 mM
Ultrapure water to 50 |al including Taq, D N A  and scfor, scback
VH as detemined 10 ng/rxn
VL as detemined 10 ng/rxn
scfor varied 0 05 nmol /rxn
scback varied 0 05 nmol/rxn
Taq polymerase 5U/[i\ 5 U/rxn
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2 3 9 6 3 SOE PCR conditions fo r  amplification ofjoined antibody light and heavy 
chain genes
92°C X 1 min 
45°C X 50 min 
72°C X 1 min 
repeat X 5 cycles
Add 0 05 mM scfor and scback primers 
5 U Taq Polymerase/rxn
92°C X 1 min 
68°C X 30 sec 
72°C X 1 min 
repeat X 25 cycles
All ramping rates were at 4°C/sec
2 3 9  7 Preparation and purification o f pAKl 00 vector using Wizard numprep 
system
A single colony of Ecoh XL 1-Blue containing pAKlOO (all vectors were kindly 
donated by Andreas Pluckthun, University of Zurich, Switzerland) was picked off an 
agarose plate and grown overnight at 37°C with vigorous shaking in 5 ml of 2 x TY 
supplemented with 30 (ig/ml tetracycline Purification of the plasmid was carried out 
using the Wizard mimprep system as per the manufacturer’s instructions The culture 
was centrifuged at 4°C at 7,000 rpm for 5 mm The supernatant was discarded and 
the cells resuspended in 250 \i\ of cell resuspention solution (50 mM Tns-HCl, pH 
7 5, 10 mM EDTA, 100 |!g/ml RNase A) 250 |il of cell lysis solution (0 2 M NaOH, 
1% (w/v) SDS) was added and the mixture inverted three times A clear lysate was 
produced from this procedure 10 jul of alkaline phosphatase was added and the 
mixture inverted four times The mixture was then incubated at room temperature for
73
5 min 350 |ul of neutralisation solution (4 09 M guanidine hydrochloride, 0 759 M 
potassium acetate, 2 12 M glacial acetic acid, pH 4 2) was added, followed by 
inverting the mixture four times and centrifuging at 14,000 rpm for 10 min The clear 
lysate was transferred to a spin column and centrifuged at 14,000 rpm for 1 min at 
room temperature Supernatant from the column was discarded and the column was 
washed with 750 |ul of column wash solution (6 mM potassium acetate, 10 mM Tris- 
HC1, pH 7 5, 60% (v/v) ethanol) by centrifuging at 14,000 rpm for 1 min at room 
temperature The column wash step was repeated using 250 jil of column wash 
solution and centrifuging at 14,000 rpm for 2 mm 50 (il of autoclaved ultrapure 
water was placed in the column and allowed to incubate for 1 min Elution of the 
column was carried out by centrifugation at room temperature at 14,000 rpm for 1 
min The purified vector was stored at -20°C in ultrapure water
2 3 9 8 Digestion o f pAKlOO and antibody light and heavy chain genes SOE PCR 
products
Digestion of pAKlOO and SOE products was performed using Sfil restriction enzyme 
pAKlOO requires digestion with Sfil restriction enzyme prior to ligation with light 
and heavy chain genes Antibody light and heavy chain gene SOE products are also 
digested with Sfil as 4 bp are spliced off from either end
2 3 9 8 1. Components fo r  digestion ofpAKlOO and antibody light and heavy chain 
genes SOE PCR products
1 5 1^ reaction buffer
0 2 1^ BSA
2 U Sfil
30-50 ng/rxn VH/VL or 50-100 ng/rxn pAKlOO
Sterile ultrapure water was added to a final volume of 10 jil
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The mixture was incubated at 50°C overnight Purification of fragments was earned 
out using a Promega purification kit as described previously in section 2 3 9 4
2 3 9 9 Ligation o f antibody light and heavy chain genes into the pAKl 00 vector
Gel purified VL/VH genes were ligated into the pAKlOO plasmid vector using the 
following conditions
60 ng pAKlOO vector
40 ng of gel purified SOE light and heavy chain genes 
10 U ligase (Promega)
2 jjl of 5X reaction buffer
Sterile ultrapure water was added to give a final volume of 10 |ul
The concentrations of SOE VL/VH and pAKlOO digests were added at a ratio of 
15 1 The reaction mixture was incubated at 15°C overnight and then transformed 
into E coh XL 1-Blue supercompetent cells
2 3 9 10 Transformation o f E  coh XL 1-Blue supercompetent cells with pAKlOO 
vector containing light and heavy chain genes and measurement o f transformation 
efficiencies
Supercompetent E coh XLl-Blue (Stratagene) cells were thawed gently on ice Cells 
were gently mixed by hand and aliquotted into two 20 ml stenlin tubes (one tube was 
for the experimental transformation and the other tube was for the control 
transformation) 1 7 |xl of p-mer cap to ethanol was added to each of the two aliquots 
of bactena, giving a final concentration of 25 mM in each tube The contents of the 
tubes were stirred gently and incubated on ice for 10 min, swirling gently at 2 mm 
intervals 0 1-50 ng of vector, containing light and heavy chain genes was added to 
one of the tubes and swirled gently 1 \x\ of pUC18 control vector was added to the 
second tube and also swirled Both tubes were then incubated on ice for 30 mm
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Cells were heat-pulsed for 45 sec at 42°C followed by incubation on ice for 2 min 
0 9 ml of SOC medium, preincubated at 37°C, was then added and the tubes 
incubated at 37°C for 1 h with shaking at 225-250 rpm pAklOO transformants were 
plated out on LB agar supplemented with 25 jug/ml chloramphenicol and 1% (v/v) 
glucose Control transformants were plated out on LB agar supplemented with 20 
|Lig/ml of ampicillin Both sets of plates were allowed to grow overnight at 37°C 
pAKlOO transformed colonies were scraped off the plates and used as library stocks 
These stocks were suspended in 15% (v/v) glycerol and stored at -80°C
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2 3 10 Production of recombinant scFv antibodies to morphine-3-glucuronide 
2 3 10 1 Preparation o f phagemidparticles
50 ml of NE medium was mnoculated with 109 cells from the library glycerol stocks 
The culture was grown in a shaking incubator at 250 rpm at 37°C until the optical 
density at 550 had reached 0 5 AU 1011 VCSM13 helper phage (Stratagene) and 25 
|l| 1 of 1 M IPTG (isopropyl-p-D-thiogalactopyranoside) were added and after 
incubation at 37°C for 15 min without agitation, the culture was diluted with 100 ml 
of LE medium The culture was shaken (250 rpm) for 2 h at 26°C followed by 
addition of 30 (ig/ml of kanamycin The culture was then allowed to continue 
shaking at 26°C for a further 8 h Phage particle precipitation was then carried out 
using PEG/NaCl
2 3 10 2 PEG/NaCl precipitation o f recombinant scFv antibodies
150 ml of the E coh XLl-Blue culture containing phage particles was transferred to a 
Sorvall RC-5B centrifuge tube and centrifuged at 10,000 rpm for 10 min at 4°C The 
supernatant was collected and one fifth the volume of PEG/NaCl (20% (w/v) 
polyethylene glycol 6000, 2 5 M NaCl) was added, followed by incubation for 1 h at 
4°C The culture was centrifuged at 10,000 rpm for 30 min and the pellet 
resuspended in 40 ml of 4% (w/v) PEG/NaCl (4% (w/v) polyethylene glycol 6000, 
2 5 M NaCl) Following mixing, it was incubated at 4°C for 20 min After 
incubation, the mixture was centrifuged at 10,000 rpm for 20 min The supernatant 
was removed and the pellet re-centrifuged at 7,000 rpm for 10 mm at 4°C to allow 
removal of any remaining supernatant The pellet was resuspended in 2 ml of sterile 
PBS This was followed by micro-centrifugation at 4,000 rpm for 10 min at 4°C to 
remove any bacterial debris The phage supernatant was collected and stored (short 
term at 4°C, long term at -80°C in 15% (v/v) glycerol solution)
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2 3 10 3 Titre ofphage particles
4 ml of 2 x TY supplemented with 30 jag/ml tetracycline was inoculated with a single 
colony from an Ecoh  XLl-Blue stock plate and grown overnight at 37°C The 
culture was then diluted 1/100 in 100 ml o f 2 x TY supplemented with 30 jig/ml 
tetracycline, and allowed to grow at 37°C with shaking (250 rpm) until the optical 
density at 550 had reached 0 5 AU After incubation for 15 min at 37°C without 
agitation, serial dilutions o f phage particles (10 M o 9) were prepared using the E coh 
XLl-Blue exponentially growing bacterial culture (180 jul Ecoh  XLl-Blue with 20 
\x\ phage) The culture was incubated for 30 min at 37°C without agitation 100 jixl of 
each dilution was plated on TYE agar containing 25 (ig/ml chloramphenicol and 1% 
(v/v) glucose Colonies were allowed to grow overnight at 37°C The colony 
forming units were counted in order to calculate the titre o f the phage particles
2 310 4 Affinity selection o f scFv antibodies by panning
An immunotube (NUNC) was coated with 100 jig/ml o f conjugate in PBS and 
incubated overnight at 4°C The tube was washed five times with PBS containing
0 05% (v/v) Tween (PBST) followed by five washes with PBS 5% (w/v in PBS) 
marvel (blocking solution) was added to the immunotube and allowed to incubate for
1 h at 37°C After washing the immunotube (as before), 4 ml o f PBS containing 2% 
(w/v) marvel and 1011 o f phagemid particles was added and incubated for 2 h at room 
temperature with gentle shaking This was followed by washing the immunotube to 
remove any non-specifically bound phage Specifically bound phage particles were 
eluted from the immunotube by addition o f 800 \i\ of 0 1 M glycine/HCl, pH 2 2, for 
10 min with shaking Eluted phage particles were then neutralised using 48 |il o f 2 M 
Tns Determining the titre of this phage was carried out as described in section
2 3 10 3
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2 3 10 5 Preparation o f library stocks from panning
4 ml of 2 x TY supplemented with 30 jiig/ml tetracycline was inoculated with a single 
colony from an Ecoh  XL 1-Blue stock plate and grown overnight at 37°C The 
culture was then diluted 1/100 in 2 x TY supplemented with 30 jig/ml tetracycline, 
and allowed to grow at 37°C with shaking (250 rpm) until the optical density at 550 
had reached 0 5 AU After allowing the culture to incubate without agitation for 15 
min at 37°C, 1-2 ml of eluted phage from panning was then re-infected into this 
Ecoh  XL 1-Blue culture This culture was again incubated for 15 min at 37°C 
without agitation, followed by centrifugation at 4,000 rpm for 10 min at room 
temperature The supernatant was discarded and the pellet resuspended in 500 jul o f  
2 x TY medium The culture was plated on NE medium and grown overnight at 
37°C This was followed by scraping the colonies off the plates (using a glass 
spreader) and resuspending in 2 x TY medium The culture was centrifuged at 4,000 
rpm for 10 min, and the pellet resuspended in 3 ml of 2 x TY medium containing 
15% (v/v) glycerol This stock was then stored at -80°C until required for further 
use
2 3 10 6 Preparation o f clones for phage ELISA
Single colonies were selected from plates and used to inoculate individual wells o f a 
96 well cell culture plate containing 200 \i\ 2 x TY containing 1% (v/v) glucose, 25 
Hg/ml chloramphenicol and 30 |ig/ml tetracycline The plate was shaken at 150 rpm 
overnight at 37°C and used as a master plate to inoculate an identical plate 30 |xl o f  
60% (v/v) glycerol was added to each well o f the master plate and this was stored at 
-20°C The second plate was grown at 37°C for 6-8 h with shaking at 150 rpm in 
200 jul 2 x TY containing 1% (v/v) glucose, 25 jig/ml chloramphenicol and 30 \xgfml 
tetracycline After allowing the plate to incubate for 15 min at 37°C without 
agitation, 25 |il of 2 x TY containing 1% (v/v) glucose, 25 |ig/ml chloramphenicol, 
1 5 mM IPTG and 5 x 109 VCSM13 helper phage per ml was added to each well, and 
incubated at 37°C for 15 min followed by shaking at 150 rpm for 2 h at 26°C Plates
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were then centrifuged at 4,000 rpm for 10 min The supernatant was discarded, and 
the pellets resuspended in 200 jal 2 x TY containing 1% (v/v) glucose, 25 |ig/ml 
chloramphenicol, 1 5 mM IPTG and 30 |ig/ml kanamycin The plate was incubated 
overnight at 26°C and centrifuged at 4,000 rpm for 10 min 75 (til o f supernatant was 
used for analysis o f phage by ELISA
2 310 7 Phage ELISA
A microtitre plate (Nunc) was coated with 100 [d of 100 \xg/m\ of M3G-THY or 
M3G-OVA and incubated overnight at 4°C Plates were washed three times with 
PBST, three times with PBS, and blocked with 100 |il o f 2% (w/v) marvel in PBS for
1 h at 37°C 75 (il o f supernatant and 25 |il o f 4% (w/v) marvel in PBS were added to 
each well for 2 h at room temperature The plates were re-washed as before, and a 1 
in 500 dilution o f anti-M13 rabbit antibody was added followed by incubation for 1 h 
at 37°C This was followed by addition of a 1 in 5000 dilution of HRP-labelled goat 
anti-rabbit antibody and incubation for 1 h at 37°C Following washing, substrate 
was added as described in section 2 3 8 1 and incubated for 30 mm at 37°C 
Substrate reactions were stopped by addition o f 25 jal of 2 M H2SO4 per well 
Absorbance was read at 492 nm
2 3 10 8 Preparation ofphage particles fo r  non-competitive and competitive phage 
ELISA
5 ml o f NE medium was mnoculated with 5 jil o f positive clone from the master
plate This culture was allowed to grow overnight at 37°C in an incubator at 250 rpm
The culture was then diluted 1/100 in 5 ml o f NE medium, and allowed to grow at
37°C with shaking (250 rpm) until the optical density at 550 nm had reached 0 5 AU 
2 5 ml o f NE medium supplemented with 5 x 109 VCSM13 helper phage and 1 5 mM 
EPTG was added and the culture incubated at 26°C overnight The culture was then
centrifuged at 4,000 rpm for 10 mm and the supernatant removed
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2 3 10 8 1 Non-competitive phage ELISA for determination o f scFv antibody titre
Protein drug conjugates of appropriate type (M3G-THY, M3G-OVA) were coated 
onto a microtitre (Nunc) plate at a concentration of 100 |ig/ml and incubated 
overnight at 4°C Plates were washed three times with PBST, three times with PBS 
and blocked with 100 fil o f 2% (w/v) marvel in PBS for 1 h at 37°C Dilutions of  
phage-scFv antibody in PBS were added to the wells o f the plate and allowed to bind 
at 37°C for 1 5 h Again the plates were washed as before and a 1 in 500 dilution of 
anti-M13 rabbit antibody was added, followed by incubation for 1 h at 37°C This 
was followed by addition of a 1 in 5000 dilution o f HRP-labelled goat anti-rabbit 
antibody and incubation for 1 h at 37°C Following washing, substrate was added as 
described in section 2 3 8 1 and incubated for 30 min at 37°C Substrate reactions 
were stopped by addition of 25 jil o f 2 M H2S 0 4 per well Absorbance was read at 
492 nm
2 310 8 2 Competitive phage ELISA for scFv antibody clones
Competitive immunoassay was performed using culture supernatant as described in 
section 2 3 10 8 1 However, standards of free analyte were mixed with antibody and 
added to the wells following coating and blocking
2 3 10 9 Isolation o f light and heavy chain genes from  pAKlOO vector from  
positive clones
Positive clones were identified from the phage ELISA and 10 jal o f each clone was 
taken from the master plate and inoculated into 10 ml of NE medium and grown 
overnight at 37°C Glycerol was added to 5 ml o f this culture to give a final 
concentration of 15% (v/v) glycerol and stored at -80°C as stock cultures The 
remaining 5 ml containing the pAKlOO vector with light and heavy chain genes was 
purified with the Wizard mmiprep system as described in section 2 3 9 7 Purified 
pAKlOO vector was digested with Sfil digestion enzyme as described in section
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2 3 9 8, and the product was run on a 0 5% (w/v) low melt agarose gel, containing 0 5 
jig/ml ethidium bromide, for 2 h at 50 V until the 800 base pair (bp) fragment 
containing the light and heavy chain genes is well separated from the digested 
pAKlOO vector The 800 bp fragment was cut from the gel with a sterile scalpel and 
the DNA purified from the low melt agarose as described in section 2 3 9 4 The 800 
bp fragment containing the light and heavy chain genes was ready for ligation into the 
pAK400 vector
2 3 10 10 Ligation o f positive light and heavy chain genes into pAK400for soluble 
expression o f  scFv antibodies
Ligation of antibody light and heavy chain genes into pAK400 was carried out using 
the same protocol as described in section 2 3 9 9 for ligation with pAKlOO
2 3 10 11 Preparation o f calcium chlonde-competent JM83 bacterial cells
A single colony of JM83 (kindly donated by the Biotechnology Department technical 
staff in DCU) was inoculated into a 5 ml culture of NE medium containing 25 |ig/ml 
of streptomycin-sulphate, and grown overnight at 37°C with shaking (250 rpm) The 
culture was then diluted 1/100 in 100 ml of NE medium containing 25 |ig/ml of 
streptomycin-sulphate, and allowed to grow at 37°C with shaking (250 rpm) until the 
optical density at 550 nm had reached 0 5 AU The culture was then cooled on ice 
for 15 min followed by centrifugation at 2,000 rpm for 20 mm at 4°C Supernatant 
was decanted and the pellet resuspended in 20 ml o f cold 100 mM MgCh Cells were 
collected by centrifugation at 2,000 rpm for 20 mm at 4°C, and resuspended in 20 mis 
of cold 50 mM CaClj The cells were allowed to incubate on ice for 30 min and 
again centrifuged at 2,000 rpm for 20 min at 4°C The supernatant was discarded and 
the pellet resuspended in 2 ml o f 50 mM CaCh The culture was stored at -80°C 
until further use
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2 3 10 12 Transformation o f  JM83 calcium chloride competent cells with pAK400 
vector
JM83 calcium chloride competent cells were transformed with pAK400 as followed
JM83 culture 200 |il
pAK400 3 \x\
The mixture was allowed to sit on ice for 1 h followed by incubation for 2 min at 
42°C The mixture was immediately placed back on ice 0 7 ml o f NE medium was 
added and incubated for 1 h at 37°C with gentle shaking The culture was plated on 
NE agar and grown overnight at 37°C Single colonies were inoculated in 5 ml 
cultures of NE medium containing 25 \xg/m\ chloramphenicol and grown overnight at 
37°C, followed by addition of glycerol to give a final concentration of 15% (v/v) 
This stock was then stored at -80°C until required for further use
2 3 10 13 Soluble expression o f  scFv in pAK400
For soluble expression, 20 to 200 ml expression medium (EM) (2 x TY containing 25 
|j,g/ml chloramphenicol) was inoculated with 200 |jl\ to 2 ml o f preculture (JM83 
harbouring the expression vector for morphine-3-glucuromde), and allowed to grow 
at 37°C with shaking (250 rpm) until the optical density at 600 nm had reached 0 5 
AU 1 mM IPTG/ml was added and the culture allowed grow for 4 h at 24°C The 
culture was centrifuged at 4,000 rpm for 10 mm and the supernatant containing 
soluble scFv antibodies stored at 4°C
2 3 10 14 Concentration o f  culture supernatant
100 ml of supernatant containing soluble scFv antibodies from the relevant cell line 
was collected as described in section 2 3 10 13 Sodium azide was added to a final 
concentration of 0 05% (w/v) to the supernatants, which were then stored at 4°C until
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required The supernatant was concentrated 10-fold to a final volume of 10 ml, using 
a stirred ultrafiltration cell with a 76 mm diaflo ultrafilter membrane, which had a 
molecular weight cut-off of 10,000 daltons The resulting concentrate was stored at 
4°C until required
2 3 1015 Purification o f soluble scFv antibodies using ProBond™ Resin
A 5 ml ProBond™ Resin column was poured and equilibrated with 50 ml o f 20 mM 
phosphate buffer, pH 7 8, containing 500 mM NaCl (running buffer) 20 ml o f  
concentrated antibody supernatant was added to the column and the flow rate 
adjusted to 1 ml/min The sample which ran through was then re-applied to the 
column three times followed by washing the column with 20 ml of running buffer 
Affinity-captured scFv antibody was eluted with running buffer containing 300 mM 
imidazole 5 ml fractions were collected The optical density o f each fraction was 
recorded at 280 nm, and those fractions containing protein were pooled and dialysed 
overnight at 4°C against 5 L PBS, and sodium azide was added to a final 
concentration of 0 05% (v/v) The sample was aliquotted (0 5 ml fractions) and 
stored at -20°C The ProBond™ Resin column was stripped and recharged using the 
following procedure
The column was washed as follows
Twice with 8 ml 50 mM EDTA to strip away nickel ions,
Once with 16 ml 0 5 M NaOH to denature and dilute protein bound to the column, 
Once with 16 ml sterile distilled water
The column was recharged with 16 ml N1CI2 (5 mg/ml) and washed with 16 ml 
distilled water Finally the charged column was stored in 20% (v/v) ethanol until use
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2 3 10 16 General enzyme immunoassay protocol using soluble scFv antibodies
2 3 10 16 1 Non-competitive ELISA for determination o f soluble scFv antibody 
titre
Protein drug conjugates o f appropriate type (M3G-THY, M3G-OVA) were coated 
onto a microtitre (Nunc) plate at a concentration of 100 |ig/ml and incubated 
overnight at 4°C Plates were washed three times with PBST, three times with PBS 
and blocked with 100 |il of 2% (w/v) marvel in PBS for 1 h at 37°C Dilutions of 
soluble scFv antibody in PBS were added to the wells of the plate and allowed to bind 
at 37°C for 1 5 h The plates were washed, as before, and a 1 in 400 dilution of anti- 
FLAG rabbit antibody was added, followed by incubation for 1 h at 37°C This was 
followed by addition of a 1 in 5000 dilution of HRP-labelled goat anti-rabbit antibody 
and incubation for 1 h at 37°C Following washing, substrate was added as described 
in section 2 3 8 1 and incubated for 30 mm at 37°C Substrate reactions were stopped 
by addition of 25 jil o f 2 M H2SO4 per well Absorbance was read at 492 nm
2 3 10 16.2. Competitive ELISA fo r  soluble scFv antibody clones
Competitive immunoassay was performed using the supernatant as described in 
section 2 3 10 16 1 However, standards o f free analyte were mixed with antibody 
and added to the wells following coating and blocking
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2 3 11. BIAcore studies
CM5 research grade sensor chips were used in all experiments Running buffer for all 
BIAcore experiments was HBS buffer, pH 7 4, containing 10 mM HEPES, 150 mM 
NaCl, 3 4 M EDTA, and 0 05% (v/v) Tween 20 The running buffer was filtered (pore 
size o f 0 22 jim) and degassed using a millipore filtration apparatus (millipore sintered 
glass filtration unit) immediately before use
2 3 111 Preconcentration studies
For all investigations, proteins were immobilised on the sensor surface by means of N- 
hydroxysuccinimide estenfication The standard conditions used lead to activation of 
30-40% of the carboxyl groups on the dextran Primary amine groups present allow 
covalent attachment of biomolecules It is necessary to carry out an initial 
"preconcentration" step, resulting from electrostatic binding of protonated amine 
groups on the biological component to negatively-charged carboxyl groups on the chip 
surface, to take place
Preconcentration for the native form of a protein can be facilitated by adjusting the pH 
below the isolectnc point (pi) However, modification via conjugation of drug 
molecules to proteins often radically alters the pi Therefore, when dealing with 
modified proteins, the correct pH for preconcentration has to be determined 
experimentally Protein solutions were prepared in 10 mM sodium acetate at a range of 
different pHs These solutions were passed over an undenvatised chip surface, and the 
degree o f electrostatic binding was monitored The highest pH at which satisfactory 
preconcentration was observed was chosen as the pH for immobilisation, since using a 
buffer below pH 4 0, inhibits the activity o f N-hydroxysuccmimide estenfication
2 3 112 Immobilisation o f interactants
The carboxymethylated dextran matrix was activated by mixing equal volumes of 
100 mM NHS (N-hydroxysuccmimide) and 400 mM EDC (N-ethyl-N-(dimethyl-
86
aminopropyl) carbodnmide hydrochloride), and injecting the mixture over the sensor 
chip surface for 7 min at a flowrate o f 5 1^ min The conjugate or analyte to be 
immobilised was diluted in 10 mM sodium acetate at the appropriate pH, and at a 
typical concentration of 50-200 fag/ml This solution was then injected over the 
denvatised chip surface for 20 mm Unreacted NHS groups were capped, and non- 
covalently bound protein removed, by injection o f 1 M ethanolamine hydrochloride, 
pH 8 5, for 7 min
2 3 113 Direct immobilisation o f parathion onto chip surface
Immobilisation of parathion directly onto the chip surface was performed outside the 
BIAcore instrument The chip was first allowed to equilibrate to room temperature 
The chip was primed for direct immobilisation by addition of 40 pil o f HBS buffer to 
the sensor chip well and allowing the chip to incubate for 5 mm at room temperature 
This solution was then removed using lint-free adsorbent paper, taking great care to 
ensure the paper did not touch the dextran matrix Equal volumes of 0 4 M EDC and 
0 1 M NHS were then mixed, and 40 (il o f the resulting solution, containing 0 05 M 
NHS and 0 2 M EDC in ultrapure water, was added to the chip well and incubated for 
15 min at room temperature The solution of EDC/NHS was then removed using 
adsorbent paper and parathion, at a concentration of 100 (ig/ml in 10 mM sodium 
acetate buffer, pH 5 5, was added to the chip well and allowed to incubate for 20 min 
The chip was then blocked by adding 40 (il o f 1 0 M ethanolamine, pH 8 5, to the chip 
well and incubating for 20 min The chip was then washed extensively with distilled 
water and dried over nitrogen The chip was stored in HBS buffer at 4°C or in a 
desiccator at room temperature until required
2 3 114 Regeneration studies
To assess the stability o f the immobilised drug-protein conjugate surfaces, a known 
concentration of antibody was passed over the chip surface, and the surface 
regenerated by passing over various concentrations of NaOH and HC1 ranging from
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1-100 mM or 1 M ethanolamine, pH 13 6 This cycle o f binding and regeneration 
was usually completed for greater than 50 cycles, and the binding signal measured to 
assess the stability and suitability o f the immobilised surface for assay purposes
2 3 115 Universal standard curve
Conjugates were immobilised as described in section 2 3 112 Serial dilutions of 
purified antibody were passed over the surface of the chip under conditions o f mass 
transport limitation (MTL) The rate o f antibody binding (dR/dT) was calculated 
from the slope of the binding curve, and plotted against the logarithm of the 
reciprocal o f the antibody dilution factor used The concentration of antibody (nM) 
in both solutions was calculated from the curve and algorithm
2 3 116 Non-specific binding studies
Purified polyclonal and scFv antibody solutions at the requisite dilution were passed 
over a dextran surface and a surface with the protein o f interest immobilised on the 
dextran matrix Non-specific binding to either dextran or immobilised protein surface 
was titred out by the addition of either molecule to the antibody solution, causing 
these non-specific antibodies to bind to either protein or dextran in solution
2 3 117 BIAcore inhibitive immunoassay
Standards o f free analyte (morphine-3-glucuronide, parathion, and cephalexin) were 
prepared at varying concentration ranges All further additions of reagents and 
incubation steps were automated Each sample was incubated with an equal volume 
of antibody, and allowed to equilibrate for a specific time interval (10 min) when 
automated, or manually for 2 h at room temperature, and then passed over the sensor 
surface The equilibrated mixtures were passed sequentially, in random order, over 
the chip surface, and the chip surface regenerated between cycles by pulses of the 
appropriate regeneration solution for each antibody type A calibration curve was
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constructed by plotting the change in response (RU) for each standard against the log of 
concentration, and sample concentrations were determined from this curve 
The intra-day variability of the assay was investigated by running a set of standards 
across the linear range three times in one day, and determining the coefficient of  
variation (CV) between the calculated concentrations for each
The inter-day variability o f the assay was assessed by running standards across the 
linear range on three different days, and determining the CV’s between concentrations 
for the standards from each of the three standard curves
2 3.11 8 Solution affinity analysis using BIAcore
Drug-protein conjugates were immobilised using conventional EDC/NHS coupling 
chemistry Purified anti-M3G scFv antibodies of known concentration were passed 
over the immobilised surface, and a calibration curve was constructed o f mass bound 
measured in terms of response units, versus antibody concentration (nM) Varying 
concentrations of M3G were incubated with a known concentration of scFv antibody 
and allowed to reach equilibrium overnight The samples were then passed over the 
immobilised surface and the binding response calculated The amount o f free 
antibody in the equilibrium mixtures was calculated using the response values 
measured from the constructed calibration curve Free antibody concentration (nM) 
was then plotted against drug concentration (nM), and using the solution phase 
interaction models in BIAevaluation 3 1 software, the overall affinity constant could 
be determined
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Production and Characterisation of Polyclonal Antibodies to
Morphine-3-glucuronide
Chapter 3
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3 1 Introduction
3 11 The Opiates
Opium is a naturally occurring substance, which can be obtained from the opium 
poppy, Papaver sommferum (Julian et a l , 1981) The name opium is derived from 
the Greek name for the dried latex (juice) extracted from the unripe capsules o f the 
opium poppy The mam active ingredient o f opium is morphine, which possesses 
analgesic properties Opioids are compounds that have morphine-like 
pharmacological activity but are not necessarily structurally related (Jaffe et a l , 
1990)
Opiates are those drugs that are structurally related to morphine (either natural or 
synthetic) and which exert actions upon the body similar to those induced by 
morphine They are used in the relief o f pain, and possess a wide variety of 
pharmacological effects and differing potency for the production of analgesia, 
sedation, respiratory depression, decreased gut motility and cough suppression (Jaffe 
et a l , 1990) The earliest writings o f the effects o f opium are dated back to 300 B C 
However, some references to opiates date back as far as 3000 B C The medicinal 
use of opium to relieve pain is well known and was extensively used for this and 
recreational purposes in Europe throughout the sixteenth and seventeenth centunes 
Opium contains at least 20 different compounds and in the early 1800’s Sertumer, a 
German pharmacist isolated morphine, which is the main active ingredient in opium 
Opium and morphine were sometimes referred to as ‘GOM’, “God’s Own Medicine” 
and were used for a wide variety o f problems i e alcoholism, asthma, dysentery and 
were also used to treat such problems as the simple cough Opium contains over 20 
alkaloids, o f which the most abundant is morphine (10-15%) followed by codeine (1- 
3%), thebaine (1-2%), noscapine (4-8%) and papaverine (1-3%) (Perrine et al ,1996) 
However, only morphine and codeine have analgesic properties Thebaine has a 
chemical structure quite similar to morphine, however, unlike morphine, it exhibits 
no analgesic effects and it causes ‘strychnine-like’ convulsions By the early part of 
the twentieth century, 1 in 400 Americans was addicted to morphine or opium
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derivatives For this reason, there was concern about the possible harmful effects and 
the addictive nature o f both morphine and other opiates This concern sparked the 
government into action and in 1914 the Harrison Narcotic Act was passed The 
conditions o f this act made the use o f opiate drugs illegal except for medical 
applications
3 12 Morphine, Heroin and Morphine-3-Glucuronide
As already stated, morphine (Figure 3 1 ) is the main active ingredient o f opium 
associated with pain relief It was first isolated in pure form in the early 19th century 
by Sertumer (Perrine et a l , 1996) Once isolated, morphine became a widely used 
drug in the United Stated as it became freely available and accessible from both drug 
and general stores Morphine became commonly used for both medicinal and 
recreational purposes, until 1914 when the Harrison Narcotic Act was passed (Julian 
e t a l , 1981) making non-medical uses o f morphine illegal
Figure 3 1 Structure of morphine.
Morphine is still used today in modern medical practice It is a potent opioid 
analgesic used traditionally for the short-term treatment o f surgical pain and for the 
long-term treatment of moderate-to-severe cancer pain Euphoria is experienced 
when morphine is administered This is an important component o f its analgesic
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effect as anxiety and agitation are greatly reduced, which are associated with a 
painful illness It can be administered intravenously or orally Oral administration is 
much less potent because o f rapid metabolism in the intestinal wall and liver This 
resulted in intravenous administration becoming the preferred route of entry as its 
effects began within an hour (Rang et a l , 1995) The most important effects of 
morphine are on the central nervous system and the gastrointestinal tract, although 
other systems have been affected to a lesser extent Constipation can be caused by 
reduced gastrointestinal motility and is a common side effect of morphine, which can 
be very severe Respiratory depression, suppression o f cough, nausea and vomiting 
and histamine release, causing bronchoconstnction and hypotension are also lesser 
pharmacological effects o f morphine (Rang et a l , 1995)
Heinrich Dreser and Felix Hoffman o f  the Friedrich Bayer laboratories first 
introduced heroin (Figure 3 2 ) in the late 1890’s Heroin is not a naturally occurring 
opiate It is a semi-synthetic opioid Both Dresner and Hoffman believed that by 
forming the acetyl ester of a naturally occurring substance (l e morphine), the 
pharmacological profile would be increased Acetylation was carried out twice on 
morphine to produce heroin (diacetylmorphine) Heroin is just over 3 times more 
potent than morphine as an analgesic l e it takes three milligrams o f heroin to 
produce the same analgesic effects as 10 milligrams o f morphine Absorption occurs 
more rapidly from the gastrointestinal tract and enters the brain faster than morphine 
Although most o f heroin’s effects are due to it being metabolised into morphine, it is 
more lipophilic and reaches the brain faster (Braithwaite et a l , 1995)
Figure 3 2 Structure of heroin
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This difference provides greater euphoric effects than morphine The majority of 
scientific studies have been carried out on morphine, due to heroin’s rapid 
transformation into morphine once present in the body Once this occurs the 
pharmacological sequence is the same for both
Morphine-3-glucuromde (Figure 3 3 ) is the mam metabolite formed in the body for 
both morphine and heroin (Figure 3 4 )  (Moffat et a l , 1986, Coyle et a l , 1987, 
Gough et a l , 1991) This characteristic o f morphine-3-glucuromde is o f great 
significance for the indirect determination of heroin or morphine usage
Figure 3 3 Structure of morphine-3-glucuromde.
3 13 Metabolism
Heroin is rapidly hydrolysed to 6-monoacetylmorphine (6-MAM) which, is 
hydrolysed to morphine following intravenous administration into humans (Goodman 
& Gilman, 1991) Results have shown this reaction to occur as rapidly as 5 min and 
high levels are found in the heart, forebrain, lungs and liver However, once heroin is 
metabolised into morphine it follows the same path of metabolism as morphine in the 
system
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HO
Diacetyl morphine (Heroin) 6-Monoacetyl morphine
HO
Morphine
Figure 3 4 Metabolic pathway of heroin Once it is metabolised to morphine, it follows the 
same pathway as in Figure 3 5
Morphine’s main effects are exerted primarily on the central nervous system, the eye, 
and the gastrointestinal tract In the case of continuous morphine use or poisoning, 
the common symptoms associated are sedation, decreased respiration rate, severe 
constipation and pinpoint pupils (Rang et a l , 1995) On administration morphine is 
quickly absorbed from the gastrointestinal tract However, due to the high first-pass 
elimination on passage through the liver, only 40% o f the drug remains present 
(Stanski et a l , 1978, Sarve et al  ^ 1981, Sawe et a l , 1986) Morphine is metabolised
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(Figure 3 5 ) by conjugation with glucuronic acid at both the 3-phenolic and 6-
alcoholic positions for excretion purposes
HO
C O O H
O
HO
H O .
Morphine-6-glucuromde Morphme-3~glucuronide
Figure 3 5 Metabolic pathway of morphine showing the production of the mam 
metabolites, morphine-3-glucuromdey morphine-6-glucuronide and normorphine.
These metabolites are known as morphine-3-glucuronide (M3G) (60%) and 
morphine-6-glucuromde (M6G) (10%) (Yoshimura et a l , 1969, Oguri et a l , 1970, 
Yeh et a l , 1979, Gong et a l , 1991, Faura et a l , 1996)) Normorphine (N), 
normorphine-glucuromde and morphine-3,6-diglucuronide are also formed in small 
quantities (Boemer and Delle, 1975, Yeh, 1975) Glucuromdation mainly occurs in 
the liver while the intestine and kidneys also possess the same ability to a lesser 
extent (Brunk et a l , 1974, Boemer et a l , 1975) Codeine is also metabolised in 
minor quantities M6G possesses significant biological activity, the most significant 
being its greater analgesic potency than morphine (Pasternak et a l, 1987, Abbott et 
a l , 1988, Osborne et a l , 1988, Frances et a l , 1992, Stain et a l , 1995) This 
discovery suggested the metabolites themselves perhaps contained the majority o f the 
analgesic properties rather than morphine Results also showed M3G to have no 
analgesic effects (Shimomura et a l , 1971) Smith et al (1990) suggested that rather 
than acting as an agonist, M3G is, in fact, an antagonist and that it may be involved in 
the development of tolerance to and dependence on morphine
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3 14  Detection of Opiates
The Misuse of Drugs Act (1971) renders the possession and use o f opiates illegal for 
non-medical purposes This creates a need for sensitive methods o f detection and 
identification of individual opiates Problems can arise in the detection of individual 
opiates as a number possess very similar characteristics and follow the same 
metabolic pathways Detection methods for opiates have traditionally been based on 
thin-layer chromatography (TLC), gas chromatography (GC), high performance 
liquid chromatography (HPLC) and capillary electrophoresis (CE)
Low et al (1995) developed an assay system using HPLC for detection of opiates and 
heroin in urine A 200 x 2 mm I D , 3 jam silica column with dichloromethane- 
pentane-diethylamine-methanol mobile phase was used The detection limits were 
found to be quite low and ranged from 4 to 20 ng/ml
Gerostamoulos et al (1995) also used HPLC for detection of morphine and it’s 
metabolites Reverse phase lon-pair chromatography was used to achieve separation 
with a Cig bonded column Acetomtnle, lauryl sulphate and sodium dihydrogen 
orthophosphate buffer at low pH was used as the mobile phase and electrochemical 
detection (ECD) in conjugation with ultraviolet (UV) spectrophotometric detection 
was used for quantification of the drugs This assay had a detection range of between 
10 and 5,000 ng/ml
Zheng et al (1998) reported on a high-performance liquid chromatography tandem 
mass spectrometry-mass spectrometry (LC-MS-MS) assay for the analysis of  
morphine, morphine glucuromdes and normorphine in plasma samples from rats 
Extraction of the analytes was carried out by using C2 solid-phase extraction 
cartridges Recoveries were found to range from 100% for morphine, 84% for 
morphine-3-glucuromde, 64% for morphine-6-glucuromde and 88% for normorphine 
The limits o f detection were 3 8 ng/ml for morphine, 5 5 ng/ml for morphine-3 - 
glucuromde, 12 ng/ml for morphine-6-glucuronide and 5 0 ng/ml for normorphine 
Beike et al (1999) developed an immunoaffinity-based extraction method for the 
determination of morphine and it’s glucuromdes in human blood Specific antisera 
against morphine, morphine-3-glucuromde and morphine-6-glucuronide were
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coupled to 1,1-carbonyldnmidazole-activated tris-acrylgel and used for 
immunoaffinity extraction of morphine and its glucuromdes from blood The 
resulting extracts were analysed by HPLC with native fluorescence detection Mean 
recoveries from spiked blood were 71, 76 and 88% for morphine, morphine-3- 
glucuromde and morphine-6-glucuromde, respectively, and the limit o f detection was 
3 ng/g blood and the limit o f quantitation was 10 ng/g blood for all three analytes 
Meng et al (2000) developed a method of analysis with increased sensitivity and 
specificity for morphine and its metabolites by using a cleaner extraction method 
The extraction method involves both the hydrophobic isolation on a carbon cartridge 
and ion-exchange isolation on ion-exchange resin The combination of these two 
steps results in the successful purification of these drugs from human plasma with 
maximum removal of interfering substances compared with a conventional Ci8 
cartridge The analytes were quantified by HPLC on a reverse-phase Ci8 column 
employing a mobile phase consisting o f 25% (v/v) acetonitrile in 0 05 M phosphate 
buffer, and 2 5 mM sodium dodecyl sulphate as the pairing ion with a combination of 
electrical and fluorometnc detection Recoveries for morphine, morphine-3 - 
glucuronide, morphine-6-glucuromde and hydromorphone after the SPE procedure 
were 86±7 1, 82±6 9, 79±6 0 and 85±6 0%, respectively Limits o f detection for this 
method are 0 1 ng/ml for morphine and 0 18 ng/ml for morphine-3-glucuronide and 
morphine-6-glucuromde and limits of quantitation are 0 25 ng/ml for morphine and 
0 45 ng/ml for morphine-3-glucuromde and morphine-6-glucuromde 
As described above there are a large number of HPLC techniques for the detection of 
opiates in biological fluids However, HPLC techniques are not extensively used in 
routine clinical laboratones for either initial screening or for the confirmation of 
samples found positive by other detection techniques (Braithwaite et a l , 1995) The 
lack of application of HPLC in clinical settings is due to the expense of the technique, 
the extraction requirement, the relatively slow analysis time and the expertise 
required for operation
The combination of gas chromatography with mass spectrometry can also be used in 
the identification of individual opiates Selected ion monitoring (SIM) provides 
sufficient sensitivity for the confirmation of immunoassay results down to the
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threshold concentrations o f 300 |ig/l (Braithwaite et a l , 1995) Mule et al (1988) 
and Cone et al (1990) both used this configuration in the identification o f 6- 
monoacetylmorphine in urine as direct evidence of heroin usage 
Naidong et a l (1999) developed a simultaneous assay for morphine, morphine-3- 
glucuromde and morphine-6-glucuronide in human plasma using normal-phase liquid 
chromatography-tandem mass spectrometry with a silica column and an aqueous 
organic mobile phase Detection ranges were 0 5-50 ng/ml for morphine, 1 0-100 
ng/ml for morphine-6-glucuromde and 10-1000 ng/ml for morphine-3-glucuromde 
In the past, the GC-MS systems were slow and expensive to operate, however, recent 
developments in the production of bench-top systems has left such systems within the 
budget o f many smaller laboratories
However, these analytical methods require many clean up steps, are very time 
consuming and may be expensive Over the years, antibody-based methods have been 
developed as favourable alternatives for either the identification or quantification of 
opiates Immunoassays have been developed and are sold commercially One well 
known system is the enzyme multiplied immunoassay technique (EMIT) (Gough, 
1991, McCIeave, 1992, Wu et a l , 1993) In this system the activity o f the conjugated 
enzyme is modulated by their interaction of the drug-specific antibody with the 
haptenated enzyme The presence of free drug causes a decrease in the modulation, 
which indicates the presence of an illicit drug
Spector et al (1971) developed a radioimmunoassay (RIA) for the quantification of 
morphine using anti-morphine antibodies The sensitivity o f the assay in serum was 
found to be between 50 to 100 pg of morphine, which provides very good 
detectability Affinity-purified morphine antibody was used to develop a solid phase 
radioimmunoassay by Steiner et al (1978) which produced a sensitive assay with 
detection limits for morphine of 500 ng/1 of serum Radioimmunoassays possess a 
number of advantages and disadvantages There is minimal cross reactivity to 
morphine metabolites or closely related opiates when using RIAs This technique is 
extremely sensitive and provides positive results for use o f heroin, morphine or 
codeine (as codeine is metabolised into morphine) As codeine is available for 
general medical use, these assays may not be used as preliminary screening assays for
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opiate abuse, they are more applicable to pharmacokinetic studies of morphine 
(Braithwaite et a l , 1995)
An enzyme-linked immunosorbent assay (ELISA) was developed by Usagawa et al 
(1993) to detect morphine using a morphine-specific monoclonal antibody 
Concentrations as low as 100 pg/ml o f morphine were detected using this assay This 
assay showed the ability o f the morphine monoclonal antibody to detect very low 
levels o f morphine confirming the usefulness of such assays for the detection of 
opiates
In 1995 Holt et al developed an amperometnc system for the detection of opiates 
This system used two microbial enzymes, acetylmorphine carboxyesterase (heroin 
esterase) and morphine dehydrogenase (MDH) They were incorporated into an 
amperometnc assay for morphine and heroin using phenazine methosulphate as a 
mediator The limits of detection for morphine were found to be 6 8 |ig/ml Holt et 
al (1996) also developed a bioluminescence assay for heroin and its metabolites 
This involved using heroin esterase, morphine dehydrogenase, and the bacterial 
luciferase Detection levels were found to be between 89 ng/ml of heroin and 2 0 
ng/ml o f morphine
The development o f enzyme-linked immunosorbent assays for the detection of 
morphine-3-glucuromde (M3G) (the main metabolite of heroin and morphine) is 
described in this chapter as very little work was reported in the literature for detection 
of M3G using such assays Two polyclonal antibodies were produced and used in the 
development of model ELISA assays to measure M3G in PBS Analytical studies 
were carried out on the precision and reproducibility of the assays The 
immunoassays were subsequently used in the analysis o f free M3G in urine
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3 2 Results
3 2 1 Production and characterisation of morphme-3-glucuronide protein 
conjugates
Conjugates to M3 G were prepared using carbodumide coupling chemistry as 
described in section 2 3 2 1 Characterisation of conjugates was indirectly carried out 
by immunisation followed by the characterisation o f the specific antibody produced 
in serum BALB/c mice were immunised (section 2 3 3 2 )  with hapten-protein- 
conjugates to elicit an immune response followed by removal o f blood 10 day’s after 
immunisation Detection of specific antibody in serum was carried out by use of 
ELISA (Figure 1 12) as described in section 2 3 8 1 Initially, M3G-BSA was coated 
on a microtitre plate followed by the addition of serial dilutions of serum ranging 
from 1/250 to 1/256,000 taken from two mice immunised with M3G-BSA to monitor 
specific antibody produced The absorbance readings obtained at each antibody 
dilution (A) was divided by the absorbance reading determined in the presence of 
zero antibody (Ao), to give a normalised reading Results indicated that antibodies 
were produced to the hapten-protein-conjugate as shown in Figure 3 6 However, a 
competition assay was carried out using these antibodies to determine the specificity 
of the antibodies to M3 G and not the carrier-protein
A competition ELISA was carried out as shown in Figure 111 and described in 
section 2 3 8 2 Standards of free M3G were prepared m PBS containing 0 5 mM 
HC1 between the ranges of 97 and 100,000 ng/ml and added to the wells o f the plate 
with a l l  ratio of antibody at a 1/8,000 dilution (antibody dilution factor determined 
from Figure 3 6) The absorbance readings at each antigen concentration (A) was 
divided by the absorbance reading determined in the presence o f zero antigen 
concentration (Ao), to give a normalised reading Results indicated that as the 
concentration of M3G increased in solution, the absorbance readings decreased 
confirming that free drug displaces antibody (Figure 3 7) The presence o f specific 
antibodies to M3G in serum indicated the successful coupling of M3G to protein 
Further M3 G conjugates were produced and characterised using the same method
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1/Antibody dilution
Figure 3.6. Analysis o f serum from mice immunised with M3G-BSA conjugate by ELISA. 
Serum was taken 10 days after immunisation from two mice immunised with M3G-BSA. 
Serial dilutions of serum from 1/250 to 1/256,000 were added to wells coated with M3G- 
BSA. A high response was found to the M3G-BSA conjugate. The optimal antibody 
dilution for a competitive ELISA taken as 50% of the maximum absorbance was found to 
be 1/8000.
Log of M3G concentration (ng/ml)
Figure 3.7. Results from a competitive ELISA using serum taken from mice immunised 
with M3G-BSA. Standards of free M3G were prepared and added in a ratio of 1:1 with a 
1/8000 dilution of antibody to the wells o f a microtitre plate coated with M3G-BSA. As free 
drug concentration increases, the absorbance signal decreases indicating the displacement 
of antibody by M3G and confirming the presence of antibodies specific to M3G.
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3 2 2 Production and characterisation of polyclonal anti-morphme-3- 
glucuronide antibodies
Polyclonal antibodies to M3G were produced, purified by saturated ammonium 
sulphate precipitation and protein G affinity chromatography The antibodies purity 
was assessed with the use o f SDS-PAGE gel electrophoresis, and the working 
dilution of the antibodies for competitive assay analysis was optimised
3 2 21 Determination of titre
New Zealand White female rabbits were immunised with hapten-protein-conjugates 
to M3G as described in section 2 3 5 2 Analysis of the antibody titre was carried out 
using the ELISA as described in section 2 3 8 1 Serial dilutions o f serum samples 
from both rabbits were prepared at ranges between 1/250 and 1/256,000 and these 
added to a microtitre plate coated with 100 |ig/ml o f M3G-BSA, followed by labelled 
anti-rabbit antibody and subsequently, chromogemc substrate The resulting titres 
were greater than 1/256,000 following immunisation and are shown in Figure 3 8 for 
both rabbit-1 (R -l) and rabbit-2 (R-2) antibodies
3 2 2 2 Purification of polyclonal antiserum
The serum was prepared as described in section 2 3 6 1 Initial purification was 
carried out on the rabbit serum by saturated ammonium sulphate precipitation, as 
described m section 2 3 7 2 Protein G affinity chromatography (section 2 3 7 3) was 
then carried out to further purify the antibodies Partially purified saturated 
ammonium sulphate precipitated-antibody was passed through the column allowing 
IgG to bind to protein G After extensive washing o f the column to remove non- 
specifically bound antibodies the M3G antibodies were eluted with glycine buffer, pH 
2 2 (Figure 3 9) Eluted fractions were collected and protein concentration monitored 
by spectrophotometnc analysis with absorbance readings at 280 nm Results 
indicated that the majority of antibody eluted within the first six to seven fractions
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These fractions were pooled and dialysed into PBS buffer The titre o f the affinity- 
purified antibody was determined using an ELISA as described in section 2 3 8 1 and 
showed a specific antibody titre o f greater than 1/500,000 for R-l and 1/1,000,000 for 
R-2
3 2 2 3 Characterisation of purified antibody by SD S-PAGE
The purity o f both R-l and R-2 antibodies were analysed by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) as described in section 2 3 7 6 and 
the gels are shown in Figures 3 10 and 3 11, respectively SDS-PAGE is a technique 
which separates proteins on the basis o f their molecular weight The samples and 
molecular weight markers were boiled with mercaptoethanol causing the polypeptide 
chains o f the immunoglobulin to separate The gel pictures show the affinity-purified 
anti-M3G antibodies (lane 4 on both Figures 3 10 and 3 11) with a molecular weight 
band at approximately 50 kDa which represents the heavy chain of the 
immunoglobulins
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1/Antibody dilution
Figure 3.8. Plot showing the antibody titres of R-l and R-2 serum. Serial dilutions of 
serum were added to wells coated with M3G-BSA. At a dilution of 1/256,000 a high 
response from both serum samples is present.
Fraction number
Figure 3.9. A typical elution profile for polyclonal anti-M3G R-l and R-2 antibodies from 
a protein-G-sepharose column. Saturated ammonium sulphate purified antibody was 
passed down the column. The column was washed and the bound antibody eluted with 0.1 
M  glycine/HCl, pH 2.2. 0.5 ml fractions were collected, and the protein concentration was 
measured by absorbance at 280 nm. The majority of antibodies for both purification’s 
eluted during the first seven fractions.
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180 kDa
116 kDa 
64 kDa 
58 kDa
48.5 kDa
36.5 kDa
26.6 kDa
1 2 3 4 5
Figure 3.10I SDS-PAGE gel of R-l affinity-purified anti-M3G antibody on a protein-G- 
sepharose column. Lanes 1 and 5 contain molecular weight markers ranging from 26.6 to 
180 kDa. Lane 2 represents unpurified R-l anti-M3G antibody rabbit serum. Lane 3 
represents rabbit antiserum purified by saturated ammonium sulphate precipitation 
followed by lane 4 representing affinity-purified saturated ammonium sulphate
precipitated antibody on a protein-G-sepharose column.
1 2 3 4 5
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Figure 3.11. SDS-PAGE gel of R-2 affinity-purified anti-M3G antibody on a protein-G- 
sepharose column. Lanes 1 and 5 contain molecular weight markers ranging from 26.6 to 
180 kDa. Lane 2 represents unpurified R-2 anti-M3G antibody rabbit serum. Lane 3 
represents rabbit antiserum purified by saturated ammonium sulphate precipitation 
followed by lane 4 representing affinity-purified saturated ammonium sulphate
precipitated antibody on a protein-G-sepharose column.
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3 2 3 Development of a competitive enzyme-linked immunosorbent assay 
(E L IS A ) for morphine-3-glucuronide
Competitive ELISA’s were developed for the detection of free M3G in solution using 
the affinity-purified polyclonal antibodies
3 2 3 1 Checkerboard E L IS A  for determination of optimal loading ratios of 
conjugate and optimal antibody dilution for R-l and R-2 anti-morphine-3- 
glucuronide polyclonal antibodies
The working dilution of these antibodies was determined using the format already 
discussed in section 2 3 8 1 M3G-OVA was coated on the wells o f a microtitre plate 
at varying concentrations from 50 to 1 56 |ig/ml Dilutions o f M3G affinity-purified 
antibody were prepared at ranges from 1/500 to 1/512,000 for R1 and 1/500 to 
1/100,000 for R2 and each dilution of antibody was added to each concentration of 
conjugate on the microtitre plate The results were plotted for R-l antibody as shown 
in Figure 3 12 The optimal conjugate loading ratio for R-l was found to be 12 5 
|ig/ml with an antibody dilution determined to be 1/50,000 Results were also plotted 
for R-2 antibody as shown in Figure 3 13 The optimal conjugate loading ratio and 
dilution for R-2 were found to be 1 56 fig/ml and 1/50,000, respectively
3 2 3 2 Linear range of detection of morphine-3-glucuronide in E L IS A  for R-l 
and R-2 polyclonal antibodies
The immunoassay format for the detection of M3G as described in section 2 3 8 2 
was used to determine the optimal range of detection of free M3G Microtitre plates 
were coated with 12 5 |ng/m 1 and 1 56 |ig/ml o f M3G-OVA for R-l and R-2 
antibodies, respectively, for the determination of the detection ranges o f each 
antibody to M3G Standards were prepared of M3G in PBS containing 0 5 mM HC1 
ranging from 4 to 500,000 pg/ml and these were added to the plate at a 1 1 ratio with 
R-l and R-2 antibodies (1/50,000 dilution) After incubation, enzyme-labelled anti­
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rabbit Ig was added, followed by chromogenic substrate The linear range of 
detection for R-l and R-2 antibodies were found to be between 244 and 250,000 
pg/ml and 122 and 31,250 pg/ml, respectively
109
14
12 -  
10
0 8 
<
5  6
4 - 
2 
0 -
100 1000 10000 100000 1000000 
1/Log of antibody dilution
Figure 3.12. Checkerboard ELISA carried out to determine the optimal dilution of 
antibody and concentration of coating conjugate for R-l polyclonal antibody. The optimal 
conjugate loading density was determined as 12.5 f i g / ml and the optimal dilution of 
antibody for use in a competitive assay was 1/50,000.
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Figure 3.13. Checkerboard ELISA carried out to determine the optimal dilution of 
antibody and concentration of coating conjugate for R-2 polyclonal antibody. The optimal 
conjugate loading density was determined as 1.56 pg/ml and the optimal dilution of 
antibody for use in a competitive assay was 1/50,000.
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3 2 3 3 Intra-day assay variability studies of R-l and R-2 anti-morphine-3- 
glucuronide polyclonal antibodies
To carry out intra-day assay variability studies, five sets o f standards ranging from 4 
to 500,000 pg/ml were prepared for each antibody and assayed on the same day and 
their means plotted The intra-day assay variability study for R -l, shown in Figure 
3 14, had a linear range of detection between 244 and 250,000 pg/ml The R2 value 
for this range was 0 99 The coefficients o f variation (CV’s) were determined to 
assess the precision of the analytical method, expressing standard deviation as a 
percent function of the mean These ranged from 1 29% to 4 68% as shown in Table 
3 1 The intra-day assay variability study for R-2 shown in Figure 3 15 had a linear 
range of detection between 62 and 31,250 pg/ml The R2 value for this range was 
0 99 The CV’s were determined and ranged from 1 81% to 6 13% as shown in Table 
3 2 The percentage accuracy values obtained for both R-l and R-2 ELISA intra-day 
assay studies were found to be variable and are listed in Tables 3 1 and 3 2
3 2 3 4 Inter-day assay variability studies of R-l and R-2 anti-morphme-3- 
glucuronide polyclonal antibodies
To carry out inter-day variability studies, five sets of standards ranging from 4 to
500,000 pg/ml were prepared for each antibody and assayed five times over five 
days The inter-day assay variability study for R-l had a linear range of detection 
between 244 and 250,000 pg/ml as shown in Figure 3 16 The R2 value for this range 
was 0 99 The CV’s were determined and ranged from 1 63% to 6 86% as shown in 
Table 3 3 The inter-day assay variability study for R-2 had a linear range of 
detection between 61 and 31,250 pg/ml as shown in Figure 3 17 The R2 value for 
this range was 0 99 The CV’s were determined and ranged from 3 06% to 11 72% 
as shown in Table 3 4 The percentage accuracy values obtained for both R-l and R- 
2 ELISA inter-day assay studies were found to be variable and are listed m Tables 3 3 
and 3 4
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Table 31 Intra-day assay variation for R-l ELISA assay Five sets of eleven standards
were analysed on the same day
M3G
Concentration,
(pg/ml)
Calculated mean
± S D , Abs
Coefficients of 
variation (C V ’s), %
%  Accuracy
250000 0 145 ±0 003 2 22 13 80
125000 0 167 ±0 003 1 92 6 08
62500 0 199 ±0 002 1 33 4 80
31250 0 221 ± 0 007 3 26 29 16
15625 0 259 ±0011 4 46 11 80
7812 5 0 292 ± 0 008 2 90 8 15
3906 25 0 333 ± 0 007 2 27 12 32
1953 1 0 374 ±0 017 4 68 28 93
976 5 0 389 ± 0 008 2 06 2 15
488 2 0 427 ±0 017 4 11 11 52
244 0 439 ± 0 005 1 29 35 90
100 1000 10000 100000 1000000 
Log of M3G concentration (pg/ml)
Figure 3*14. Intra-day competitive ELISA assay of R-l antibody for determination of the 
optimal range of detection offree M3G using an antibody dilution of 1/SO,000 M3G-OVA 
was coated at a concentration of 12 5 pg/mL The absorbance at 405 nm is inversely 
proportional to the amount of free drug in solution. The linear range of detection was 
found to be between 488 and 250,000pg/mL
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Table 3 2 Intra-day assay variation for R-2 ELISA assay Five sets of nine standards
were analysed on the same day
M 3G
Concentration,
(pg/ml)
Calculated mean 
± S.D., Abs
Coefficients of 
variation (C V ’s), 
%
%  Accuracy
31250 0 157 ±0 0041 2 64 6 90
15625 0 203 ± 0 0055 2 71 18 47
7812 5 0 219 ±0 0104 4 74 22 34
3906 25 0 253 ±0 0155 6 13 32 87
1953 1 0 304 ± 0 0055 1 81 6 39
976 5 0 341 ±0 0109 3 21 951
488 2 0 399 ±0 0180 4 53 22 60
244 0 440 ± 0 0166 3 77 25 89
122 0 458 ±0 0140 3 05 7 27
61 5 0 491 ± 0 0299 6 09 16 73
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Figure 315 Intra-day competitive ELISA assay of R-2 antibody for determination of the 
optimal range of detection offree M3G using an antibody dilution o f1/50,000 M3G-OVA 
was coated at a concentration of L56 #g/mL The linear range of detection was found to be 
between 61 and 31,250pg/ml
y = -0 0557Ln(x) + 0 7295
i 1 i---- - -------------- r
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Table 3 3 Inter-day assay variation for R-l ELISA assay Five sets of ten standards were
analysed over five different days
M3G
Concentration,
(pg/ml)
Calculated mean 
± S D , A/Ao
Coefficients of 
variation (CV’s), 
%
% Accuracy
250000 0 341 ± 0  019 5 51 4 00
125000 0 401 ± 0 027 6 75 4 98
62500 0 467 ± 0  031 6 49 8 08
31250 0 524 ± 0 036 6 86 21 83
15625 0 587 ± 0  036 5 89 29 28
7812 5 0 655 ± 0 035 5 07 30 45
3906 25 0 733 ± 0 046 6 45 19 04
1953 1 0 753 ± 0 028 3 27 94 66
976 5 0 882 ± 0 028 3 08 6 29
488 2 0 922 ± 0  016 1 63 42 27
244 0 979 ± 0 035 3 46 60 24
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Figure 316. Inter-day competitive ELISA assay of R-l antibody for determination of the 
optimal range of detection of free M3G using an antibody dilution o f1/50,000 M3G-OVA 
was coated at a concentration of 12*5 pig/mL The linear range of detection was found to be 
between 244 and 250,000pg/ml
y = -0 0994Ln(x) +1 5724 
R2 = 09938
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Table 3 4 Inter-day assay variation for R-2 ELISA assay Five sets of nine standards
were analysed over five different days
M 3G
Concentration,
(pg/ml)
Calculated mean
± S D , A/Ao
Coefficients of 
variation (C V ’s), 
%
%  Accuracy
31250 0 308 ± 0 024 7 99 4 79
15625 0 396 ± 0 034 8 57 5 01
7812 5 0 446 ± 0 052 11 72 21 17
3906 25 0 532 ± 0 052 9 87 11 83
1953 1 0 631 ±0 063 10 07 8 19
976 5 0 704 ± 0 063 8 98 4 73
488 2 0 809 ±0 053 6 57 25 84
244 0 863 ± 0 058 6 80 8 75
122 0 926 ± 0 028 3 06 3 55
61 0 977 ± 0 032 3 32 30 91
10 100 1000 10000 100000 
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Figure 3 17 Inter-day competitive ELISA assay of R-2 antibody for determination of the 
optimal range of detection offree M3G using an antibody dilution o f1/50,000. M3G-OVA 
was coated at a concentration of 156 fjg/mL The linear range of detection was found to be 
between 61 and 31,250pg/mL
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3 2 4 Urine analysis of anti-morphine-3-glucuromde antibodies
The quantitative determination of M3G in urine samples was also investigated The 
ionic composition of urine can vary considerable from sample to sample To 
compensate for the potential o f great inter-individual variability in the salt 
composition o f urine, the antibody sample was prepared in PBS of twice the normal 
ionic strength (2 x PBS) Known samples o f M3G ranging from 10 to 50,000 pg/ml 
were spiked into control urine and assayed for the presence of free drug with both R- 
1 and R-2 polyclonal antibodies
3 2 4 1 Intra-day assay variability studies of R- l and R-2 anti-morphine-3- 
glucuronide polyclonal antibodies in urine
To carry out intra-day assay variability studies, five sets o f standards ranging from 10 
to 50,000 pg/ml were prepared in urine for each antibody and assayed on the same 
day and their means plotted The intra-day assay variability study for R-l had a 
linear range of detection between 30 and 7,812 pg/ml The R2 value for this range 
was 0 99 The CV’s were determined and ranged from 1 76% to 8 47% as shown in 
Table 3 5 The intra-day assay variability study for R-2 had a linear range of  
detection between 30 and 1,950 pg/ml The R2 value for this range was 0 98 The 
CV’s were determined and ranged from 0 00% to 3 77% as shown in Table 3 6 The 
percentage accuracy values obtained for both R-l and R-2 ELISA intra-day assay 
studies in urine were found to be variable and are listed in Tables 3 5 and 3 6
3 2 4 2 Inter-day assay variability studies of R-l and R-2 anti-morphine-3- 
glucuronide antibodies in urine
To carry out inter-day variability studies, five sets o f standards ranging from 10 to
50,000 pg/ml were prepared for each antibody and assayed five times over five days 
The inter-day assay variability study for R-l had a linear range of detection between 
30 and 7,812 pg/ml as shown in Figure 3 18 The R2 value for this range was 0 99
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The CV’s were determined and ranged from 4 71% to 8 31% as shown m Table 3 7 
The inter-day assay variability study for R-2 had a linear range of detection between 
30 and 1,953 pg/ml as shown m Figure 3 19 The R2 value for this range was 0 98 
The CV’s were determined and ranged from 1 04% to 7 77% as shown in Table 3 8 
The percentage accuracy values obtamed for both R-l and R-2 ELISA mter-day assay 
studies in urine were found to be variable and are listed in Tables 3 7 and 3 8
Log of M3G concentration (pg/ml)
Figure 3 18» Inter-day competitive ELISA assay of R-l antibody for determination of the 
optimal range of detection of free M3G in urine using an antibody dilution of 1/50,000 
M3G-OVA was coated at a concentration o f 12 5 fig/mL The linear range of detection was 
found to be between 30 and 7,812 pg/ml
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Figure 319, Inter-day competitive ELISA assay of R-2 antibody for determination of the 
optimal range of detection of free M3G in unne using an antibody dilution of 1/50,000 
M3G-OVA was coated at a concentration of 156 fjg/mL The linear range of detection was 
found to be between 30 and 1,950pg/mL
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Table 3 5 Intra-day variation for R -l ELISA assay in urine. Five sets o f nine standards
were analysed on the same day
M 3G
Concentration,
(pg/ml)
Calculated mean 
± S.D., Abs
Coefficients of 
variation (C V ’s), 
%
%  Accuracy
7812 0 101 ± 0  008 8 47 26 48
3906 0 115 ± 0  002 2 28 2 58
1953 0 132 ± 0  002 1 91 18 12
976 0 150 ± 0  002 1 76 39 24
488 0 182 ± 0  014 7 80 8 60
244 0 203 ± 0011 5 68 16 80
122 0 234 ± 0  017 7 52 5 81
61 0 257 ± 0 006 2 34 4 24
30 0 284 ± 0  010 3 80 12 00
Table 3 6. Intra-day assay variation for R-2 ELISA assay in urine. Five sets of seven 
standards were analysed on the same day
M 3G
Concentration,
(pg/ml)
Calculated mean
± S D  ,A bs
Coefficients of 
variation (C V ’s), 
%
%  Accuracy
1953 0 066 ± 0  0041 3 15 21 77
976 0 072 ± 0 0055 0 00 14 65
488 0 088 ± 0  0104 3 00 0 001
244 0 097 ± 0  0155 2 73 25 40
122 0 115 ± 0  0055 3 61 1 12
61 0 123 ± 0  0109 2 60 30 63
30 0 147 + 0 0180 3 77 23 66
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Table 3 7 Inter-day assay variation for R-l ELISA assay in urine» Five sets of nine
standards were analysed over five different days
M 3G
Concentration,
(pg/ml)
Calculated mean
± S D , A/A0
Coefficients of 
variation (C V ’s), 
%
%  Accuracy
7812 0 338 + 0  020 6 01 53 55
3906 0380 + 0018 4 76 0 00
1953 0 435 + 0  036 831 19 86
976 0 496 ± 0 040 8 16 35 86
488 0 598 + 0  036 6 14 4 91
244 0 673 ± 0 036 5 35 4 09
122 0 772 ± 0 049 6 35 16 98
61 0 826 + 0 050 6 13 0 00
30 0 9 6 ± 0 042 4 71 0 03
Table 3 8 Inter-day variation for R-2 ELISA assay in urine. Five sets of seven standards 
were analysed over five different days
M 3G
Concentration,
(pg/ml)
Calculated mean
± S D , A/Aq
Coefficients of 
variation (C V ’s), 
%
%  Accuracy
1953 0 422 ± 0 004 1 04 15 46
976 0 4 6 5 + 0  021 4 61 18 13
488 0 578 ± 0 044 7 70 7 99
244 0 622 ± 0 040 6 50 27 45
122 0 749 ± 0 032 4 35 11 47
61 0 7 9 6 1 0  061 111 18 03
30 0 920 ± 0 034 3 73 13 53
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The specificity o f the polyclonal antibodies to morphine-3-glucuromde is critical for 
the performance of the immunoassay Cross reactivity studies were carried out with a 
number of available drugs for this purpose using the ELISA developed as described 
in section 2 3 8 2 Microtitre plates were coated with 12 5 \xg/m\ o f M3G-OVA for 
R-l antibody and 1 56 jig/ml o f M3G-OVA for R-2 antibody and blocked with 
2% (w/v) marvel Standards of morphine, codeine, nor-codeine and 6-
mo noacetyl morphine (6-MAM) were prepared and added to the microtitre plate at a 
1 1 ratio with antibody at a dilution of 1/50,000 Table 3 9 shows the percentage 
inhibition o f each compound
Table 3 9 Cross reactivity studies o f affinity-purified anti-morphine-3-glucuromde 
polyclonal antibodies with structurally related molecules
3 2 5 Cross reactivity studies of R -l and R-2 polyclonal antibodies
Compound Inhibition expressed 
as a percentage of the 
slope of R-l
Inhibition expressed 
as a percentage of the 
slope of R-2
Morphine-3- 
glucuromde
100% 100%
Morphine 83% 42%
Codeine 92% 97%
Nor-codeine 0 8% 56%
6-monoacetyl morphine 97% 98%
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3 3 Discussion
Polyclonal antibody production is the main focus o f the work described in this 
chapter Production of polyclonal antibodies begins with the preparation of a suitable 
antigen Small haptens such as M3G (461 5 Da) are not immunogenic, and so require 
conjugation to a larger camer-protein, such as BSA, OVA or THY (Hermanson, 
1996) The coupling chemistry used to prepare such immunogenic hapten-carrier 
protein molecules is an important consideration for the production of antibodies with 
the correct specificity Many methodologies for conjugation exist and vary 
depending on the functional groups which are available on both the antigen and the 
carrier molecule Production o f conjugates should also take into consideration the 
orientation of the antigen to produce optimal presentation to the immune system 
When considering conjugation of morphine-3-glucuronide, the structure was analysed 
and a carboxyl group was located on the glucuronide This carboxyl group may be 
used to conjugate morphine-3-glucuronide to amine groups present on proteins 
utilising carbodnmide coupling chemistry This coupling process allows 
carbodnmide to react with carboxylic groups available on the M3G molecule at the 
glucuronide site This forms a highly active 0-acyhsourea intermediate which reacts 
with the amine present on the carrier protein o f interest to form an amide bond 
allowing the release of the EDC mediator
Spectrophotometnc analysis o f conjugates could not be carried out due to both M3G 
and protein exhibiting the same characteristics, as both compounds show the presence 
of shoulders between 200 nm and 280 nm This presented a problem for 
characterisation of conjugates by UV/visible spectroscopy However, 
characterisation o f conjugates was carried out by immunising BALB/c mice and 
monitoring of specific antibody produced Initially, conjugates were thoroughly 
dialysed to remove small molecular weight components Dialysis would remove any 
unbound M3G as the molecular cut off weight for the dialysis tubing was 10,000 
daltons allowing M3G bound to protein to remain If the conjugation reaction had 
failed to couple protein and M3G, M3G would be removed from the mixture 
Immunisation of such a conjugate would only produce specific antibody to protein
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However, once coupling had occurred, immunisation o f BALB/c mice would produce 
specific antibody to both protein and M3G 10 days after immunisation to allow 
production of antibody, serum was taken from the mice and prepared as described in 
section 2 3 6 2 The same conjugate was used for both immunisation and screening 
This specific antibody was monitored by ELISA as described in section 2 3 8 1 A 
titre of the antibody present in serum was carried out against the M3G-BSA 
conjugate and found to titre out at 1 in 200,000 The dilution of antibody was 
determined for a competitive assay, allowing the antibody to be the limiting factor in 
the assay by picking a dilution of antibody on the linear part o f the curve (Figure 
3 6 )  This resulted in the use of a 1 in 8,000 dilution of antibody Competition 
assays were carried out to determine the antibody specificity to M3G These 
competitive assays confirmed that specific antibody to M3G was present in serum 
Figure 3 7 shows that the antibodies can detect free drug in a range of 100 to 100,000 
ng/ml This confirmed that M3G was coupled to BSA Further conjugates were 
produced to OVA and THY and characterised in the same manner
Polyclonal antibodies to morphine-3-glucuromde were then produced by immunising 
New Zealand White rabbits with the EDC/NHS coupled M3G-BS A conjugate Once 
a titre o f over 1/256,000 (Figure 3 8) from serum was obtained, the animal was 
sacrificed and the serum removed
Initial purification of the antibodies from both animals was performed by saturated 
ammonium sulphate precipitation Affinity purification of anti-M3G polyclonal 
antibodies was then carried out, employing high pH elution of the antibody from the 
protein G affinity column Figure 3 9 illustrates the elution profile for both 
antibodies on a protein-G column Characterisation o f the purity o f the antibodies 
was carried out by SDS-PAGE gel (Figures 3 10 and 3 11)
Both purified polyclonal anti-M3G antibodies were produced for the detection of the 
drug M3G in a competitive immunoassay format in which free drug in solution and 
surface bound M3G-OVA conjugate compete with one another to bind to antibody
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For this type of competitive assay to function effectively, a number of parameters 
must be optimised The limits o f detection in competitive ELISA’s are a function of 
the antibody affinity, and the equilibrium between both the free and immobilised 
conjugate As a result, too high a concentration of coating conjugate will shift the 
binding equilibrium in favour of binding to the ELISA plate and cause reduced 
sensitivity to free antigen in solution Similarly, the concentration of antibody used 
must be the limiting factor If this were not the case, antibody would be capable of 
binding to free drug and bound conjugate in excess, resulting in a signal that could 
not be measured The optimal antibody concentration was determined by titres of the 
two polyclonal antibodies and taking between 50-70% of the maximum binding 
Therefore, it is essential to optimise both the loading concentration of sohd-phase 
conjugate and the optimal dilution of antibody
Checkerboard ELISA’s were carried out for both polyclonal antibodies for the 
determination of the optimal loading conjugate concentration and the optimal 
antibody dilution Conjugate concentrations for R-l and R-2 were found to be 
optimal at 12 5 (Figure 3 12) and 1 56 jig/ml (Figure 3 13 ), respectively These 
concentrations were chosen as increasing concentrations did not give an increase in 
signal and gave the widest linear detection range over the range of antibody dilutions 
used
The antibody dilution used for both R-l and R-2 polyclonal antibodies was 1/50,000 
(Figures 3 12 and 3 13) resulting in these dilutions o f antibodies being the limiting 
factor in the assay These working dilutions for both R-l and R-2 antibodies were 
picked from the linear portion of the antibody dilution curve, where minimal changes 
in antibody concentration give the greatest change in absorbance readings Antibody 
dilutions chosen from the asymptotes o f the antibody dilution curve show minimal 
changes in response to changes in antibody concentration and may not be used 
Controls were also carried out by adding antibody to wells coated with OVA Results 
reflect that there is negligible specific antibodies present to the screening conjugate 
protein
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A model competitive assay was developed for these antibodies in PBS where 
standards o f M3G ranging from 4 to 5007000 pg/ml were prepared and mixed with 
purified polyclonal antibody at dilutions o f 1/50,000 Both antibodies showed 
competition within these ranges R-l showed a range of detection between 244 to
250,000 pg/ml (Figure 3 14) and R-2 showed a range of detection between 61 to 
31,250 pg/ml (Figure 3 15) Both assays displayed excellent linearity and both 
antibodies show very low limits of detection Intra-day and inter-day assay 
variability statistics were then analysed in an attempt to look at the reproducibility of 
the assay Intra-day and inter-day assay coefficients o f variation (CV’s) for R-l were 
found to be between 1 29 to 4 68% and 1 63 to 6 86%, respectively, for 5 replicates 
(Tables 3 1 and 3 3 )  Intra-day assay CV’s for R-2 were found to be between 1 81 to 
6 13% for 5 replicates, however, inter-day assay CV’s for R-2 were found to be higher 
and ranged between 3 06 to 11 72% (Tables 3 2 and 3 4 )  These results indicate that 
using R-l anti-M3G antibody gives an accurate, specific and reproducible assay The 
low nature o f the CV’s for R-l shows that the assay may be used to detect real samples 
However, the CV’s for the R-2 assay were higher indicating that the assay may not 
provide as accurate a result as the R-l antibody, however the R-2 antibody was still 
suitable for this assay format Studies carried out on the percentage accuracy levels for 
both R-l and R-2 intra- and inter-day assays were found to be relatively high resulting 
in the assay becoming more applicable as a confirmatory assay for the use o f illicit 
drugs
Having shown that both polyclonal antibodies were suitable for use in an assay of this 
type, the aim was to develop a method of detection of M3G in complex biological 
matrices The matrix of study in this chapter is urine
As already discussed in section 3 1 3 the main metabolites o f heroin and morphine 
are known as morphine-3-glucuromde (M3G) (60%) and morphine-6-glucuromde 
(M6G) (10%) (Yoshimura et a l , 1969, Oguri et a l , 1970, Yeh et a l , 1979) This 
characteristic o f morphine-3-glucuromde is significant as detection of this compound 
directly relates to heroin or morphine usage The development of an immunoassay
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for the detection of M3G in urine can be applied to relate back to use o f heroin or 
morphine due to both of these molecules producing M3G as one of their metabolites
A competitive assay in urine was developed for both anti-M3G antibodies to 
investigate the ability o f the antibodies to detect real samples Standards o f M3G 
ranging from 10 to 50,000 pg/ml were prepared in urine and mixed with purified 
polyclonal antibody Both antibodies showed competition within these ranges R-l 
showed a range of detection between 30 to 7,812 pg/ml and R-2 showed a range of 
detection between 30 to 1,953 pg/ml These results when compared to the assays 
developed in PBS are favourable as the detection limits for both antibodies have 
decreased when using urine as the biological matrix R-l antibody has lowered its 
detection range by three orders o f magnitude, from a lower detection limit o f 244 
pg/ml in PBS to 30 pg/ml in urine R-2 has also lowered its detection limits from 122 
pg/ml in PBS to 30 pg/ml in urine This is a very favourable result as assays with the 
ability to detect low quantities of the drug are desirable However, the advantage of 
lower detection limits for these assays also produces a disadvantage as the overall 
range of detection of the drug decreases Intra-day and inter-day assay variability 
statistics were again analysed in an attempt to look at the reproducibility o f the assays 
in urine Intra-day and inter-day CV’s for R-l were found to be between 1 76 to 8 47% 
and 4 71 to 8 31% respectively for 5 replicates (Tables 3 5 and 3 7 )  Intra-day CV’s 
for R-2 were found to be between 0 00 to 3 77% for 5 replicates, however, inter-day 
CV’s for R-2 were found to be higher and ranged between 1 04 to 7 77% (Tables 3 6 
and 3 8 ) The low nature of the CV’s demonstrates the applicability o f the assay to be 
used in the analysis o f samples Further studies were earned out on the percentage 
accuracy levels for both R-l and R-2 intra- and inter-day assays in urine and results 
produced relatively high values which correlated to the results found when the assays 
were performed in PBS resulting in these assays becoming more applicable for use as a 
confirmatory test for drug abuse
Cross reactivity is defined as a measure of the antibody response to structurally 
similar molecules One of the initial steps in designing an immunoassay is the
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assessment o f reactivity toward structurally similar molecules (Wild, 1994) Serial 
dilutions o f the cross reactive analyte o f interest are prepared with similar dilutions of 
the specific antigen and a competitive ELISA carried out as described in section 
2 3 8 1 Table 3 9 shows the percentage inhibition of each compound using the slope 
of the line, if 100% inhibition equals the slope of the line for the M3G immunoassay 
Competitive assays were carried out with a range of metabolites o f heroin 
Morphine, codeine, 6-monoacetylmorphine and nor-codeine standards were prepared 
and added onto a microtitre plate with a mixture o f both R-l and R-2 antibodies at 
dilutions o f 1/50,000 Results for both R-l and R-2 were comparative except for their 
recognition of morphine and nor-codeine R-l antibody shows twice as high 
percentage recognition for morphine as R-2 antibody and while R-l antibody shows a 
negligible response to nor-codeine, R-2 antibody shows 56% cross reactivity The 
cross-reactivity o f the affinity-purified polyclonal antibodies demonstrates an almost 
identical cross-reactivity to codeine and 6-monoacetylmorphine These results show 
that both antibodies possess high cross reactivity with the metabolites of heroin 
However, as M3G is the mam metabolite the assay may still be used for real sample 
analysis
Overall, the competitive immunoassay for quantitative determination of M3G in urine 
compares well with the traditional analytical methods The assay developed in our lab 
has extremely low levels of detection While many of the ELISA based assays have 
concentrated on the detection of heroin and morphine, many of the traditional analytical 
tools have been used for the development o f assays to heroin’s metabolites
The assays developed in our lab to M3G compare favourable to assays in the literature 
Of the analytical techniques discussed in section 3 14, the HPLC method developed by 
Meng et al (2000) has a lower limit of detection As very little work has been carried 
out in the development o f ELISA assays to M3G, morphine ELISA assays are used as a 
comparison of limits o f detection of this family of molecules Radioimmunoassays 
developed by Spector et al (1971) and Steiner et al (1978) have limits of detection of 
50 pg/ml and 500 pg/ml, respectively, for morphine In comparison to the detection
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limits of these assays, the assay developed in our lab compares very well Our assay is 
also a much simpler assay, with lower costs and does not require a radiation suite, as in 
the case o f these assays One ELISA assay developed for detection of morphine by 
Usagawa et al (1993), however, in comparison to the assays developed in our lab has 
proved to possess limits o f detection as low as 100 pg/ml and thus possesses similar 
detection limits compared to our assays With respect to the detection of opiates using 
HPLC, GC or MS methods as described in section 3 14, even though these method can 
detect low concentrations of drug, these methods require many clean up steps and are 
expensive resulting in the need for alternative methods of detection
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Development of a BIAcore-based Inhibition Immunoassay 
for the Detection of Morphine-3-glucuronide in 
Biological Matrices
Chapter 4
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4 1 Introduction
4 11 Biosensors
The development of rapid analytical devices such as biosensors for the detection of  
compounds has grown enormously over the past few decades (Pancrazio et a l , 1999, 
Rogers, 2000) Biosensors are devices incorporating a biological sensing element 
coupled to a variety o f transducing mechanisms (i e electrochemical, optical- 
electronic) When biological molecules interact specifically and reversibly, a change 
occurs in one or more physio-chemical parameters associated with the interaction 
This change causes the production of ions, electrons, gases, heat, mass or light 
These quantities are then converted by transducers into electrical signals and 
displayed in a suitable form The transducer translates the response o f the biological 
component into a readable electronic signal (Rogers, 2000) The use of biosensors 
has ranged from environmental monitoring (Dennison and Turner, 1995), medical 
applications (Connolly, 1995) to the detection of coumarins (Keating et a l , 1999) and 
mycotoxins (Daly et a l , 2000)
The biological component o f a biosensor should possess a high degree o f specificity 
and stability, should not contaminate the sample and should retain biological activity 
when immobilised (Hall, 1990) The specificity o f the biosensor is completely 
dependent on the properties of the biological component as the biological component 
must recognise the analyte for there to be an interaction Biosensors may be divided 
into two categories, the catalytic sensor and the affinity sensor The catalytic sensor 
works on the principle that the molecules bind and alter the analyte in some way 
The affinity-based sensors actually monitor the binding between the two molecules 
The use o f biomolecules and biological systems in biosensors was reviewed by 
McCormack et al (1998), and may be divided into the following groups enzymes, 
antibodies, whole cells, receptors, tissues, nucleic acids, lectins and antigens 
Recently, several commercial biosensors have been developed using surface plasmon 
resonance (SPR) technology as their detection method In particular, the BIAcore
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SPR-based biosensor has become a very important tool in the detection of a number 
of analytes.
4.1.1.1. Surface plasmon resonance (SPR ) biosensors
Several biosensors have been developed based on the phenomenon o f surface 
plasmon resonance. This phenomenon allows the detection o f biomolecular 
interactions in ‘real-time’. The principle behind SPR is described in the context o f  
BIAcore for convenience. At an interface between two media o f different refractive 
index (e.g. glass and water), light coming from the side o f the higher refractive index 
is partly reflected and refracted. Above a certain critical angle o f  incidence, the light 
is totally internally reflected and no light is refracted across the interface between the 
two surfaces o f different refractive index.
Glass prism
Figure 4.1. Under conditions of total internal reflection at a metal-coated interface, an 
evanescent wave propagates into the medium of lower refractive index on the non­
illuminated side.
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Under total internal reflection conditions (TIR), an electromagnetic field component 
called the evanescent wave penetrates into the medium o f lower refractive index a 
short distance in the order of one wavelength (Figure 4 1) As the evanescent wave 
moves further away from the interface into the lower dense medium, the wave decays 
exponentially If the interface between the media is coated with a thin layer of metal 
(in the case o f BIAcore, this metal layer is gold), containing electron clouds at the 
surface and the passage of the evanescent wave through this metal layer causes the 
plasmons to resonate which results in a quantum mechanical wave known as a 
surface plasmon Some of the energy o f the reflected light (incident light) is taken up 
by the surface plasmon wave, resulting in a dip in the intensity o f reflected light at a 
certain angle being observed (Panayotou et a l , 1993) The incident light angle at 
which this dip is observed is known as the SPR angle The SPR angle is dependent 
on a number of factors These factors include the properties o f the metal film (eg  
thickness, uniformity and composition), the wavelength and polarisation of incident 
light and the refractive index o f the media on either side o f the metal film In real­
time BIA, the properties o f the metal film, the wavelength and refractive index of the 
denser medium are kept constant The SPR signal can be used to monitor the 
refractive index of the aqueous layer immediately adjacent to the gold metal layer 
The light source in the BIAcore instrument is a high-efficient light emitting diode 
with a wavelength in the near infra-red region This light is focused on an interface 
consisting of glass and gold on the sensor chip in a wedge shaped beam, producing a 
fixed range of incident angles (Figure 4 2) A two-dimensional diode array is used to 
monitor the reflected light Changes in the refractive index are a direct result of 
changes in the mass or concentration on the surface of the chip and this characteristic 
of SPR has been used to monitor biological interactions (Figure 4 3) The change in 
reflected light is interpolated as a sensorgram (Figure 4 4)
At the heart o f the BIAcore instrument, as with the majority o f SPR-based 
commercially available instruments, is the sensor chip as shown in Figure 4 5 The 
BIAcore sensor chip consists o f a glass slide with a thin layer of gold deposited on 
one side Gold was chosen as it possesses the characteristics o f chemical inertness
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and good SPR response This gold layer was in turn covered with a covalently bound 
carboxymethylated dextran matrix attached by a hydroxyalkyl thiol linker layer The 
matrix allows the covalent immobilisation of analytes onto the surface o f the chip and 
increases sensitivity by increasing the binding capacity o f the surface
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Incoming
Figure 4.2. Shows the operation of surface plasmon resonance (SPR) in the BIAcore 
biosensor instrument. Antibody (Y) is immobilised onto the surface of the chip using 
conventional EDC/NHS chemistry. Light from a high intensity light emitting diode (LED) 
is focused onto the gold chip surface by means of a prism under conditions of total internal 
reflection. A two-dimensional photo-diode array was used to measure the reflected light 
Under conditions o f total internal reflection at a metal-coated interface, an evanescent 
wave propagates into the medium of lower refractive index on the non-illuminated side. 
This leads to a dip in the intensity o f reflected light at a particular angle known as the SPR 
angle (SPR angle = angle a) and this is shown as a blue line in the Figure above. This 
SPR angle is sensitive to a variety offactors such as the refractive index at the gold film  
side of the interface and any biospecific interactions.
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Incoming
Figure 4.3. Shows the injection of antigen (•) over a chip surface immobilised with 
antibody (Y). The specific interaction of antigen binding to the antibody causes an 
increase in the mass bound at the sensor chip surface resulting in changes in the refractive 
index. This change in the refractive index is responsible for a shift in the resonant angle 
of the reflected light as the angle changes from a in Figure 4.2 to b above. As changes in 
the resonant angle are a direct result of changes in the mass or concentration on the 
surface of the chip, the mass of analyte binding to the chip surface may be determined.
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Figure 4.4. The SPR angle may be seen as a dip in the intensity of the reflected light As 
an antibody:antigen interaction occurs, changes in the resonant angle (0) are monitored 
continuously and displayed as a sensorgram. Biomolecular interactions at the chip surface 
causes a mass change and an increase in the SPR angle which is seen as a gradual 
increase in the signal of the sensorgram. The signal is interpolated into response units 
(RU) by the instrument software. An increase o f 1000 RU as a result of a biomolecular 
interaction corresponds to approximately 1 ng/mnt2 of protein present on the chip surface.
The matrix also provides a hydrophilic environment with very low non-specific 
binding. The matrix forms one wall o f a micro-flow cell where interactions are 
monitored. The carboxymethylated side o f the chip comes in contact with the 
solution o f interest, while the gold side o f the chip is illuminated from the other side, 
through the glass. SPR is generated through the interaction o f the light energy with 
the gold film and this is used to monitor concentrations o f analyte on the surface o f  
the chip. There are currently a wide variety o f different sensor chips available for the 
BIAcore instrument for varying purposes. However, all chips use the same optical 
principle.
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Figure 4.5. Diagram representing the surface o f the BIAcore carboxymethylated 5 (CM5) 
sensor chip. The surface o f the chip consists of three layers: glass, a thin gold film and a 
carboxymethylated dextran layer. The carboxymethylated dextran matrix is bonded to the 
gold film through an inert linker layer. This matrix allows the covalent immobilisation of 
analytes onto the surface of the chip.
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Figure 4.6. Schematic sensorgram illustrating the binding of analyte to immobilised 
ligand. Before the start of the injection of sample the initial steady baseline is due to the 
flow of running buffer over the chip surface. As the sample is injected over, the initial 
bulk refractive index changes causing a sharp increase in the signal This is followed by a 
steady increase in signal over the course o f the injection as binding of the two interactants 
is allowed to occur. At the end of the sample injection a sharp decline or final bulk 
refractive index change in the signal is observed as the running buffer is again passed over 
the surface which is a result o f a change in the refractive index of the buffer. The 
difference in the recorded response units (RU) between the signal after the injection and 
the initial baseline response units corresponds to the amount of interactant that remains 
bound to the sensor chip surface.
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A typical sensorgram for binding o f analyte to immobilised ligand is shown in Figure 
4 6 Running buffer flowing over the surface at a fixed volume per min produces the 
initial level baseline at the sensor surface A sharp rise in signal is then observed at 
the precise moment of the injection of sample over the surface This is due to a 
difference in the bulk refractive index between the running buffer and the sample 
buffer The binding can be seen as an initial jump or initial bulk refractive index 
change in the signal followed by a steady increase in signal over the course o f the 
injection This is because large quantities of analyte bind followed by the sensor 
surface slowly becoming saturated resulting in the steady signal At the end of the 
sample injection, a sharp decrease in the signal is observed as running buffer o f lower 
refractive index is again allowed to pass over the surface The difference in the 
recorded response units (RU) between the signal after the injection and the initial 
baseline response units corresponds to the amount o f interactant that remains bound 
to the sensor chip surface A change in response unit signal o f 1000 RU corresponds 
to a change in surface concentration on the sensor chip of about 1 ng/mm2 (Stenberg 
e t a l , 1991)
The BIAcore biosensor has a number of major advantages compared with 
conventional detection techniques The absence of a need for labelling is o f major 
significance as it minimises interference with the binding interaction being studied 
and also eliminates expensive and time-consuming purifications in many situations 
Real-time analysis o f mteractants is also one of the mam advantages of the BIAcore 
instrument as interactions may now be monitored as they occur providing valuable 
diagnostic information as well as kinetic data Further advantages include the ability 
of the chip to be reused a significantly large (up to 1000 times) number of times and 
also the ability o f the instrument to allow rapid and automated analysis The BIAcore 
instrument is provided as a complete system, which includes processing unit, sensor 
chip, controlling computer and the appropriate software for data collection and 
analysis
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4.1.1.2. IAsys biosensor
The IAsys series o f optical biosensors are analytical instruments that utilise advanced 
resonant mirror optical biosensor technology and apply it to the recognition of 
biomolecules. A dielectric layer o f high refractive index is used instead of the gold 
sensing layer in BIAcore (Cush et a l, 1993). The sensor consists o f a glass prism 
coated with a thin layer o f silica and high refractive index resonant layer (e.g. 
titanium), which is in contact with the sample solution (Figure 4.7). Polarised laser 
light is directed at the prism and under conditions o f total internal reflection 
illuminates the underside o f the sensor surface at angles greater than the critical 
angle. At one angle which is known as the resonant angle, a component o f light can 
couple through the low refractive index layer and propagate along the high refractive 
index layer before being coupled back into the prism. During resonance a phase shift 
occurs between the reflected electric (TE) and magnetic (TM) modes resulting in a 
phase shift in the measured response which is observed as constructive interference 
and can be measured in ‘real-time’. The resonant angle at which coupling occurs is 
essentially dependent on the refractive index at the surface o f the sensor. As a result, 
changes in the refractive index or mass will change the resonant angle corresponding 
to signal increases as mass increases and signal decreases as mass decreases.
Figure 4.7. Illustration of the resonant mirror configuration. Incident light is passed 
through a prism and undergoes total internal reflection at the boundary with the low 
refractive index layer and generates an evanescent field. The resonant angle at which 
coupling occurs is essentially dependent on the refractive index at the surface of the 
sensor. Binding interactions can be monitored using this instrument as shifts in reflected 
light are related to mass change on the sensor chip surface.
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4.I.I.3. Miniature TI-SPR sensor
The miniature TI-SPR device was first released in 1996 by Texas Instruments, and 
consists o f a light emitting diode (LED), polarizer, thermistor allowing correction due 
to temperature changes and two 128 silicon photo diode arrays (Figure 4.8). These 
components are mounted on a single platform using conventional semi-conductor- 
based opto-electronic manufacturing techniques (Melendez et al., 1996). The 
platform is encapsulated in an epoxy resin moulding structure in the form o f the 
Kretchmann geometry prism. The width o f light produced by the light emitting diode 
is controlled by the polarizer and reduces the emission o f transverse electric radiation. 
Under conditions o f total internal reflection the wedged shaped beam is directed onto 
a linear photo diode array by a mirror. An SPR-induced minimum is determined by 
processing the signal from the photo diode array in ‘real-time’ using dedicated signal 
software (Kukanskis et a l, 1999). Temperature fluctuations can also be corrected 
during analysis as there is a built in temperature sensor in the device. This system is 
available in a hand-held format and is known as the Spreeta™ device which 
possesses a control box housing the components o f the instrument, which may be 
attached to a laptop to produce a portable device (Figure 4.9).
lb  Flowcell Reflecting
Mirror
Optical Plastic 
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Emitting 
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Figure 4.8. Cross-section of miniature TI-SPR instrument The instrument consists of an 
electro-optical component mounted on a single platform encapsulated in an optically 
transparent plastic. Changes in mass are related to changes in the resonant angle and this 
change is measured by the photodiode array.
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Figure 4.9. Schematic of TI-SPR device fitted with flow celi A control box interfaces with 
the device and this may be installed on a personal computer. SPR-MINI MS-Windows 
software can be used for data acquisition and processing to produce a display via a virtual 
control panel as shown on the laptop.
4.1.2. Applications of SPR technology
With the birth o f SPR technology and the ability to monitor interactions between 
biomolecules in ‘real-time’ the applications involving SPR technology has grown 
quickly over recent years. The characteristic o f label-free detection o f binding 
interactions between molecules is also considered to be o f great significance in the 
future development o f assays as previous labelling procedures have shown to affect 
the binding activities o f antibodies (H0yer-Hansen et al., 2000). Applications o f SPR 
biosensing systems have been used by Quinn et al. (1997) for the detection o f blood 
group antigens in whole blood using antibodies. Assays have also been developed 
using the SPR-based BIAcore biosensor, for detection o f aflatoxin Bj (Daly et a l,
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2000) These applications show that SPR technology is a powerful technique in the 
study of both surface properties and surface interactions SPR technology has the 
potential to measure a number of factors ranging from rates o f adsorption, total 
amounts o f immobilised material, degree of desorbtion o f material from the surface, 
relative binding affinities, equilibrium constants, association of analyte on the surface 
and dissociation o f analyte off the surface These can all be measured quickly and in 
‘real-rime’
4 12 1 Application of SPR technology for the measurement of small molecular 
weight analytes and characterisation of target molecules
The most obvious problem with SPR technology is the analysis o f small molecules 
As changes in the refractive index are mass dependent the ability of the sensor to 
detect low molecular weight compounds is compromised This problem however 
may be overcome by linking small molecules to larger carrier molecules When 
developing BIAcore-based assays for detection of these small molecular weight 
molecules, the format used most frequently is an inhibition assay In this assay 
format, the immobilisation of the analyte is performed by immobilisation o f a carrier 
molecule with the analyte of interest attached Standards o f free analyte mixed with 
specific antibody are then passed over the surface Excess antibody is allowed to 
bind to the surface and the amount o f antibody bound is inversely proportional to the 
amount o f free analyte in solution
Daly et a l (2000) developed an inhibition assay for the detection o f aflatoxin Bj 
using carrier proteins (BSA) as the ligand for immobilisation onto the surface of the 
chip Polyclonal antibodies were produced to aflatoxin Bi and found to be 
regenerable using an organic solution consisting o f 1 M ethanolamine with 20% (v/v) 
acetomtnle, pH 12 0 The polyclonal antibodies were added to standards o f free 
aflatoxin and passed over the surface immobilised with aflatoxin Bi-BSA The 
remaining free antibody bound to the surface o f the chip, providing a signal inversely 
proportional to the amount o f free aflatoxin in solution
143
Keating et a l (1999) also developed an inhibition assay for the determination of total- 
7-hydroxycomann (7-OHC) in human serum samples using the BIAcore biosensor 
A 7-OHC-BSA conjugate was produced and immobilised onto the chip surface 
Standards o f free 7-OHC were premixed with a polyclonal anti-7-OHC antibody and 
injected over the surface As in the previous assay excess antibody bound to the 
immobilised conjugate, generating a binding response that was inversely proportional 
to the amount o f 7-OHC in solution The assay had a range o f detection for 7-OHC 
of between 0 5 to 80 jag/ml
The BIAcore biosensor has been used to develop a number of different assays to 
various analytes Hams and Patel, (1995) developed an inhibition BIAcore assay for 
the detection of food borne pathogens Salmonella and Listeria Polyclonal antibodies 
to bacterial cell wall antigens were added to cultures o f food samples and filtered to 
remove all bacteria The filtrate was passed over a chip surface with anti-Fab 
antibody immobilised producing a signal when free antibody bound to the surface
Further developments in SPR technology have been made with the development of 
the BIAcore 3000 instrument This instrument has increased sensitivity, reduced 
flow cell size compared to the BIAcore 2000 and possesses on-line reference curve 
subtraction enabling better detection o f small molecular weight analytes (Morton & 
Myszka, 1998)
Markgren et a l (1998, 2000) monitored the binding of an inhibitor to HIV-1 
proteinase and showed how the BIAcore instruments may be used in the selection of 
binders HIV-1 was immobilised onto the surface of a chip and inhibitors were 
detectable by analysis o f their association and dissociation rates Malmquist, (1999) 
demonstrated the ability to monitor the weak-affmity interaction o f lactose binding to 
an immobilised antibody Nieba et a l (1996) developed a method utilising 
competition assays on BIAcore for measuring the true affinities o f binding 
interactions Kampranis et a l (1999) also studied the binding kinetics between wild- 
type and mutant DNA gyrases to novobiocin Results from the SPR analysis allowed 
the identification of residues responsible for binding of novobiocin to the DNA 
gyrases
144
This ability o f the BIAcore biosensor instruments to monitor the binding interactions 
o f small molecules will have a significant impact on the pharmaceutical industry 
Previous characterisation and development o f a small molecule drug was estimated to 
take 5-7 years with a cost o f $500 million dollars However, the technology is now 
available for the identification of potential new drug molecules more rapidly and with 
less expense The lack o f labelling requirements and the ability o f the BIAcore 
instruments to use very low quantities of sample enables the BIAcore to be used as a 
secondary screening tool BIAcore has the ability to provide binding information not 
available from normal screening methods as the interaction may be monitored in 
’real-time' while also providing both affinities and binding kinetics (Markgren et a l , 
2000) Small molecule detection may also be useful in pharmacological studies An 
important example o f this is the ability to screen drug candidates These may be 
screened for binding to carrier plasma proteins and lipoproteins as well as for 
membrane permeability Thus, information may be acquired on the oral adsorption 
to, and transfer across, the gastrointestinal tract and exchange across the blood/organ 
barrier of these molecules (Rich & Myszka, 2000)
4 12 2 Membrane surface applications
As advances are made in SPR technology, new areas o f analysis become possible 
One such area of analysis is the monitoring of protein interactions with lipid surfaces 
and membrane-associated proteins Such analysis is possible using the newly 
developed HPA (hydrophobic) and LI (lipophilic) sensor chips produced by BIAcore 
to create stable membrane surfaces within the flow cell The HPA chip possesses a 
self-assembly monolayer of alkylthiols covalently linked to the gold surface It is 
then possible to fuse liposomes to this surface to form a hybrid lipid monolayer 
(Evans & MacKensie, 1999) This monolayer may then be used to monitor 
interactions The LI chip differs as it contains an alkyl chain immobilised to the 
dextran matrix In this case, liposomes are captured on the surface, forming a stable 
lipid bilayer which mimics the biological membranes (Rich & Myszka, 2000)
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Further advantages o f using lipid surfaces on such chips may be seen in the ability to 
specifically orientate the proteins within the membrane and also multiple interactions 
may be monitored due to the fluidity o f the membrane resulting in protein diffusion 
through the membrane (Celia et a l , 1999) Celia et a l (1999) observed the binding 
of soluble T-cell receptors (TCRs) to major histocompatibility complex (MHC) 
molecules attached to the membrane Danehan et a l (1999) described a new method 
to estimate the fraction o f drug absorbed in the human intestine based on sensor 
technology Liposomes were immobilised onto the surface o f the chip and the 
interaction between drugs and liposomes were monitored directly using SPR 
technology In all 27 drugs were studied and results correlated with previous studies 
carried out on fractions of drugs absorbed by humans
4 12 3. Proteomics
Proteomics is an area o f research devoted to determine the function o f the encoded 
protein repertoire to find out how it regulates the behaviour o f individual cells and, 
ultimately, the whole animal throughout its development both in health and disease 
In its infancy, proteomics was the word used to describe technology that allowed 
large scale protein separation and mass identification In a paper by Celis et al 
(1989) the expression of proteins was analysed at the same time from human cells in 
order to study cell proliferation and differentiation This study, to provide an 
overview of a number of proteins expressed at one time when a cell is carrying out a 
particular function, is recognised today as proteomics However, recently proteomics 
has divided into three areas, protein profiling, interaction analysis and structural 
genomics Characteristics of the BIAcore instrument are real-time monitoring, an 
auto injection system and the ability to analyse large numbers of samples while using 
small amounts of material These provide a platform for analysis in the area of 
proteomics (Natsume, 2000) Generally 2D gel electrophoresis is used to separate 
and analyse 5,000 proteins simultaneously Identification o f the proteins is carried 
out by cutting the proteins from the gel followed by digestion with trypsin into 
fragments The fragments are then identified by comparing them with databases of
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protein or DNA sequences with the use o f mass spectrometry However, this process 
is very time consuming and this is why new quicker methods of identification are 
being developed Sonksen et a l (1998) developed a method, which combined BIA 
technology with Mass spectrometry Affinity bound molecules were recovered from 
the surface o f the BIAcore chip in a few microliters, ready for MS analysis BIAcore 
provides information on the concentration of protein bound to the surface of the chip 
while MS reveals the identity o f the compound by molecular mass determination 
Calculation o f the total surface molar concentration o f affinity-bound molecules was 
possible by combining the information provided by the two instruments
4 13 BIAcore as a tool in antibody engineering
Antibodies with the desired affinities and specificity’s for use in biomedical or 
industrial applications are required Hybndoma technology has been used for this
purpose for more than a decade However, recent developments in genetics have
<
produced an explosion in the development o f genetically engineered antibodies 
(Parmley & Smith, 1988, McCafferty et a l , 1990) With this new technology, 
screening of combinatonal phage display libraries prompted the development of 
novel systems capable of selecting antibodies of the desired specificities The 
BIAcore biosensor provides a simple and rapid approach for screening of 
recombinant antibody fragments, kinetic selection o f phage displayed antibodies, 
characterisation and epitope mapping of monoclonal antibodies and their fragments 
(Malmborg & Borrebaeck, 1995)
In the past, ELISA has been the most common method used for screening 
recombinant antibodies However, due to the nature o f the ELISA method being 
based on equilibrium, antibodies with high "off-rates" may be lost This problem 
may be solved with the used of BIAcore as this instrument enables the evaluation of 
the entire binding pattern An example o f this was published by Marks et a l (1992) 
where bacterial cultures were screened for positive antibodies by direct injection into 
the biosensor without any previous purification Clones were selected with up to 300 
times improved affinities using this method Malmborg et a l (1996) also showed
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that it is possible to increase specific phage titres by 10-57% by using elution and re- 
screenmg of eluted phage selection procedures on BIAcore
The BIAcore instrument may also be used to further characterise already screened 
clones Deng et a l (1994) reported that low affinity anti-carbohydrate antibody 
clones when subjected to random mutagenesis resulted in clones with higher affinities 
being obtained In this case the BIAcore was used to characterise these clones and it 
was found that the increased affinity was mainly due to an increased association rate 
constant
BIAcore may also be used to perform epitope mapping allowing the complete 
characterisation o f interactions by studying the stoichiometry and kinetic 
characteristics o f antibodies Fagerstam et a l (1990) characterised epitopes on 
recombinant HIV-1 core protein p24 for 29 mouse monoclonal antibodies by fixing 
antibody on the surface with capture antibody followed by injection o f antigen This 
was followed by injection o f a further antibody to analyse if each antibody bound to a 
different epitope on the antigen
Finally, SPR technology may be used to determine the active concentration o f single 
chain antibody concentrations in crude periplasmic fractions (Kazemier et a l , 1996) 
This allows screening of antibodies with respect to their affinities, as the 
concentration o f active antibody is required for this purpose
The development o f BIAcore-based immunoassays for the detection of M3G as a 
model system in PBS and in biological matrices is investigated in this chapter Two 
polyclonal antibodies were developed and used for an inhibition-based BIAcore 
immunoassay application The ability o f the model assays to measure free drug 
concentrations was studied Subsequently, the assays were developed and used in the 
measurement o f M3G in urine samples The assays were also assessed with respect 
to accuracy and precision
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4 2 Results
For the development o f a model inhibition BIAcore assay to M3G in PBS, the first 
step o f such an assay was the immobilisation o f morphine-3-giucuromde-ovalbumin 
(M3G-OVA) onto the surface of a CM5 sensor chip The immobilisation chemistry 
used was EDC-mediated NHS estenfication as discussed in section 2 3 112 For the 
successful immobilisation of M3G-OVA onto the surface o f the sensor chip, it is 
essential to maximise the interaction between the carboxymethylated dextran surface 
and the conjugate of interest To achieve maximum binding, a preconcentration study 
of M3G-OVA was carried out as described in section 2 3 11 1 100 jug/m 1 o f M3G-
OVA was prepared in 10 mM sodium acetate buffer This solution was aliquotted 
and each aliquot adjusted to the required pH by addition of 10% acetic acid These 
solutions were then injected over an underivatised chip surface Figure 4 10 shows 
the differing degree of binding of conjugate to the surface at pHs ranging from 3 6 to 
4 7 The optimal pH determined from this graph for immobilisation o f M3G-OVA is 
4 3 All subsequent immobilisations o f M3G-OVA were carried out by preparing the 
conjugate at this pH
4 2.2 Immobilisation of morphme-3-glucuronide-ovalbumin conjugate
The immobilisation o f conjugates onto the surface of a CM5 chip was carried out as 
described in section 2 3 112 The chip surface was activated by passing over a 
solution of EDC/NHS followed by the M3G-OVA conjugate, prepared in 10 mM 
sodium acetate, pH 4 3 The unreacted sites were then capped by passing over a 
solution of 1 M ethanolamine, pH 8 5 Figure 4 11 shows a typical sensorgram for 
the immobilisation of M3G-OVA onto the surface of a chip The total amount of 
protein bound to the surface o f the chip after immobilisation was found to be 
approximately 6,500 response units (RU)
4 2.1 Preconcentration of morphine-3-gIucuronide-ovalbumin conjugate
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Figure 410 Preconcentration of M3G-OVA conjugate onto the surface of a CM-dextran 
chip Solutions of 100 pg/ml of M3G-OVA in 10 mM acetate buffer at a range of pHfrom 
3 6 to 4J  were passed over the same unactivated chip surface at 2 jM/min for 2 nun. 
Electrostatic attraction between the negatively charged dextran layer and the positively 
charged protein is enhanced in the presence of the acetate buffer A measurement of 
preconcentration was taken 5 sec before the end of the injection. As the injection finishes 
the protein is dissociated from the surface of the chip by the ionic strength of the HBS 
buffer (ISO mM NaCl) passing over the surface. The optimal pH for immobilisation was 
determined to be pH 4 3 All subsequent immobilisations of M3G-OVA were carried out 
using 100 fjg/ml of M3G-OVA prepared in 10 mM sodium acetate buffer, pH 4 3
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Figure 4.11. Typical sensorgram fo r the immobilisation o f M3G-OVA onto the surface o f 
a sensor chip. (1) HBS buffer is passed over the sensor chip. (2) A solution o f 0.05 M  
NHS and 0.2 M  EDC is passed over the sensor chip surface resulting in activation o f the 
carboxymethylated dextran on the chip surface. (3) Again HBS buffer is passed over the 
surface and the baseline returns to normal with a small increase in response units which 
can be attributed to the binding o f NHS-esters to the surface. (4) A solution o f 100 fig/ml 
o f M3G-OVA prepared in 10 mM acetate buffer, pH  4.3, was passed over the surface fo r 20 
nun. (5) Shows the amount o f bound protein to the surface o f the chip and this is 
recorded. (6) Deactivation o f the surface NHS-esters was carried out with 1 M  
ethanolamine hydrochloride (pH 8.5) which removes weakly bound protein. (7) The value 
recorded here is the amount o f protein bound to the surface o f the chip and this figure is 
presented as response units (RU). 6,500 RU bound to the surface o f the chip.
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4 2 3 Development of a model inhibition assay for morphine-3-glucuronide in 
PBS
For the successful development of an inhibition BIAcore assay to M3G, a number of 
parameters must be optimised Regeneration o f the surface is essentia! for the 
surfaces repeated use in assay formats Also removal of non-specific interactions is 
important
1/500 dilutions o f both R-l and R-2 antibodies were found to produce a binding 
response o f antibody of approximately 450 RU and 400 RU, respectively 
Regeneration conditions for both R-l and R-2 polyclonal antibodies were optimised 
R -l antibody required two pulses for 2 mm followed by a 1 min pulse of 1 M 
ethanolamine, pH 13 6 R-2 antibody required three 1 mm pulses in the order o f 40 
mM HC1, 40 mM NaOH followed by 40 mM NaOH Figure 4 12 shows a typical 
sensorgram for the binding and regeneration o f R -l polyclonal antibody to M3G- 
OVA immobilised onto the surface of the chip
Non-specific interactions between both anti-M3G R-l and R-2 polyclonal antibodies 
were analysed for both the earner protein used to prepare the conjugate and the 
dextran matrix on the surface o f the sensor chip Binding of the polyclonal antibodies 
to either OVA or dextran would result in high background signals and have a 
negative effect on the sensitivity o f the assay Polyclonal R -l and R-2 antibodies 
were passed over both immobilised M3G-OVA, OVA and dextran surfaces at 
dilutions o f 1/500 Figures 4 13 and 4 14 show the binding of R -l and R-2 polyclonal 
antibodies, respectively, to these surfaces Binding of both R-l and R-2 antibodies to 
the OVA and dextran surfaces were found to be negligible as less than 10 RU bound 
compared with approximately 400 RU binding to the conjugate immobilised surface 
for each antibody
Once the regeneration conditions for both antibodies were optimised, the antibody 
solutions were repeatedly injected and the surface regenerated in order to conduct 
regeneration studies These studies demonstrated that for the R -l antibody, it was 
possible to regenerate the surface up to approximately 60 times (Figure 4 15) After 
58 cycles o f binding and regeneration, the response after the injection of the last
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binding pulse was 377 6 RU compared with the first binding pulse o f 451 8 RU 
This resulted in a 16% decrease in antibody binding capacity over this number of 
regenerations However, between cycles 1 and 10 there is a 13 4% drop After the 
first 10 cycles, the binding capacity o f the remaining regeneration cycles drops by 
only 2 6% Consequently, assays performed using such conjugate surfaces were 
exposed to at least 10 regeneration cycles prior to sample analysis Studies 
performed on the R-2 antibody demonstrated that it was possible to regenerate the 
surface up to approximately 50 times (Figure 4 16) After 51 cycles o f binding and 
regeneration, the response after the injection of the last binding pulse was 365 7 RU 
compared with the first binding pulse of 422 8 RU The ligand binding capacity was 
shown to decrease by approximately 13 5% over the course o f the regeneration 
cycles
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Figure 4.12. Typical sensor gram fo r the binding and regeneration o f R -l polyclonal 
antibody to M3G-OVA immobilised onto the surface o f the chip. (1) A 1/500 dilution o f 
antibody was passed over the surface o f the chip with M3G-OVA immobilised with 
approximately 400 response units o f antibody binding. The surface was regenerated by 
passing 1 M  ethanolamine, pH  13.6, over the surface with an initial 2 min (2) pulse 
followed by a 1 min pulse o f the same solution (3).
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Figure 413  Overlay plot demonstrating the binding o f  affinity-purified R~1 polyclonal 
antibody to immobilised M3G-0VA (— ) and OVA (—) surfaces and also over a blank 
dextran surface (—) There was negligible binding to the control OVA and dextran 
surfaces However, approximately 450 response units o f  R-l antibody bound to the 
immobilised M3G-0VA surface indicating the antibody is specific to the M3G portion o f  
the conjugate.
Time (sec)
Figure 414  Overlay plot demonstrating the binding o f  affinity-purified R-2 polyclonal 
antibody to immobilised M3G-OVA (— ) and OVA (— ) surfaces and also over a blank 
dextran surface (— ) This resulted in negligible binding to the control OVA and dextran 
surfaces. However, approximately 400 response units o f  R-2 antibody bound to the 
immobilised M3G-OVA surface indicating the antibody is specific to the M3G portion o f  
the conjugate.
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Figure 4.15. Typical regeneration profile fo r  approximately 60 cycles o f a 4 min binding 
pulse o f affinity-purified R -l polyclonal antibody to the surface o f a chip immobilised with 
M3G-OVA. A 1/500 dilution o f polyclonal antibody was used and the surface regenerated 
with one 2 nun pulse followed by a 1 min pulse o f 1 M  ethanolamine, pH  13.6. After 58 
cycles o f binding and regeneration, the response after the injection o f the last binding 
pulse was 377.6 RU compared with the first binding pulse o f 451.8 RU. The ligand binding 
capacity was shown to decrease by approximately 16% over the course o f the regeneration 
cycles. However, between cycles 1 and 10 there is a 13.4% drop. After the first 10 cycles, 
the binding capacity o f the remaining regeneration cycles drops to 2.6%. When 
performing assays the first 10 regenerations were disregarded.
500 n------------------------------------------------------------------------------------------------
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Figure 416. Typical regeneration profile fo r  approximately 50 cycles o f  a 4 nun binding 
pulse o f  affinity-purified R-2 polyclonal antibody to the surface o f  a chip immobilised with 
M3G-OVA Polyclonal antibody at a 1/500 dilution was used and the surface regenerated 
with three 1 nun pulses in the order o f  40 mM HCl, 40 mM NaOH followed by 40 mM  
NaOH After 51 cycles o f  binding and regeneration, the response after the injection o f  the 
last binding pulse was 365 7 RU compared with the first binding pulse o f  422.8 RU The 
ligand binding capacity was shown to decrease by approximately 13 5% over the course o f  
the regeneration cycles As can be seen there is some fluctuation in the binding o f  
antibody to the surface o f  the chip which may be dependent on the regeneration solutions 
used.
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For the determination of the range of detection o f M3G for a BlAcore inhibition 
assay, a range o f standards o f M3G were prepared in PBS ranging from 11 to 48,800 
pg/ml for R -l and from 122 to 250,000 pg/ml for R-2 antibody The affinity purified 
polyclonal antibodies to M3G were mixed with the corresponding concentration of 
free M3G using the BlAcore autosampler, and allowed to equilibrate for 10 min The 
samples were then passed over the surface of the sensor chip immobilised with M3G- 
OVA in random order, followed by regeneration of the surface using the appropriate 
regeneration solution for each antibody (R-l antibody two pulses for 2 min and 1 
min of 1 M ethanolamine, pH 13 6, R-2 antibody three 1 mm pulses in the order of 
40 mM HC1, 40 mM NaOH followed by 40 mM NaOH) Typical antibody binding 
responses for each mixture o f antibody and drug concentration is shown in Figures 
4 17 and 4 18 for R -l and R-2 antibodies, respectively Figure 4 17 and 4 18 also 
show that as the free drug concentration increases in solution the binding response of 
antibody decreases Calibration curves for both R-l and R-2 antibodies were 
constructed by plotting the change in response for each standard o f free drug against 
the concentration of M3G The range of detection for R -l and R-2 antibodies were 
found to be between 762 and 24,400 pg/ml (Figure 4 19) and 976 and 31,250 pg/ml 
(Figure 4 20), respectively
4 2 3.1 Determination of the range of detection of morphme-3-gIucuronide in
PBS in a BlAcore inhibition assay for R -l and R-2 anti-niorphine-3-gIucuronide
polyclonal antibodies
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Figure 417. An overlay plot fo r a typical set o f  binding curves taken from  one o f  the 
replicates in an inhibition assay. M3G standards ranging from 762 to 24,400 pg/ml o f  free 
drug were mixed with R -l polyclonal antibody and passed over an M3G-OVA immobilised 
surface. The measured binding response was used to construct the calibration curves for  
the intra-day assay variability studies, and used to calculate the normalised binding 
response in conjunction with 2 other normalised binding response curves fo r the inter-day 
assay variabdity studies
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Figure 4 18. An overlay plot for a typical set of binding curves taken from one of the 
replicates in an inhibition assay M3G standards ranging from 976 to 31,250 pg/ml offree 
drug were mixed with R-2 polyclonal antibody and passed over an M3G-OVA immobilised 
surface. The measured binding response was used to construct the calibration curves for 
the intra-dqy assay variability studies.
160
To carry out intra-day assay variability studies, three sets o f a range of standards of 
M3G were prepared m PBS ranging from 11 to 48,800 pg/ml for R -l and from 122 to 
250,000 pg/ml for R-2 antibody and assayed on the same day and their means plotted 
The intra-day assay variability study for R-l shown in Figure 4 19 had a range of 
detection between 762 and 24,400 pg/ml The coefficients o f variation (CV’s) were 
determined to assess the precision o f the analytical method, expressing standard 
deviation as a percent function of the mean These ranged from 3 29% to 15 04% as 
shown in Table 4 1 The intra-day assay variability study for R-2 antibody shown in 
Figure 4 20 had a range o f detection between 976 and 31,250 pg/ml The CV’s were 
determined and ranged from 2 07% to 7 09% as shown in Table 4 2
4.2 3 3. Inter-day assay variability studies of R-l and R-2 anti-morphme-3- 
glucuronide polyclonal antibodies
To carry out inter-day variability studies, three sets o f standards o f M3G were 
prepared in PBS ranging from 11 to 48,800 pg/ml for R -l and from 122 to 250,000 
pg/ml for R-2 antibody and assayed three times over three days The binding response 
at each M3G concentration (Rag) was divided by the antibody binding response 
determined in the presence o f zero M3G concentration (Ro) to give a normalised 
binding response, which allowed inter-day variability comparison of the assay to be 
made The inter-day assay variability study for R -l, carried out over six 
concentrations, had a range o f detection between 762 and 24,400 pg/ml as shown in 
Figure 4 21 The CV’s were determined and ranged from 1 31% to 11 98% as shown 
in Table 4 3 The inter-day assay variability study for R~2 had a range o f detection 
between 976 and 31,250 pg/ml as shown in Figure 4 22 The CV’s were determined 
and ranged from 4 06% to 8 19% as shown in Table 4 4
4 2 3 2 Intra-day assay variability studies of R -l and R-2 anti-morphme-3-
glucuronide polyclonal antibodies
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Table 41 Intra-day assay CV’s for R-l antibody BIAcore inhibition assay Three sets of
six standards ranging from 762 to 24,400 pg/nd were analysed on the same day and the
CV’s calculated.
M3G Concentration, 
(pg/ml)
Calculated mean ± S.D , 
RU
Coefficients of variation
(CV’s), %
24400 23 43 ± 3 52 15 04
12200 48 23 ± 3 55 7 37
6100 125 1 6 1 4  11 3 29
3050 223 25 1 9  40 4 21
1525 319 8 6 1 2 9  63 9 26
762 343 1 6 1 2 4  12 7 03
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Figure 4 19 Intra-day assay curve for M3G using the R-l polyclonal antibody on an 
M3G-OVA immobilised chip surface The residual plot shows the excellent correlation of 
the data set to the four-parameter model f i t  The calibration curve was constructed using 
BIAevaluation 31 software package. The results shown are the average of triplicate 
results and the range of detection of free M3G was found to be between 762 and 24,400 
pg/nd.
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Table 4 2 Intra-day assay CVs for R-2 antibody BIAcore inhibition assay Three sets of
six standards ranging from 976.5 to 31,250 pg/ml were analysed on the same day and the
CVs calculated.
M3G Concentration, 
(pg/ml)
Calculated mean ± S D ,  
RU
Coefficients of variation
(CV’s), %
31250 15 90 ± 1 126 7 09
15625 21 36 ± 1 159 5 42
7812 5 41 20 ± 0  854 2 07
3906 25 98 86 ± 4  521 4 57
1953 1 179 46 ± 6  782 3 78
976 5 206 46 ± 7 454 3 61
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Figure 4 20 Intra-day assay curve for M3G using the R-2 polyclonal antibody on an 
M3G-OVA immobilised chip surface The residual plot shows the excellent correlation of 
the data set to the four-parameter model f i t  The results shown are the average of triplicate 
results and the range of detection offree M3G was found to be between 976.5 and 31,250 
pg/ml
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Table 4 3 Inter-day assay CPs for R-l antibody BIAcore inhibition assay Three sets of
six standards ranging from 762 to 24,400 pg/ml were analysed over three different days
and the CV*s calculated
M3G Concentration, 
(pg/ml)
Calculated mean ± S D., 
R/Ro
Coefficients of variation
(C V ’s), %
24400 0 063 ±0007 11 98
12200 0 14810014 9 85
6100 0 390 ±0 036 9 37
3050 0 744 1 0 065 8 83
1525 0 954 1 0 078 8 26
762 0 963 10  012 1 31
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Figure 4 21 Inter-day assay curve for M3G using the R-l polyclonal antibody on an 
M3G-OVA immobilised chip surface. The results shown are the average of triplicate 
results and the range of detection of free M3G was found to be between 762 and 24,400 
pg/mi The binding response at each M3G concentration (Rag) was divided by the antibody 
binding response determined in the presence of zero M3G concentration (Ro) to give a 
normalised binding response (R/Ro)
1 -
100 1000 10000 100000 
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Table 4 4 Inter-day assay CV’s for R-2 antibody BIAcore inhibition assay Three sets of
six standards ranging front 9765 to 31,250 pg/ml were analysed in triplicate for three
assays over three different days and the CV’s calculated from these assays
M3G Concentration, 
(pg/ml)
Calculated mean 1  S.D., 
R/Ro
Coefficients of variation 
(CV’s), %
31250 0 084 ± 0 003 4 06
15625 0 1 2 6 1 0  008 6 84
7812 5 0 2 7 4 1 0 0 1 1 4 28
3906 25 0 7 0 1 1 0  057 8 19
1953 1 0 8 8 6 1 0  022 5 24
976 5 0 9 8 7 1 0  053 5 45
100 1000 10000 100000 
Log of M3G concentration (pg/ml)
Figure 4 22 Inter-day assay curve for M3G using the R-2 polyclonal antibody on an 
M3G-OVA immobilised chip surface. The residual plot shows the excellent correlation of 
the data set to the four-parameter model f i t  The results shown are the average of triplicate 
results and the range of detection offree M3G was found to be between 976 5 and 31,250 
pg/mL The binding response at each M3G concentration (Rag) was divided by the antibody 
binding response determined in the presence of zero MSG concentration (R0) to give a 
normalised binding response (R/Ro)
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4 2 4 Urine analysis of anti-morphine-3-glucuronide antibodies
The quantitative determination o f M3G in urine samples was also investigated The 
ionic composition of urine can vary considerable from sample to sample To 
compensate for the potential wide inter-individual variability in the salt composition 
of urine, the antibody sample was prepared in PBS of twice the normal ionic strength 
(2 x PBS) Known samples of M3G ranging from 11 to 48,800 pg/ml for R -l and 
from 122 to 250,000 pg/ml for R-2 antibody were spiked into control urine and 
assayed for the presence of free drug with both antibodies Figure 4 23 and 4 24 
show that as the free drug concentration increases in solution the binding response of 
antibody decreases Calibration curves for both R-l and R-2 antibodies were 
constructed by plotting the change in response for each standard of free drug against 
the concentration o f M3G The range of detection in urine for R -l and R-2 antibodies 
were found to be between 762 and 24,400 pg/ml (Figure 4 25) and 976 and 62,500 
pg/ml (Figure 4 26), respectively
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24400 pg/ml
Time (sec)
Figure 4.23. An overlay plot fo r a typical set o f binding curves in a BlAcore inhibition 
assay developed in urine. M3G standards containing 762 to 24,400pg/ml o f free drug were 
mixed with R -l polyclonal antibody and passed over an M3G-OVA immobilised surface. 
The measured binding response was used to construct the calibration curves fo r the intra­
day assay variability studies, and used to calculate the normalised binding response in 
conjunction with 2 other normalised binding response curves fo r  the inter-day assay 
variability comparison.
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Figure 4 24 An overlay plot for a typical set of binding curves in a BIAcore inhibition 
assay developed in urine. M3G standards containing 976 to 62,500pg/nd of free drug were 
mixed with R-2 polyclonal antibody and passed over an M3G-OVA immobilised surface. 
The measured binding response was used to construct the calibration curves for the intra­
day assay variability studies, and used to calculate the normalised binding response in 
conjunction with 2 other normalised binding response curves from assays for the inter-day 
assay variability comparison.
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To carry out intra-day assay variability studies, three sets o f standards o f M3G were 
prepared ranging from 11 to 48,800 pg/ml for R -l and from 122 to 250,000 pg/ml for 
R-2 antibody in urine and assayed on the same day and their means plotted The 
intra-day assay variability study for R -l had a range o f detection between 762 and 
24,400 pg/ml (Figure 4 25) The CV’s were determined and ranged from 2 07% to 
8 70% as shown in Table 4 5 The intra-day assay variability study for R-2 had a 
range of detection between 976 and 62,500 pg/ml (Figure 4 26) The CV’s were 
determined and ranged from 0 44% to 1 92% as shown in Table 4 6
4 2 4 2 Inter-day assay variability studies of R- l and R-2 anti-morphine-3- 
glucuronide antibodies in urine
To carry out inter-day variability studies, three sets of standards o f M3G were 
prepared in PBS ranging from 11 to 48,800 pg/ml for R -l and from 122 to 250,000 
pg/ml for R-2 antibody and assayed three times over three days The inter-day assay 
variability study for R -l had a range of detection between 762 and 24,400 pg/ml as 
shown in Figure 4 27 The CV’s were determined and ranged from 2 95% to 10 80% 
as shown in Table 4 7 The inter-day assay variability study for R-2 had a range of 
detection between 976 and 62,500 pg/ml as shown in Figure 4 28 The CV’s were 
determined and ranged from 1 48% to 11 24% as shown in Table 4 8
4 2 4 1 Intra-day assay variability studies of R -l and R-2 anti-morphine-3-
glucuronide polyclonal antibodies in urine
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Table 4 5 Intra-day assay CVs for R-l antibody BIAcore inhibition assay in urine. Three
sets of six standards ranging from 762 to 24,400pg/ml were analysed on the same day and
the CV*s calculated.
M 3G Concentration, 
(pg/ml)
Calculated mean ± S D , 
RU
Coefficients of variation 
(C V ’s), %
24400 14 6610 40 2 76
12200 37 83 13 29 8 70
6100 81 33 11 77 2 19
3050 122 3012 80 2 29
1525 159 561744 4 66
762 181 6613 76 2 07
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Figure 4 25
an M3G-OVA immobilised chip surface. The results shown are the average of triplicate 
results and the range of detection of free M3G was found to be between 762 and 24,400 
pg/ml
100 1000 10000 100000
Log of M3G concentration (pg/ml)
Intra-day assay curve for M3G in urine using the R-l polyclonal antibody on
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Table 4 6. Intra-day assay CV*s for R-2 antibody BIAcore inhibition assay in urine. Three
sets of seven standards ranging front 976.5 to 62,500pg/nd were analysed on the same day
and the CV*s calculated.
M3G Concentration, 
(pg/ml)
Calculated mean ± S D , 
RU
Coefficients of variation
(CV’s), %
62500 30 40 ± 0 400 1 32
31250 39 76 ± 0 763 1 92
15625 66 13 ± 0  550 0 83
7812 5 159 40 ± 0  800 0 50
3906 25 256 50 ±1 135 0 44
1953 1 304 36 ± 3 842 1 26
976 5 313 70 ± 3  019 0 96
100 1000 10000 100000 1e6
Log of M3G concentration (pg/ml)
Figure 4 26. Intra-day assay curve for M3G in urine using the R-2 polyclonal antibody on 
an M3G-OVA immobilised chip surface. The results shown are the average of triplicate 
results and the range of detection offree M3G was found to be between 9765 and 62,500 
pg/nd.
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Table 4 7 Inter-day assay CV’s for R-l antibody BIAcore inhibition assay in urine. Three
sets of six standards ranging from 762 to 24,400 pg/ml were analysed over three different
days and the CV’s calculated.
M3G Concentration, 
(pg/ml)
Calculated mean ± S.D , 
R/Ro
Coefficients of variation
(CV’s), %
24400 0 104 ± 0  011 10 80
12200 0 196 ± 0  013 6 90
6100 0 501 ± 0  014 2 95
3050 0 671 ± 0  029 4 46
1525 0 903 ± 0 096 10 63
762 0 993 ± 0 064 651
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Figure 4 27 Inter-day assay curve for M3G in urine using the R-l polyclonal antibody on 
an M3G-OVA immobilised chip surface. The results shown are the average of triplicate 
results and the range of detection of free M3G was found to be between 762 and 24,400 
pg/mL
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Table 4 8. Inter-day assay CV’s for R-2 antibody BIAcore inhibition assay in urine. Three
sets of seven standards ranging from 976.5 to 62,500 pg/nd were analysed over three
different days and the CV’s calculated
M3G Concentration, 
(pg/ml)
Calculated mean ± S D , 
R / R ij
Coefficients of variation 
(CV’s), %
62500 0 101 ± 0  007 7 82
31250 0134 ± 0 0 0 8 6 09
15625 0 213 ± 0  005 2 63
7812 5 0 465 ± 0 0 5 2 11 24
3906 25 0 818 ± 0 0 2 5 3 10
1953 1 0 963 ± 0  019 2 07
976 5 0 995 ± 0  014 1 48
100 1000 10000 100000 1e6
Log o f M3G concentration (pg/ml)
Figure 4 28. Inter-day assay curve for M3G in urine using the R-2 polyclonal antibody on 
an M3G-OVA immobilised chip surface The results shown are the average of triplicate 
results and the range of detection offree M3G was found to be between 976 5 and 62,500 
pg/ml
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4 3 Discussion
For the successful development o f an inhibition BIAcore assay to M3G, a number of 
parameters were optimised The first step in setting up such an immunoassay was the 
immobilisation o f M3G-OVA onto the surface of a CM5 sensor chip Immobilisation 
o f conjugates to the surface of the chip at sufficiently high yields to carry out routine 
sample analysis may prove difficult when using EDC/NHS chemistry, as many 
hapten-protein conjugates are characterised by veiy acidic isoelectric points It is 
essential to maximise the interaction between the dextran surface o f the chip and the 
conjugate o f interest in order to immobilise as much conjugate as possible onto the 
surface of the chip At pH values greater than 7, the surface o f the chip has a net 
negative charge Proteins prepared in low ionic strength buffers, which result in the 
pH of the proteins being below their isoelectric point (pi), cause the proteins to be 
electrostatically attracted to this surface By preparing proteins in varying pHs of this 
buffer, the attraction between each protein solution and the surface of the chip may be 
monitored and the pH which provides optimal binding of conjugate to the surface of 
the chip may be determined This preconcentration step is an effective way to 
determine the solutions required for optimal immobilisation of conjugate onto the 
surface o f the chip Figure 1 10 shows the optimal pH for immobilisation of M3G- 
OVA was found to be pH 4 3
The immobilisation of conjugates onto the surface of a CMS chip (section 2 3 112) 
requires a number o f steps The carboxyl groups m the hydrogel of the chip are 
activated by employing EDC/NHS chemistry The water soluble EDC transforms 
surface carboxyl groups into active ester functional groups in the presence of NHS 
These surface NHS esters are then available to react with a suitable amine group 
Conjugates prepared in low ionic solutions optimised from the preconcentration step 
are passed over the surface and binding allowed to occur Immobilisation o f M3G- 
OVA resulted in approximately 6,500 RU binding to the surface of the chip as shown 
in Figure 4 11 corresponding to a protein concentration on the chip o f approximately 
6 5 ng/mm2
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Non-specific binding analysis o f the antibodies was carried out by passing both R-l 
and R-2 antibodies over an OVA immobilised surface and an undenvatised dextran 
surface For both R-l (Figure 4 13) and R-2 (Figure 4 14) antibodies the non-specific 
interactions were found to be negligible This result shows that the antibodies are 
specific for M3G rather than the carrier molecule o f the conjugate
An important consideration when using BIAcore as an immunoassay tool is the 
ability o f the antibodies to be regenerated from the surface o f the chip The 
regeneration of the immunosensor surface is o f critical importance for the 
development o f an assay The use o f hapten-protein conjugates immobilised on the 
surface of the chip can prove difficult when trying to regenerate a surface capable of 
high affinity antibody antigen interactions This may result in the need for harsh 
regeneration solutions to regenerate the surface, which can denature the immobilised 
conjugate The binding-capacity o f both antibodies to conjugate immobilised 
surfaces were determined by a series of binding and regeneration sequences to assess 
how many regenerations were possible before the binding-capacity falls below the 
desired performance parameters (< 20%) (Wong et a l , 1997) Ideally, it is preferable 
to be able to perform multiple binding and regenerations of antibody on the surface of 
one denvatised chip Regeneration conditions for both R -l and R-2 polyclonal 
antibodies were optimised R-l antibody required two pulses for 2 min followed by a 
1 min pulse of 1 M ethanolamine, pH 13 6 R-2 antibody required three 1 min pulses 
in the order o f 40 mM HC1, 40 mM NaOH followed by 40 mM NaOH Results from 
surface regeneration studies showed that R -l antibody was regenerable 
approximately 60 times (Figure 4 15) with a loss of 16% antibody binding capacity 
over this number o f regeneration’s However, between cycles 1 and 10 there was a 
13 4% drop After the first 10 cycles, the binding capacity o f the remaining 
regeneration cycles drops by only 2 6% Consequently, assays performed using such 
conjugate surfaces were exposed to at least 10 regeneration cycles prior to sample 
analysis to minimise loss in antibody binding capacity Studies performed on the R-2 
antibody demonstrated that it was possible to regenerate the surface approximately 50
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times (Figure 4 16) resulting in a 13 5% decrease in antibody binding capacity over 
this number o f regeneration’s
These results are favourable for the development o f BIAcore inhibition assays as both 
antibodies can be regenerated a sufficient number of times without the binding- 
capacity falling below the desired performance parameters This enables the 
development of an inhibition assay
A model inhibition assay was then developed as described in section 2 3 11 7 for 
M3G in PBS for both R -l and R-2 polyclonal antibodies Standards of M3G ranging 
from 11 to 48,800 pg/ml for R -l and from 122 to 250,000 pg/ml for R-2 antibody 
were mixed with R-l and R-2 affinity-purified antibodies at dilutions o f 1/500 These 
mixtures were allowed to incubate for 10 mm followed by injecting them over the 
M3G-OVA immobilised surface for 4 mm The antibody binding response to the 
surface is inversely proportional to the concentration of free drug in solution These 
binding responses were plotted in Figure 4 19 for R -l and Figure 4 20 for R-2 
antibodies and showed that the detection range of R -l antibody for M3G was 
between 762 and 24,400 pg/ml and R-2 antibody was between 976 and 31,250 pg/ml
Both assays displayed low limits o f detection Intra-day and inter-day assay 
variability statistics were then analysed in an attempt to look at the reproducibility of 
the assay Intra-day analysis was compared by taking the mean of each antibody 
binding response at each concentration o f  free M3G for an assay on one day and 
plotting this response on a standard curve against the concentration o f M3G The 
binding response at each antigen concentration (Rag) were divided by the antibody 
binding response determined in the presence o f zero antigen concentration (Ro), to 
give the normalised binding response used for the determination o f inter-day assay 
analysis Inter-day assay precision utilised the mean from each of the three days as 
described by Wong et a l (1997) Intra-day and inter-day assay coefficients of 
variation (CV’s) for R -l were found to be between 3 29 to 15 04% and 1 13 to 11 98%, 
respectively, for 3 replicates (Tables 4 1 and 4 3) Intra-day assay and inter-day assay
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CV’s for R-2 were found to be between 2 07 to 7 09% and 4 06 to 8 19% for 3 
replicates (Tables 4 2 and 4 4) These results indicate that using R-l and R-2 anti-M3G 
antibodies gives accurate, specific and reproducible assays
Both R-l and R-2 antibodies demonstrate low detection limits o f M3G in the BIAcore 
biosensor format However, the R-l antibody shows relatively high CV’s in both the 
intra-day and inter-day assays as they reach 15% R-2 antibody shows CV variations 
do not reach higher than 8%
Having completed the analysis of both antibodies for the development of BIAcore 
inhibition assays in PBS, results showed both antibodies were suitable for application 
on this biosensor The antibodies were found to have negligible non-specific 
interactions with both the carrier protein and the dextran surface Both R -l and R-2 
antibodies were regenerable from the surface o f the chip approximately 60 and 50 
times, respectively This demonstrated the stability of the conjugate on the surface and 
the applicability o f these antibodies to such an assay system With all these 
considerations, and the fact that both antibodies were applicable to this system 
producing excellent results, the aim was to develop a method for the detection o f M3G 
in biological matrices
An inhibition assay was then developed for detection o f M3G in urine as described in 
section 2 3 117 Considerable variations in the ionic composition of urine are evident 
from different samples To compensate for the variation in urine salt composition, the 
antibodies were prepared in 2 x PBS R -l antibody showed a range of detection 
between 762 to 24,400 pg/ml and R-2 showed a range of detection between 976 5 to 
62,500 pg/ml Intra-day and inter-day assay coefficients o f variation (CV’s) for R-l 
were found to be between 2 07 to 8 70% and 2 95 to 10 80%, respectively, for 3 
replicates (Tables 4 5 and 4 7) Intra-day assay and inter-day assay CV’s for R-2 were 
found to be between 0 44 to 1 92% and 1 48 to 11 24% for 3 replicates (Tables 4 6 and 
4 8) The low nature o f the CV’s indicates the reproducibility o f these assays when 
used in sample analysis for the detection o f M3G These low CV’s may be attributed
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to the use o f 2 x PBS as the diluent for the antibodies in these assays as without the 
stabilising affect o f this buffer the pH and ionic strength of unne may have interfered 
with the antibody-antigen interaction
BIAcore technology may be used as an alternative for traditional analytical detection 
systems such as HPLC, CE and ELISA techniques In this case, the BIAcore assay 
developed in our lab compares favourably with other methods o f detection for M3G 
Of the analytical techniques discussed in section 3 1 4, only the HPLC method 
developed by Meng et al (2000) has a lower limit of detection than our assay Also the 
majority of the methods discussed involve some type of sample clean up When 
comparing the M3G assays developed in this chapter to previous assays developed 
using the BIAcore biosensor, results are favourable as both assays developed were 
capable of detecting M3G at pg concentrations BIAcore inhibition assays developed 
by Daly et a l (2000) and Keating et a l (1999) to the mycotoxin aflatoxin Bi and 7- 
hydroxycomarin, respectively, possess limits of detection for aflatoxin Bi of 3 ng/ml 
and 50 ng/ml o f 7-hydroxycomarin
Further comparison of other assays developed include radioimmunoassays developed 
by Spector et al (1971) and Steiner et a l (1978) which have limits o f detection of 50 
pg/ml and 500 pg/ml, respectively, for morphine One ELISA assay developed for 
detection of morphine by Usagawa et a l (1993) has very low limits of detection down 
as low as 100 pg/ml These assays are more sensitive, however, for screening and 
confirmatory analysis, the assay discussed in this chapter is suitable to such 
applications
The purpose of opiate analysis in biological samples is mainly earned out to monitor 
therapeutic levels in patients, drug concentrations in human and animal pharamokinetic 
studies, for the investigation of opiate abuse for drug control as well as to characterise 
causes o f intoxication or death in cases o f clinical, pathological or forensic interest 
(Rashid et a l , 1998) As opioids are metabolised into morphine and then morphine-3- 
glucuromde and various other pharmacologically active compounds, there is a need for
178
sensitive and specific methods of detection of free and glucuromdated forms (Wemly et 
a t, 1993)
The relationship between heroin and other CNS depressants resulting in death by 
overdose is of prime importance and has several implications for research purposes At 
present, very little information is available on blood morphine levels in living, 
intoxicated heroin users Methods for the determination of opiates in living and fatal 
overdose cases are desirable as they would contribute to our understanding of opiate 
related fatalities (Darke and Zador, 1996)
Opiates are widely used clinically in the relief o f moderate to severe pain in advanced 
cancer patients Detection systems may also be used for the clinical study of opiate 
concentrations in blood and urine in the determination o f dose requirements for patients 
in severe pain as monitoring of pain relief may be correlated to specific opiate 
concentrations (Sawe, 1986)
Detection of opiate abuse in rehabilitation centres, industry (includes pre-employment 
testing and for-cause testing), correctional departments and emergency rooms is also of 
pnme importance The testing options for opiates include screening only and screening 
and confirmation of specific opiates or any opiate found Due to the fact that some 
legally available opiates (codeine) result in false positives, the cut-off concentrations 
were raised (cut-off concentration for morphine and codeine were raised from 300 to 
2000 ng/ml) in 1997 in an attempt to prevent these false positives The detection range 
of the assays developed in this chapter are lower than the cut-off concentrations, 
however, they may be used to determine positive results by dilution o f samples to 
within the detection range of the assay (Welsh, 1998)
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Production of Murine Recombinant Antibody Libraries for 
Selection of Anti-Morphine-3-gIucuronide Single Chain Fv 
(scFv) Antibodies for Applications to Immunoassays
Chapter 5
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5 1 Introduction
5 11 The Krebber system for the production of single chain Fv (scFv) 
antibodies
The main requirement o f recombinant antibody technology, using hybridomas or 
immune repertoires as the source of DNA, is the reliable cloning o f functional light 
and heavy chain genes For this purpose, Krebber developed a standard phage 
display system optimised for robustness, vector stability, tight control o f scFv-Agene 
III expression, primer usage for PCR amplification o f variable region genes, scFv 
assembly strategy and subsequent directional cloning using a single rare cutting 
restriction enzyme The Krebber (Krebber et a l , 1997) system allows the rapid 
harvesting of antigen binding scFvs derived from spleen cell repertoires o f mice 
immunised with morphine-3-glucuromde conjugates
A single phagemid vector system used to efficiently express intact scFv fragments on 
the surface of phage was produced by Krebber The vector is known as pAKlOO 
(Figure 5 1 A) and contains a tetracycline (tet) resistance gene, which was picked to 
allow monitoring of digestion by gel electrophoresis and origin o f replication for E  
coh and a chloramphenicol (cam) gene used in the selection of scFv fragments It 
also contains an origin o f phage replication and has directional cloning sites for PCR- 
amplified SOE products The SOE-PCR product is ligated down stream of the single 
pelB leader sequences for efficient E  coh penplasmic transport allowing a low level 
of scFv-glll expression upon induction by IPTG The SOE-PCR product is ligated to 
the C terminal to the gin gene sequence where, upon expression, it forms a fusion 
protein The lac repressor is present to produce strain-dependent lac promoter 
expression The phagemid is now ready to produce phage particles with the help of 
helper phage For soluble expression of scFv fragments the pAK400 (Figure 5 1 B) 
vector is used as the g ill gene has been removed with the addition of a much stronger 
Shine-Dalgarno sequence (SDT7glO) to enhance protein expression in the JM83 
expression host
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An outline o f the Krebber system is shown in Figure 5 2 The first step in the 
production o f a recombinant library using this system was to isolate mRNA from 
murine splenocytes either pre-immunised with an antigen or from an unimmumsed 
mouse The mRNA isolated should theoretically contain the full repertoire o f antigen 
specificities Complementary DNA (cDNA) may then be synthesised from the 
mRNA using random hexamer primers which complement the 5' end of the mRNA 
and using reverse transcriptase to convert mRNA into its cDNA strand 
This cDNA is then used as a template for the PCR amplification of light and heavy 
chain genes using a primer mix specific for this amplification followed by thermal 
cycling to amplify these fragments The PCR pnmers are so designed that they also 
introduce restriction sites at the ends o f the amplified genes for ligation into the 
pAKlOO vector The amplified light and heavy chain genes are then joined together 
by splice by overlap extension (SOE) PCR and this product is purified and digested 
along with the pAKlOO vector with the Sfil restriction enzyme (Figure 5 3 )  The 
digested scFv genes are then ligated into the digested vector and transformed into E  
coh
Helper phage is used to package phagemid DNA into a virion This results in the 
expression of recombinant antibodies on the surface of the phage Screening for 
specific scFvs is carried out by propagation o f E  coh resulting in the excretion of 
virions into the supernatant After separation of phage from cells by centrifugation, 
the phage are added to wells o f a microtitre plate coated with the antigen of interest, 
resulting in binding of specific scFv’s After washing to remove non-specific scFv’s, 
specific fragments are removed from the plate and isolated
Production o f soluble scFv’s is carried out by digestion of the specific DNA from 
positive clones and religation into the pAK400 vector (with the g ill gene removed to 
inhibit phage production) containing a much stronger Shine-Dalgarno sequence for 
increased expression This vector is transformed into JM83 cells for soluble 
expression
As discussed in the paper produced by Krebber et a l (1997), their system contains a 
number o f improved features compared to other systems The Krebber system
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contains more diverse primers enabling the amplification o f more light and heavy 
chain genes The system also contains a FLAG peptide for easier purification and 
splice by overlap extension (SOE) PCR for efficient assembly o f scFv fragments 
Further features include using only one restriction enzyme for digestion of SOE 
products and vectors and insertion of an amber codon allowing switching between 
expression of scFv attached to phage and soluble scFv by changing the expression 
host
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Sfil S fil
Figure 5.1. (A) The pAKlOO phagemid vector. Replication in E. coli is via the Col E l ori 
Resistance is via the cam (chloamphenicol) and tet (tetracycline) resistance genes. For 
phage packaging, pAKlOO carries the intrinsic region from  f l  phage. Directional insertion 
o f light and heavy chain genes ligated to produce SOE product is via the S fil restriction 
enzyme sites, which are downstream from  the Lac promoter/operator and the pelB leader 
sequence. Downstream o f the SOE insertion position is the g ill, fo r  phage surface 
expression o f scFv fragments. (B) The pAK400 vector is used fo r soluble expression o f 
scFv fragments, there are two main differences from  the pAKlOO vector. The g ill  gene is 
replaced with a 6 His tag fo r  IMAC purification and a much stronger Shine-Dalgarno 
sequence fo r enhancement o f protein expression.
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Genetic source for antibody fragment 
production
•Non-immunised/Immunised Mouse
•Hybridomas --------
•Naïve genes for spleen or bone marrow 
• Synthetic genes
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Phage display scFv antibody Soluble scFv expression
Figure 5.2. Schematic diagram illustrating the production o f antibody fragments using the 
Krebber system. Antibody ntRNA is isolated from  a suitable source as listed above. The 
mRNA undergoes reverse transcription and PCR amplification using families o f variable 
5f primers and constant 3 T primers, encoding a restriction sit fo r cutting with Sfil. 
Amplified light and heavy chain genes are joined together by SOE-PCR. Vector and PCR 
product are digested, ligated and transformed in E.colL Phage expression is brought about 
by infection with helper phage, and affinity selection takes place against the desired 
antigen immobilised to a solid support. When specific clones have been isolated, soluble 
antibody may be expressed by religating specific light and heavy chain genes into the 
pAK400 vector (with g il l  gene removed).
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Figure 5.3. Diagrammatic representation o f S fil restriction digestion o f amplified scFv 
fragment and pAKlOO vector. S fil is the only restriction enzyme used in this system fo r  
antibody cloning.
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5 2 Results
5 2 11 Immunisation of mice with morphine-3-glucuronide-bovine serum 
albumin conjugate
Balb/c mice were immunised with a carbodnmide-coupled bovine serum albumini
conjugate to M3 G as described in section 2 3 5 2 Immunisations were carried out 
by subcutaneous and mtrapentoneal injections o f conjugate in Freund's adjuvant and 
the antibody concentrations monitored by taking blood samples to estimate the titre of 
specific antibody Analysis o f the titre was earned out using the ELISA as described 
in section 2 3 8 1
Serial dilutions of mouse serum from 1/300 to 1/300,000 were prepared and added to 
wells o f a microtitre plate coated with M3G-OVA conjugate, followed by labelled 
anti-rabbit antibody and chromogemc substrate Serum from both mice gave a very 
high response to M3G-OVA and both antibodies titred out at about 1/300,000 (Figure 
5 4) On control wells coated with OVA, there was a negligible response indicating 
the antibodies are specific to the M3G portion o f the conjugate These serum 
titrations indicated a sufficient response from the host to isolate splenomic mRNA as 
described in section 2 3 9 1 The concentrations o f isolated mRNA taken from mice 
are listed in Table 5 1
5 2 1 Production of murine scFv antibody libraries to morphine-3-glucuromde
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Figure 5.4. Overlay plot showing the antibody titres o f Mouse-1 and Mouse-2 serum 
before sacrifice. Serial dilutions o f serum were added to wells coated with M3G-0VA. 
Both mice immunised with M3G-BSA gave similar titres o f greater than 1/150,000 to the 
M3G-OVA conjugate and showed minimal non-specific interactions with OVA.
Mouse Num ber mRNA Concentration (¿ig/|il)
1.1. 7.34
1.2. 8.52
1.3. 10.88
2.1. 6.76
2.2. 7.71
2.3. 11.43
Table 5.1. Showing the concentration o f isolated mRNA from  2 mice immunised with 
M3G-BSA. Spleen cells from  each mouse were aliquotted into three samples and the 
concentration o f mRNA o f each aliquot determined
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5 2 12  Selection of primers for amplification of light and heavy chain genes
The set o f mouse primers (section 2 3 9 3 1) described in this chapter for the 
amplification o f mouse light and heavy chain genes have been optimised to 
incorporate all mouse Vh, and VK sequences collected by the Kabat data base 
(Kabat et a l y 1991) and combine extended primer sets described by Kettleborough et 
al (1993), 0rum  e ta l  (1993) and Zhou e ta l (1994)
5 2 13 Amplification of V  region genes and assembly into the scFv format
Reverse transcription to synthesise cDNA was initially carried out on mRNA isolated 
from mice spleen cells immunised with M3G-BSA Using the standard protocol for 
the amplification of heavy and light chain genes as described in section 2 3 9 3 3 
primers amplified a single band of approximately 400 bp for both light and heavy 
chain genes using this cDNA To amplify light chain genes the V l back primer mix 
was paired with five Vl forward primers and to amplify heavy chain genes the Vh 
back mix was paired with four Vh forward primers In all cases, the first PCR 
amplification yielded sufficient amounts of products for cloning, with a sharp band 
produced at the predicted band of 375-402 bp (Figure 5 5) for Vl or 386-440 bp 
(Figure 5 6) for Vh These fragments were purified from the gel as described in 
section 2 3 9 4 and their concentration determined (Table 5 2)
5 2 14 Splice by overlap extension (SO E ) PC R
All amplified Vl and Vh domains after purification were linked together by SOE- 
PCR to produce a combined molecular weight fragment o f approximately 800 bp 
(Figure 5 7)
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5 2 15 Digestion of pAKlOO vector and SO E-PCR products formed by linking 
antibody light and heavy chain genes
The pAKlOO vector and SOE-PCR products formed by linking antibody light and 
heavy chain genes were digested with Sfil restriction enzyme as shown in Figure 5 7 
for digestion o f SOE-product and Figure 5 8 for digestion of pAKlOO and described 
for both in section 2 3 9 8 Figure 5 7 shows the optimisation o f concentrations 
required of Sfil restriction enzyme for the digestion of SOE-PCR product resulting in 
20 units of restriction enzyme being required to digest the fragment fully Figure 5 8 
identifies two mam bands labelled A and B A represents cut pAKlOO vector ready 
for ligation with cut SOE-PCR product while B represents the tetracycline gene 
fragment cut from the vector Band A was purified from the gel as described in
section 2 3 9 4 and the concentration determined (Table 5 2)
5 2 16 Ligation of antibody light and heavy chain genes into the pAKlOO vector
After purification, the SOE-PCR fragment was ligated into the pAKlOO vector at a
molar ratio o f vector to insert o f 1 5 1 as described in section 2 3 9 9
5 2 17 Transformation of E coli X L l-B lue  supercompetent cells with pAKlOO 
vector containing light and heavy chain genes
Supercompetent E co li XLl-Blue cells, with a transformation efficiency of 1 0 x 109 
cfu/jiig o f DNA, were used for the production o f a recombinant antibody library to 
M3G using the procedure described in section 2 3 9 10 Ligation reactions of 
pAKlOO vector and SOE-PCR products were transformed resulting in the production 
o f a M3G recombinant library consisting o f approximately 5 x 103 transformants
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Figure 5.5. Gel showing the amplification o f murine light chain genes from  mouse 1.1 
immunised with M3G-BSA. Lanes: (1) 100 bp molecular weight makers. (2) Negative 
control fo r PCR without any cDNA. (3-8) Amplified 400 bp fragment using primer 
combinations listed in section 2.3.9.3.L under conditions described in section 2.3.9.3.3.
1
1500 b p  1
 400 bp
Figure 5.6. Gel showing the amplification o f murine heavy chain genes from  mouse 1.1 
immunised with M3G-BSA. Lanes: (1) 100 bp molecular weight makers. (2-6) Amplified 
400 bp fragment using primer combinations listed in section 2.3.9.3.I. under conditions 
described in section 2.3.9.3.3. (8) Negative control fo r PCR without any cDNA.
Figure 5.7. Gel showing undigested SOE-PCR product and optimisation o f double 
digestion o f SOE-PCR product using S fil restriction enzyme. Lanes: (1) 100 bp molecular 
weight markers. (2) Shows amplified VL and VH domains linked by SOE-PCR, (3) SOE- 
PCR product digested using 10 units o f S fil restriction enzyme. (4) Digested SOE-PCR 
using 20 units o f S fil restriction enzyme.
1 2 3 4 5
Figure 5.8. Restriction digestion o f pAKlOO vector. Lanes: (1) 100 bp molecular weight 
markers. (2-5) Gel showing the digestion o f pAKlOO vector with S fil restriction enzyme. 
(A) Represents digested pAKlOO plasmid with S fil restriction enzyme. (B) Represents 
digested insert from  plasmid after restriction digest proving the digestion o f the pAKlOO 
plasmid.
Table 5 2 Showing the concentration of DNA of the components for library production
Samples Concentration o f DNA (ng/fil)
M3G Heavy chain Mouse No 1 1 37 7
M3G Heavy chain Mouse No 2 1 39 7
M3G Light chain Mouse No 1 1 25 6
M3G Light chain Mouse No 2 1 172
Splice by Overlap extension (SOE) 75
Digested SOE 4 9
PAK 100 Vector 16 3
PAK 400 Vector 185
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5 2 21 First round selection and screening of functional scFv sequences to 
morphine-3-glucuromde from morphine-3-glucuronide recombinant antibody 
library using phage E L IS A
After transformation of the ligation reaction into supercompetent E co h  XLl-Blue 
cells, production of phagemid particles from the M3 G recombinant antibody library 
was carried out as described in section 2 3 10 1 This resulted in a phage titre 
(section 2 3 10 3 ) o f approximately 4 x 1010 phage particles being produced These 
phage particles were then used in the first round affinity selection o f scFv antibodies 
by panning with M3G-OVA as described in section 2 3 10 4 After panning and 
elution from the immunotube a titration was carried out on the remaining phage 
resulting in a 5 1 x 106 phage particle count Bacterial phage stock cultures were 
produced as described in section 2 3 10 5 after the first round of panning 
95 individual clones (Table 5 3 and Figure 5 9) from the M3G recombinant antibody 
library, following the first round of affinity selection, were grown separately and 
infected by helper phage as described in section 2 3 10 6 The recombinant scFvs, 
displayed on the surface o f filamentous phage, were screened on a plate coated with 
M3G-thyroglobuhn (THY) for antigen binding in a typical phage ELISA as described 
in section 2 3 10 7 Results from the phage ELISA showed that all clones analysed 
possessed affinity to the conjugate producing absorbance readings o f 1 or higher Six 
positive clones, B8, C6, E2, E3, G3 and H5 were selected on the bases of the strength 
of their absorbance readings for characterisation with respect to their affinity for free 
drug However, all the clones showing high absorbance values may be positive 
clones, six were chosen as a model system
5.2 2 Production of single chain Fv antibodies to morphine-3-glucuronide
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5 2 2 2 Analysis of supernatant of anti-morphine-3-glucuronide clones for the 
presence of specific scFv
Competitive phage ELISA’s were carried out for the six clones selected as described 
in section 2 3 10 8 2 Standards of free drug were prepared at drug concentrations of 
50, 25 and 5 |ig/ml and added to neat supernatant at a ratio o f 1 1 The mixtures were 
then added to the wells o f a microtitre plate coated with 100 |ig/ml o f M3G-THY 
Results indicated that the E3 clone was the only clone to exhibit affinity for free M3G 
(Figure 5 10) as absorbance readings decreased as drug concentrations increased
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Table 5.3. Phage ELISA data o f 95 randomly selected clones after the first round o f 
panning o f the M3G library screened against M3G-OVA. Six scFv antibody clones (bold) 
were picked and analysed fo r their ability to recognise free M3G.
1 2 3 4 5 6 7 8 9 10 11 12
A 1.176 1.146 1.150 1.093 1.156 1.102 0.369 1.155 1.154 1.196 1.166 1.143
B 1.141 1.093 1.184 1.099 1.097 1.131 1.118 1.164 1.156 1.111 1.120 1.124
C 1.119 1.107 1.098 1.126 1.104 1.191 1.080 1.120 1.127 1.158 1.113 1.192
D 1.194 1.152 1.102 1.094 1.057 1.119 0.850 1.166 1.086 1.089 1.082 1.159
E 1.112 1.210 1.213 1.175 1.103 1.092 1.150 1.156 1.094 1.092 1.037 1.160
F 1.090 1.095 1.122 1.138 1.111 1.156 1.147 1.122 1.157 1.108 1.122 1.177
G 1.185 1.138 1.174 1.132 1.148 1.147 1.083 1.130 1.125 1.115 1.151 1.223
H 1.176 1.104 1.142 1.170 1.203 1.076 1.113 1.070 1.133 1.146 1.109 0.276
Figure 5.9. Graphical representation o f absorbance data from  ELISA carried out on 95 
clones after the first round o f panning. B8, C6, E2, E3, G3 and H5 scFv antibody clones 
were picked in order to study their ability to bind to free M3G.
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Figure 5.10. Competition enzyme immunoassay carried out fo r free M3G at drug 
concentrations o f 50, 25 and 5 ug/ml on supernatant o f six scFv antibody clones picked 
from  the first round o f panning. As in the cases o f B8, C6, E2, G3 and H5 scFv antibody 
clones, no competition was noted However, the E3 clone shows competition fo r free M3G.
197
5 2 2 3 Second round selection and screening of functional scFv sequences to 
morphine-3-glucuronide from morphine-3-glucuronide recombinant antibody 
library using phage E L IS A
Production o f phagemid particles from the M3 G recombinant antibody library first 
round panning stocks was carried out as described in section 2 3 10 1 This resulted 
in a phage titre (section 2 3 10 3 ) of approximately 6 2 x 1011 phage particles being 
produced M3G-THY conjugate was used as the coating conjugate for the second 
round panning procedure as described in section 2 3 10 4 After panning and elution 
from the immunotube a titration was carried out on the remaining phage resulting in a
6 0 x 108 phage particles count Bacterial phage stock cultures were produced after 
the second round of panning as described in section 2 3 10 5
Again as for the first round of panning, 95 individual clones following the second 
round of affinity selection, were grown separately and infected by helper phage as 
described in section 2 3 10 6 The recombinant scFvs, were screened on a plate 
coated with M3G-OVA for antigen binding in a typical phage ELISA as described in 
section 2 3 10 7 Results from the phage ELISA are shown m Table 5 4 and Figure 
5 11 showing absorbance readings and a graphical representation of the higher 
absorbance readings, respectively Six positive clones, B3, C12, D2, F8, G4 and G12 
were selected on the bases o f the strength of their absorbance readings for 
characterisation with respect to their affinity for free drug
5 2 2 4 Analysis of supernatant of anti-morphine-3-glucuronide clones for the 
presence of specific scFv after second round of panning
Competitive phage ELISA5 s were carried out for the six clones selected as described 
in section 2 3 10 8 2 Standards o f free drug were prepared at drug concentrations of 
50 |Lig/ml, 25 |ig/ml and 5 jig/ml and added to neat supernatant at a ratio o f 1 1 The 
mixtures were then added to the wells o f a microtitre plate coated with 100 (ig/ml of 
M3G-OVA Results indicated that the G12 clone was the only clone to exhibit 
affinity for free M3 G (Figure 5 12)
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Table 5.4. Phage ELISA data o f 95 randomly selected clones after the second round o f 
panning o f the M3G library screened against M3G-THY. Six scFv antibody clones (bold) 
were picked and analysedfor their ability to recognise free M3G.
1 2 3 4 5 6 7 8 9 10 11 12
A 0.492 0.657 0.664 0.634 0.625 0.654 0.565 0.652 0.702 0.568 0.571 0.591
B 0.637 0.592 1.043 0.630 0.660 0.709 0.673 0.532 0.669 0.645 0.762 0.687
C 0.654 0.592 0.884 0.681 0.514 0.767 0.609 0.690 0.850 0.746 0.670 1.035
D 0.564 0.984 0.818 0.558 0.695 0.730 0.887 0.602 0.721 0.693 0.768 0.634
E 0.462 0.526 0.669 0.834 0.818 0.629 0.677 0.616 0.746 0.646 0.699 0.670
F 0.582 0.626 0.597 0.756 0.675 0.578 0.498 1.092 0.740 0.678 0.651 0.660
G 0.520 0.760 0.602 0.913 0.724 0.636 0.606 0.822 0.639 0.698 0.882 0.931
H 0.570 0.765 0.610 0.529 0.589 0.662 0.595 0.715 0.690 0.700 0.713 0.198
Figure 5.11. Graphical representation o f absorbance data from  ELISA carried out on 95 
scFv antibody clones after the first round o f panning. B3, C12, D2, F8, G4 and G12 
clones were picked in order to study their ability to bind to free M3G.
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Figure 5.12. Competition enzyme immunoassay carried out fo r free M3G at drug 
concentrations o f 50, 25 and 5 jig/ml on supernatant o f six scFv antibody clones picked 
from  the second round o f panning. As in the cases o f B3, C12, D2, F8 and G4 clones, no 
competition was noted However, the G12 clone clearly shows competition fo r free M3G.
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5.2.2.5. Broad range competition phage ELISA for positive clones
To further characterise the positive clones screened from the first two rounds o f 
panning and to confirm the ability o f the scFv antibody clones to recognise free M3G 
over a broader range o f drug concentrations, competitive phage ELISA’s were carried 
out on both E3 and G l2 clones. Standards o f free drug were prepared at drug 
concentrations ranging from 195 to 50,000 ng/ml and added to neat supernatant at a 
ratio o f 1:1. The mixtures were then added to the wells o f a microtitre plate coated 
with 100 |ig/ml o f M3G-THY for the E3 clone and 100 jig/ml o f M3G-OVA for the 
G l2 clone. Results indicated that both clones had the ability to recognise free M3G 
over a broad range (Figure 5.13). Further analysis was carried out on the E3 clone for 
the development o f a model system as the E3 clone produced the most accurate linear 
detection range and seems to have the ability to detect lower concentrations o f M3G.
Log of M3G concentration (ng/ml)
Figure 5.13. Competition phage ELISA carried out on supernatant o f positive scFv 
antibody clones screened from  round one and round two panning. Standards o ffree M3G 
between 195 and 50,000 ng/ml were prepared and added to the wells o f a microtitre plate 
coated with conjugate (M3G-THYfor the E3 clone and M3G-OVA fo r the G12 clone) in a 
ratio o f 1:1 with neat supernatant. As free drug concentration increases, the absorbance 
signal decreases indicating the presence o f antibodies specific to M3G.
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5 2 2 6 Digestion of E3 scFv antibody light and heavy chain genes and pAK400 
vector for production of soluble E3 scFv antibody
E3 clone antibody light and heavy chain genes were digested with Sfil restriction 
enzyme as shown in Figure 5 14 There are two mam bands present labelled A and 
B A represents cut pAKlOO vector while B represents the fragment cut from the 
vector containing E3 light and heavy chain genes
The pAK400 vector is used for the production of soluble scFv fragments Digestion 
o f the pAK400 vector is shown in Figure 5 15 showing two main bands present 
labelled B and C B represents the digested pAK400 plasmid while C represents 
digested insert from plasmid after restriction digest as described in section 2 3 9 8 
The band represented by B was gel-purified as described in section 2 3 9 4 and the 
concentration determined (Table 5 2) followed by ligation with E3 clone light and 
heavy chain genes
Ligation reactions o f pAK400 vector and E3 light and heavy chain genes were 
transformed into calcium chloride JM83 competent cells as described in section 
2 3 10 12 resulting in the production of E3 clones capable o f producing soluble scFv 
antibodies
5 2 2 7 Purification and characterisation of E3 soluble scFv antibodies
Soluble E3 scFv antibodies were produced in supernatant as described in section 
2 3 10 13 and purified using Probond™ resin as described in section 2 3 10 15 The 
purified E3 scFv antibody was characterised using both SDS-PAGE gel (section 
2 3 7 6 )  and western blot analysis (section 2 3 7 8 )  as can be seen in Figures 516 
and 5 17, respectively SDS-PAGE gel shows the presence of a band at the molecular 
weight o f 32 kDa while Western blotting confirms that the band at 32 kDa is in fact 
scFv antibody as the detection antibody used was an anti-FLAG antibody capable of 
recognising the 6 His tag present on the scFv antibody
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Figure 5.14. Restriction digestion o f pAKIOO vector containing E3 clone genes. Lanes: 
(1) 100 bp molecular weight markers. (2-5) Gel showing the digestion o f pAKIOO vector 
with S fil restriction enzyme. (A) Represents digested pAKIOO plasmid (B) Represents 
digested insert from  plasmid after restriction digest containing light and heavy chain genes 
fo r E3 clone.
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Figure 5.15. Restriction digestion o f pAK400 vector. Lanes: (I) 100 bp molecular weight 
markers. (2-6) Gel showing the digestion o f pAK400 vector with S fil restriction enzyme. 
(A) Represents undigested pAK400 plasmid (B) Represents digested pAK400 plasmid (C) 
Represents digested insert from  plasmid after restriction digest.
1 2 3 4
Figure 5.16. SDS-PA GE gel analysis o f purified E3 scFv antibody. Lanes 1 & 4 contain 
prestained molecular weight markers ranging from  26 kDa to 116 kDa. Lane 2 represents 
concentrated purified E3 scFv antibody showing a strong molecular weight band o f 32 kDa 
relative to the 36.5 kDa marker (Lactic Dehydrogenase). Lane 3 represents supernatant 
from  E3 clone.
1 2  3 4
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Figure 5.17. Western blot analysis o f purified E3 soluble scFv antibody. Lanes 1 & 4 
contain prestained molecular weight markers ranging from  6.5 kDa to 45 kDa. Column 2 
represents concentrated purified E3 scFv antibody showing a specific molecular weight o f 
32 kDa. Lane 3 represents supernatant from  E3 clone. However, the supernatant was 
dilute and showed no band at 32 kDa.
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5 2 3 Development of a competitive enzyme-linked immunosorbent assay 
(E L IS A ) for morphine-3-glucuronide 
5 2 3 1 Checkerboard E L IS A  for determination of optimal loading ratio of 
conjugate and optimal E3 scFv antibody dilution
The working dilution o f these antibodies was determined using the format already 
discussed in section 2 3 10 16 1 M3G-THY was coated on the wells o f a microtitre 
plate at varying concentrations from 3 125 to 100 |ag/ml, and blocked with 2% (w/v) 
marvel Dilutions o f purified E3 scFv antibody were prepared at ranges from 1/2 
(488 jag/ml) to 1/32 (30 5 (ig/ml) and each dilution of antibody was added to each 
concentration of conjugate on the microtitre plate The results were plotted for the E3 
scFv antibody as shown in Figure 5 18 The optimal conjugate loading ratio was 
found to be 50 |ug/ml with the optimal antibody dilution determined to be 1/10
5 2 3 2 Intra- and inter-day assay variability studies of E3 scFv antibody
To carry out intra-day assay variability studies, three sets of standards were prepared 
for the antibody and assayed on the same day and their means plotted The intra-day 
assay variability study for E3 antibody shown in Figure 5 19 had a linear range of 
detection between 3 05 and 48 8 ng/ml The R2 value for this range was 0 98 The 
coefficients o f variation (CV’s) were determined to assess the precision o f the 
analytical method, expressing standard deviation as a percent function of the mean 
These ranged from 2 64% to 8 03% as shown in Table 5 5 The inter-day assay 
variability study for E3 scFv antibody also had a linear range of detection between 
3 05 and 48 8 ng/ml as shown in Figure 5 20 The R2 value for this range was 0 98 
The CV’s were determined and ranged from 2 52% to 12 55% as shown in Table 5 6 
Studies on the % accuracy level values showed relatively high values for the mter- 
assay variability studies (Table 5 6)
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Figure 5.18. Checkerboard ELISA carried out to determine the optimal dilution o f 
antibody and concentration o f coating conjugate fo r  E-3 scFv antibody. The optimal 
conjugate loading density was determined as 50 /Jg/ml and the optimal dilution o f antibody 
fo r use in a competitive assay was 1/10.
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Table 5 5 Intra-day assay variation for E-3 scFv antibody ELISA assay Three sets offive
standards ranging from 3 05 to 48 8 ng/ml were analysed on the same day
M 3G
Concentration,
(ng/ml)
Calculated mean 
± S .D , Abs
Coefficients of 
variation (C V ’s), 
%
%  Accuracy
48 8 0 296 ± 0 007 264 14 42
24 4 0 42510 031 7 38 5 57
122 0 54910 031 5 79 19 27
6 1 0 60910 024 3 94 6 88
3 05 0 70910 056 8 03 7 54
0 9
0 8
0 7
~  0 6  
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Figure 519 Intra-day competitive ELISA assay o f E-3 scFv antibody for determination of 
the optimal range o f detection o f free M3G using an antibody dilution o f 1/10 M3G-THY 
was coated at a concentration o f 50 fig/mL The linear range o f detection was found to be 
between 3 05 and 48 8 ng/ml
y = -0 1458Ln(x) + 0 8825 
K2 = 0 984
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Table 5 6. Inter-day assay variation for E-3 scFv antibody EUSA assay To carry out
triplicate analysis, three sets of five standards ranging from 3 05 to 48 8 ng/ml were
analysed over three different days
M3G
Concentration,
(ng/ml)
Calculated mean
± S D ,  A/Ao
Coefficients of 
variation (CV’s), 
%
% Accuracy
48 8 0 578 ± 0 072 12 55 55 46
24 4 0 658 + 0 058 8 83 42 37
12 2 0 780 ± 0 026 3 40 40 68
6 1 0 854 ± 0 022 2 63 20 81
3 05 0 954 ± 0 024 2 52 8 19
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Figure 5 20,L Inter-day competitive ELISA assay o f  E-3 scFv antibody for determination of  
the optimal range o f  detection o f  free M3G using an antibody dilution o f 1/10 M3G-THY 
was coated at a concentration o f  50 fig/mL The linear range o f  detection was found to be 
between 3 05 and 48 8 pg/ml
y = -0 1837Ln(x) +1 1436 
R2 = 0 982
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Table 5 7 Cross reactivity studies o f purified anti-morphme-3-glucuromde E-3 scFv 
antibody with structurally related molecules
Compound Inhibition expressed as 
100% inhibition of E-3 
antibody
Morphine-3-glucuromde 100%
Morphine 23 9%
Codeine 28 4%
Nor-codeine 6 5%
6-monoacetyl morphine 15 7%
5 2 4 Cross reactivity studies of E3 scFv antibody
The specificity o f the E3 scFv antibody to morphine-3-glucuromde is critical for the 
performance of the immunoassay Cross reactivity studies were carried out with a 
number of available drugs for this purpose using the ELISA developed as described 
in section 2 3 10 16 2 Microtitre plates were coated with 50 jug/ml o f M3G-THY 
and blocked with 2% (w/v) marvel Standards of morphine, codeine, nor-codeine and 
6-monoacetylmorphine (6-MAM) were prepared and added to the microtitre plate at a 
1 1 ratio with antibody at a dilution o f 1/10 Table 5 7 shows the percentage 
inhibition o f each compound indicating the E3 scFv cross reacts with morphine, 
codeine and 6-monoacetylmorphine
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5 2 5 Analysis of E3 scFv on the BIAcore biosensor
5 2 5 1 Preconcentration and immobilisation of morphine-3-glucuronide- 
thyroglobulin conjugate
For the development of a model inhibition BIAcore assay to M3G in PBS? the first 
step of such an assay was the immobilisation of morphine-3-glucuromde- 
thyroglobulin (M3G-THY) onto the surface of a CM5 sensor chip The 
immobilisation chemistry used was EDC-mediated NHS estenfication as discussed in 
section 2 3 112 To achieve maximum binding, a preconcentration study of M3G- 
THY was carried out as described in section 2 3 111 and shown in Figure 4 10 100 
M-g/ml o f M3G-THY was prepared in 10 mM sodium acetate buffer at a range of pH’s 
from 3 7 to 4 7 These solutions were then injected over an undenvatised chip 
surface and the optimal pH determined for immobilisation of M3G-THY was 4 3 
All subsequent immobilisation’s of M3G-THY were carried out by preparing the 
conjugate at this pH
5 2 5 2 Development of a model inhibition assay for morphine-3-glucuronide in 
PBS
For the successful development o f an inhibition BIAcore assay to M3G, regeneration 
of the surface is essential for the surfaces repeated use in assay formats Also 
removal o f non-specific interactions is important A 1/2 dilution of E3 scFv antibody 
was found to produce a binding response o f approximately 200 RU Regeneration 
conditions for the E3 scFv antibody were optimised and found to require a 1 min 
pulse o f 10 mM NaOH
Non-specific interactions o f the E3 scFv antibody for both the earner protein used to 
prepare the conjugate and the dextran matrix on the surface of the sensor chip were 
analysed and found to be negligible The E3 scFv antibody was passed over both 
immobilised M3G-THY, THY and dextran surfaces at dilutions o f 1/2 Figure 5 21 
illustrates the binding of E3 scFv antibody to these surfaces Once the regeneration
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conditions for both antibodies were optimised, surface regeneration studies were 
conducted by a series o f antibody binding and regeneration pulses These studies 
demonstrated that for the E3 scFv antibody, it was possible to regenerate the surface 
up to approximately 30 times (Figure 5 22) resulting in a 15% decrease in antibody 
bmdmg capacity over this number o f regenerations
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Time (sec)
Figure 5 21 Shows overlay plot demonstrating the binding of affinity purified E-3 scFv 
antibody to immobilised M3G-THY (—) and THY (—) surfaces and also over a blank 
dextran surface (— ) There was negligible binding to the control THY and dextran 
surfaces However, approximately 200 response units of E-3 antibody bound to the 
immobilised M3G-THY surface indicating the antibody is specific to the M3G portion of 
the conjugate
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Figure 5.22. Typical regeneration profile fo r approximately 30 cycles o f a 2 min binding 
pulse o f purified E-3 antibody to the surface o f a chip immobilised with M3G-THY. A 1/2 
dilution o f antibody was used and the surface regenerated with a 1 min pulse o f 10 mM  
NaOH. After 30 cycles o f binding and regeneration, the response after the injection o f the 
last binding pulse was 167.7 RU compared with the first binding pulse o f 197.2 RU. The 
ligand binding capacity was shown to decrease by 14.9% over the course o f the 
regeneration cycles.
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For the determination o f the range of detection of M3G for a BIAcore inhibition 
assay, a range of standards o f M3G were prepared in PBS ranging from 1 5 to 3,125 
ng/ml for E3 scFv antibody The purified antibody to M3G was mixed with the 
corresponding concentration o f free M3G, and allowed to equilibrate for 1 h The 
samples were then passed over the surface of the sensor chip immobilised with M3G- 
THY in random order, followed by regeneration o f the surface using a 1 mm pulse of 
10 mM NaOH A typical antibody binding response for each mixture of antibody and 
drug concentration is shown in Figure 5 23 A calibration curve was constructed by 
plotting the change in response for each standard of free drug against the 
concentration o f M3G The range of detection for the E3 scFv antibody was found to 
be between 6 10 and 195 ng/ml (Figure 5 24)
5 2 5 4 Intra- and inter-day assay variability studies of E3 scFv antibody
To carry out intra-day assay variability studies, three sets o f standards were prepared 
for the antibody and assayed on the same day and their means plotted The intra-day 
assay variability study for E3 shown in Figure 5 24 had a range o f detection between
6 10 and 195 ng/ml The CV’s were determined and ranged from 0 62% to 1 55% as 
shown in Table 5 8 The inter-day assay variability study carried out over three 
separate days for the E3 scFv antibody had a range of detection between 3 05 and 195 
ng/ml as shown in Figure 5 25 and CV’s ranged from 0 96% to 6 36% as shown in 
Table 5 9
5 2 5 3 Determination of the range of detection of morphine-3-glucuromde in
PBS in a BIAcore inhibition assay using E3 anti-morphine-3-glucuronide scFv
antibodies
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-195 ng/ml 
97.5 ng/ml 
-48.8 ng/ml
24.4 ng/ml 
12.2 ng/ml 
-6.10 ng/ml
Time (sec)
Figure 5.23. An overlay plot fo r a typical set o f binding curves in an inhibition assay. 
M3G standards ranging from  6.10 to 195 ng/ml o f free drug were mixed with E-3 scFv 
antibody and passed over an M3 G~ THY-immobilised surface. The measured binding 
response was used to construct the calibration curves fo r the intra-day assay variability 
studies, and used to calculate the normalised binding response in conjunction with 2 other 
normalised binding response curves fo r the inter-day assay variability studies.
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Table 5 & Intra-day assay CV*s for E-3 scFv antibody BIAcore inhibition assay Three
sets of six standards ranging from 610 to 195 ng/ml were analysed on the same day and
the CV’s calculated
M3G Concentration, 
(ng/ml)
Calculated mean ± S D , 
R U
Coefficients of variation
(CV’s), %
195 35 83 ± 0 404 1 13
97 5 41 10 ± 0  458 1 11
48 8 72 1 6 1 0  929 1 29
24 4 128 90 ± 0 793 0 62
12 2 175 80 ± 2  535 1 44
6 10 194 2 6 1 3  008 1 55
o(0c
o
a»
&
o>
«
£
Figure 5 24 Intra-day assay curve for M3G using the E-3 scFv antibody on an M3G-THY 
immobilised chip surface The residual plot shows the excellent correlation of the data set 
to the four-parameter model f i t  The results shown are the average of triplicate results and 
the range of detection offree M3G was found to be between 610 and 195 ng/ml
250 -r
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Table 5 9 Inter-day assay CV*s for E-3 scFv antibody BIAcore inhibition assay Three
sets of seven standards ranging from 3 05 to 195 ng/ml were analysed over three different
days and the CV*s calculated
M3G Concentration, 
(ng/ml)
Calculated mean ± S.D , 
R/Ro
Coefficients of variation
(CV’s), %
195 0 186 ± 0  008 4 56
97 5 0212 ± 0 011 551
48 8 0 342 ± 0  016 4 77
24 4 0 600 ± 0 038 6 36
12 2 0 820 ± 0 040 4 94
6 10 0 898 ± 0  051 5 72
3 05 0 945 ± 0 009 0 96
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Figure 5 25 Inter-day assay curve for M3G using the E-3 scFv antibody on an M3G- 
THY-wunobilised chip surface* The results shown are the average of triplicate results and 
the range of detection of free M3G was found to be between 3 05 and 195 ng/mL The 
binding response at each M3G concentration (Rag) was divided by the antibody binding 
response determined in the presence of zero M3G concentration (Ro) to give a normalised 
binding response (R/Ro)
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5 2 6 Urine analysis of anti-morphine-3-glucuronide E3 scFv antibody
The quantitative determination o f M3G in urine samples was also investigated 
Known samples o f M3G ranging from 1 5 to 3,125 ng/ml were spiked into control 
urine and assayed for the presence of free drug using the E3 scFv antibody Figure 
5 26 shows that as the free drug concentration increases in solution the binding 
response o f antibody decreases A calibration curve was constructed by plotting the 
change in response for each standard o f free drug against the concentration of M3G 
The range of detection in urine was found to be between 3 05 and 97 ng/ml (Figure 
5 27)
5 2 6.1. Intra- and inter-day assay variability studies of E3 scFv antibody in 
urine
The intra-day assay variability study for E3 shown in Figure 5 27 had a range of 
detection between 3 05 and 97 5 ng/ml The CV’s were determined and ranged from 
0 39% to 5 35% as shown in Table 5 10 The inter-day assay variability study carried 
out for the E3 scFv antibody had a range of detection between 3 05 and 97 5 ng/ml as 
shown in Figure 5 28 and CV’s ranged from 0 48% to 18 38% as shown in Table 
5 11
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Figure 5 26. An overlay plot for a typical set of binding curves in an inhibition assay in 
urine M3G standards ranging from 3 05 to 97 5 ng/ml offree drug were nuxed with E-3 
scFv antibody and passed over an M3G-THY-immobilised surface. The measured binding 
response was used to construct the calibration curves for the intra-day assay variability 
studies, and used to calculate the normalised binding response in conjunction with 2 other 
normalised binding response curves for the mter-day assay variability studies.
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Table 510 Intra-day assay CPs for E-3 scFv antibody BIAcore inhibition assay in urine.
Three sets of six standards ranging from 3 05 to 97 5 ng/ml were analysed on the same day
and the CV*s calculated
M3G Concentration, 
(ng/ml)
Calculated mean ± S D ,  
R U
Coefficients o f variation
(CV’s), %
97 5 28 13 ± 1 504 5 35
48 8 33 20 ± 0 529 1 59
24 4 36 20 ± 0141 0 39
12 2 47 06 ± 0  513 1 09
6 10 58 40 ± 0 435 0 75
3 05 59 06 ± 1 274 2 16
65
61
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41
37
33
29
25
10 100 
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Figure 5 27 Intra-day assay curve for M3G in urine using the E-3 scFv antibody on an 
M3G-THY-immobihsed chip surface. The results shown are the average of triplicate 
results and the range of detection of free M3G was found to be between 3 05 and 97 5 
ng/ml
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Table 5.11 Inter-day assay CV’s for E-3 scFv antibody BIAcore inhibition assay in urine.
Three sets of six standards ranging from 3 05 to 97 5 ng/ml were analysed over three
different days and the CV’s calculated
M3G Concentration, 
(ng/ml)
Calculated mean ± S.D , 
R/Ro
Coefficients of va nation
(CV’s), %
97 5 0 435 ± 0 002 0 59
48 8 0 508 ± 0 093 18 38
24 4 0 587 ± 0 052 8 98
12 2 0 7 1 4 1 0  068 9 58
6 10 0 8 5 4 1 0  004 0 48
3 05 0 9 2 9 1 0  007 0 77
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Figure 5 28 Inter-day assay curve for M3G in unne using the E-3 scFv antibody on an 
M3G-THY-immobihsed chip surface The results shown are the average of triplicate 
results and the range of detection of free M3G was found to be between 3 05 and 97 5 
ng/mi The binding response at each M3G concentration (Rag) was divided by the antibody 
binding response determined in the presence of zero M3G concentration (Ro) to give a 
normalised binding response (R/Ro)
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5 2 7 Solution Phase Steady State Affinity determinations
The use o f BIAcore technology has been used to determine the dissociation constant 
of the E3 scFv antibody by using ‘real-time5 biomolecular interaction A known 
concentration of anti-M3G scFv antibody was serially doubly diluted in PBS buffer 
and used to construct a calibration curve of free antibody concentration versus 
response as described in section 2 3 118 and shown in Figure 5 29 A known 
concentration of antibody was then mixed with known concentrations o f M3 G and 
allowed to reach equilibrium Each antibody drug mixture was passed over the 
surface of a chip immobilised with M3G-THY and assayed for ‘free-unliganded’ 
anti-M3G scFv antibodies The concentration of free antibody at equilibrium was 
determined by reference to the standard curve
Equation 5 1 Shows the model fo r solution phase affinity
The equilibrium dissociation constant was calculated by constructing a plot of free
anti-M3G scFv antibodies against free M3G concentration as shown in Figure 5 30 
Equation 5 1 is used as the model for the solution phase affinity constant as the model 
calculates monovalently bound antibody For scFv analysis, this is ideal as the scFv 
possess one antigen binding site The equilibrium dissociation constant for the E3 
scFv antibody was found to be Kd = 2 13 x 108 M
Where Bfree is the free concentration of anti-M3G scFv 
A  is the total concentration of M3G 
B  is the total anti-M3G scFv concentration
Kd is the equilibrium dissociation constant
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ScFv concentration (M)
Figure 529 Serial doubling dilutions of anti-morphine-3-glucuromde antibodies of 
known concentration (M) were passed sequentially over an M3G- THY-coated sensor chip 
surface. A calibration plot was constructed of anti-M3G scFv antibodies (M) versus 
response measured (RU) The calibration plot was then used to calibrate the concentration 
offree antibody at equilibrium, results shown are the average o f triplicate measurements.
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Figure 5 30 Determination of overall solution equilibrium constant for E3 scFv clone and 
M3G on an M3G-THY-coated chip surface. M3G concentrations were plotted against free 
M3G scFv antibody concentration, determined by reference to a calibration plot of anti- 
M3G antibodies. A 1-1 interaction model was used to describe the interaction (equation 
51), and fitted to the data set using BIAevaluation software, deriving an equilibrium 
dissociation constant of KD= 213 x Iff8 M, for the interaction between E3 clone and M3G
Log of M3G concentration
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5 3 Discussion
The mouse antibody titres produced by immunisation with M3G-BSA were 
extremely high Both mice produced titres of approximately 1/300,000 Titrations of 
1/1000 are adequate for scFv production However, higher titres are preferable This 
indicated a high concentration of B-cells producing specific antibody Splenomic 
mRNA was isolation from these spleen cells and used in the production of a 
recombinant antibody library The isolated mRNA was used in the production of 
cDNA followed by the amplification o f the light and heavy chain genes
In many cases, primer sets have been too restncted to amplify either particular light 
or heavy chain genes However, the set o f primers produced by Krebber et a l (1997) 
and used in this chapter have been extended and optimised They incorporate all 
mouse Vh, V x and VK sequences collected by the Kabat data base (Kabat et a l , 1991) 
and combine extended primer sets described by Kettleborough et a l (1993), 0rum  et 
al (1993) and Zhou et a l (1994) The PCR for the production of light and heavy 
chain genes was optimised and the conditions used are described in section 2 3 9 3 3 
Bands of light (375-402 bp) and heavy (386-440 bp) chain gene amplification can be 
seen in Figures 5 5 and 5 6, respectively Results show that the bands for both light 
and heavy chain genes are very clear with minimal production o f non-specific bands 
This is a significant result as production o f non-specific bands would lower the 
concentration and diversity of the specific bands and decrease the overall diversity o f 
the recombinant library produced using the PCR products
Purification o f amplified light and heavy chain genes was performed as described in 
section 2 3 9 4 The light and heavy chain genes were then assembled together by 
splice by overlap extension (SOE) PCR (Figure 5 7) (Horton et a l , 1989) To avoid 
the occurrence o f incorrect overlaps during assembly PCR, the four (Gly4Ser) repeats 
in the single chain linker region were encoded by different codons (Krebber et a l , 
1997) ScFv fragments may have a tendency to dimerize or aggregate In order to 
reduce the occurrence o f this, the linker between the V l and V h regions is 20 amino-
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acids in length rather than the 15 amino acids long variant which is frequently used 
(Krebber et a l , 1997) The SOE-PCR product was purified and digested along with 
pAKlOO vector This was followed by ligation of digested SOE-PCR product with 
digested pAKlOO as described in section 2 3 9 9 Attempts to clone digested heavy 
and light chain SOE-PCR products into the digested pAKlOO vector produced low 
yields o f  transformants (5 x JO3) The failure to produce high numbers of 
transformants may be due to the inefficiency o f the SOE-PCR and pAKlOO to digest 
or to ligate together properly Inadequate overhangs can reduce the efficiency of 
restriction digestion However, due to the pre-immumsed nature o f the splenomic 
cells, which contain highly specific mRNA for production of antibodies to M3G, low 
levels o f efficiency may in fact produce specific scFv antibodies
Selection o f scFv antibodies to M3G was carried out by rounds o f affinity selection 
panning to enrich for antibodies recognising the M3G conjugates The first round of 
panning was carried out by using M3G-OVA as the screening conjugate while M3G- 
THY was used for the subsequent round of panning in order to inhibit the possibility 
of screening for scFv’s specific to the earner protein Results from the first round of 
panning showed 100% of clones selected showing recognition for the M3G-THY 
conjugate which would seem to suggest a non-specific or high back round as the 
cause for such a result However, due to the DNA for library production onginating 
from pre-immumsed splenomic mRNA, results were assumed to be accurate as this 
would suggest the amplified light and heavy chain genes were of a highly specific 
nature After the second round of panning, results also showed high levels of 
response to the conjugate for the clones analysed
Screening of positive scFv producing clones was performed by growing individual 
colonies separately and infecting them with helper phage as described in section 
2 3 10 6 The recombinant scFvs, displayed on the surface o f the filamentous phage, 
were tested for antigen binding in a typical phage ELISA This would simultaneously 
show the recognition of scFv for antigen, while also demonstrating extracellular 
expression if  culture supernatant were used However, clones may prove negative in
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phage ELISA when culture supernatant is analysed but may in fact be positive clones 
This may result due to scFv’s not being efficiently secreted due to particular protein 
structures that result in misfolding and intracellular aggregation (Buchner and 
Rudolph, 1991) This would result in positive scFv antibodies not reaching the 
extracellular matrix, such as the supernatant, causing the ELISA screening technique 
to produce a negative result
Six clones found to be positive in phage ELISA were picked from each round of 
panning and further characterised by antigen competition studies to verify that the 
binding was antigen specific In each round of panning one clone was found to be 
antigen specific and these clones were E3 (Figure 5 10) from round one and G12 
(Figure 5 12) from round two At this point the E3 clone was picked for further 
characterisation and analysis as a soluble scFv in order to develop a model system for 
M3G detection
As the E3 clone possesses antigen-specific characteristics as shown by phage display, 
the next step was to produce a soluble scFv antibody This was carried out by 
digestion of the pAKlOO vector harbounng the light and heavy chain genes o f the E3 
clone and sub-cloning into the pAK400 vector for soluble expression in a JM83 cell 
line Expression medium devoid of glucose was used to increase expression levels of 
recombinant protein (De Beilis and Schwartz, 1990) The pAK400 vector also 
contains a much stronger Shine-Dalgarno sequence (Krebber et a l , 1997), resulting 
in a further significant enhancement of protein expression However, the increase in 
expression levels did not occur for the E3 clone as can be seen in Figure 5 18 
illustrating a titration of purified and concentrated scFv in which the scFv titres out at 
1/32 However, enough antibody was produced to carry out further analysis
A ProBond™ resin column was used in the purification o f scFv antibodies as 
described in section 2 3 10 15 ScFv fragments produced in this library contain a six 
histidine tag allowing purification by IMAC (Lindner et a l , 1992) However, using 
this column was not successful as can be seen in Figure 5 16, as the concentrated
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sample o f scFv contains a number o f non-specific bands This problem has been 
encountered before and may be due to the protein o f interest being present in small 
fractions only This results in several contaminating proteins binding to the column 
and co-eluting with the specific protein (Muller et a l , 1998) Examples o f such
contaminating proteins produced by E  coh are superoxidase dismutase, 
chloramphenicol acetyltransferase, cAMP receptor protein, heat-shock protein and 
many more as described by Wulfing et a l (1994) Further options were analysed for
the secondary purification of the scFv and using an anti-FLAG mAb immunoaffmity 
column was a possible option (Kalinke et a l , 1996) However, due to the lack of 
availability o f a good anti-FLAG antibody this option was not pursued With regards 
to purification, this is an area which may need further optimisation in the future to 
produce a high level o f scFv purity The IMAC-purified scFv was analysed further 
for the purpose o f developing a model system From the SDS-PAGE gel and the 
Western blot analysis it is evident that scFv was purified and concentrated up into a 
usable concentration o f 976 77 |J.g/ml The non-specific bands in the SDS-PAGE gel 
are present but may not effect the further characterisation of the scFv
The purified scFv was then used in the development o f a competitive enzyme-linked 
immunosorbent assay for M3G A checkerboard ELISA for determination o f optimal 
loading ratios of conjugate and optimal anti-morphine-3-glucuronide scFv antibody 
was performed and results are shown in Figure 5 18 An M3G-THY conjugate 
concentration was found to be optimal at 50 (ig/ml This concentration was chosen as 
increasing concentrations o f conjugate did not give an increase in signal and gave the 
widest linear detection range over the range of antibody dilutions used
The scFv antibody dilution used for E3 scFv antibodies was 1/10 resulting in the 
dilution of antibody being the limiting factor in the assay Antibody dilutions chosen 
from the asymptotes o f the antibody dilution curve would show minimal changes in 
response to small changes in antibody concentration resulting in an assay with very 
low sensitivity levels The working dilution for the scFv antibody was picked from
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the linear portion o f the dilution curve as minimal changes in antibody concentration 
give the greatest change in absorbance readings Results showed minimal binding of 
scFv to THY indicating negligible specific antibodies present to the protein part of 
the conjugate As the screening conjugate used was M3G-OVA, there should be 
minimal binding of scFv antibody to any other protein and this is confirmed by the 
low level o f non-specific binding of the scFv
A model competitive ELISA assay was developed for this antibody in PBS where 
standards o f M3G ranging from 1 5 to 781 ng/ml were prepared and mixed with 
purified antibody at dilutions of 1/10 The E3 scFv antibody showed a range of 
detection between 3 05 and 48 8 ng/ml The assay displayed excellent linearity with 
very low limits o f detection Intra-day and inter-day assay variability statistics were 
then analysed in an attempt to look at the reproducibility o f the assay Intra-day and 
inter-day assay coefficients of variation (CV’s) for the E3 scFv were found to be 
between 2 64 to 8 03% and 2 52 to 12 55%, respectively This result indicates that this 
anti-M3G antibody gives an accurate, specific and reproducible assay The low nature 
of the CV’s shows that the assay may be used to detect samples o f M3G in urine 
Studies earned out on the % accuracy levels resulted in high values particularly for the 
inter-day variability studies indication the assay may only be applicable for 
confirmatory assay analysis However, the main problem associated with the assay is 
the concentrations o f antibody used to perform the assay A 1/10 dilution o f antibody 
is required for the assay, limiting the number o f assays that can be performed due to the 
amount of antibody available Further analysis o f this antibody for sample analysis in 
ELISA was not earned out for this reason as the quantities o f antibody required were 
too great
Cross reactivity is defined as a measure o f the antibody response to structurally 
similar molecules Table 5 7 shows the inhibition expressed as 100% inhibition of 
the E3 scFv antibody Competitive assays were carried out with a range of 
metabolites o f heroin Morphine, codeine, nor-codeine and 6-monoacetylmorphine 
standards were prepared and added onto a microtitre plate with a mixture of a 1/10 
dilution of E3 scFv antibody As results indicate the scFv antibody shows some cross
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reactivity with morphine, codeine and 6-monoacetylmorphme with very little cross 
reactivity to nor-codeine These results demonstrate that the scFv recognises an 
epitope common to some of the molecules related to morphine-3-glucuromde
Having shown that the E3 scFv antibody was suitable for use in an ELISA assay of this 
type, the aim was to develop a similar method of detection o f M3G using the BIAcore 
biosensor
For the successful development o f an inhibition BIAcore assay to M3G a number of 
parameters were optimised as discussed in chapter 4 The first step in setting up such 
an immunoassay was the immobilisation o f M3G-THY onto the surface of a CM5 
sensor chip It is essential to maximise the interaction between the dextran surface of 
the chip and the conjugate of interest in order to immobilise as much conjugate as 
possible onto the surface of the chip, this was achieved by preparing the M3G-THY 
conjugate in sodium acetate buffer, pH 4 3
Non-specific analysis was carried out by passing the scFv antibody over a THY- 
lmmobilised surface and an underivatised dextran surface For the scFv antibody the 
non-specific interactions were found to be negligible This result shows that the 
antibody is specific for M3G rather than the carrier molecule o f the conjugate
As discussed in chapter four an important consideration when using BIAcore as an 
immunoassay tool is the ability o f  the antibodies to be regenerated from the surface of 
the chip The binding-capacity o f antibody to conjugate immobilised surfaces was 
determined by a series o f binding and regeneration sequences to assess how many 
regenerations were possible before the binding-capacity falls below the desired 
performance parameters (< 20%) Ideally, it is preferable to be able to perform 
multiple binding and regenerations of antibody on the surface of one denvatised chip 
Regeneration conditions for the E3 scFv antibodies were optimised and found to 
require a 1 mm pulse of 10 mM NaOH Results from surface regeneration studies
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showed that the antibody was regenerable approximately 30 times with a loss of 
14 9% antibody binding capacity over this number o f regeneration’s
These results are favourable for the development o f BIAcore inhibition assays as the 
E3 scFv antibody can be regenerated a sufficient number o f times without the 
binding-capacity falling below the desired performance parameters This enables the 
development o f an inhibition assay The optimised regeneration solutions required 
were found to be of a low concentration resulting in minimal damage being caused to 
the surface immobilised conjugate during the assay
Model inhibition assays were then developed as described in section 2 3 11 7 for 
M3G in PBS Standards o f M3G were prepared and mixed with the E3 punfied 
antibody at a dilution o f 1/2 followed by incubation at 37°C for 1 h to allow the 
reactions to reach equilibrium These mixtures were then passed over an M3G-THY 
immobilised surface for 2 mm resulting in an antibody binding response to the 
surface being inversely proportional to the concentration o f free drug in solution 
This binding response was plotted in Figure 5 24 showing that the detection range of 
the E3 scFv antibody for M3G was between 6 10 and 195 ng/ml
Studies were performed on the intra- and inter-day variability o f the assay The CV’s 
for both were found to be low, especially in the intra variability assay where CV 
values were typically found to be lower than 2% Inter variability CV’s were found 
to be slightly higher in the order of approximately 5%, however, these are well within 
the desired performance parameters Overall, these results indicate that the E3 scFv 
anti-M3G antibody gives accurate, specific and reproducible assays in PBS
An inhibition assay was then developed for detection o f M3G in urine as described in 
section 2 3 117 The E3 scFv antibody showed a range of detection of M3G between 
3 05 and 97 5 ng/ml Intra-day and inter-day assay coefficients o f variation (CV’s) for 
the assay were found to be between 0 39 to 5 35% and 0 48 to 18 38%, respectively 
The overall results from the CV’s for the assays developed in urine were found to be
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low A CV of 18 38% was seen for the 48 8 ng/ml concentration o f M3G in the inter­
day variability studies However, all other points within the assay are below 10% 
indicating the assay may be used for sample analysis
The assays developed in our lab to M3G using both the ELISA and BIAcore formats 
compare favourably to some HPLC and GC-MS assays in the literature Of the 
analytical techniques discussed in section 3 14, assays developed by Low et al (1995), 
Zheng et al (1998) and Beike et al (1999) have detection limits down to low ng/ml 
levels compared to a detection limit of 3 ng/ml for the assays developed in our lab 
However, assays developed by Meng et al (2000), Spector et a l (1971) and Steiner et 
al (1978) have all shown to have detection limit in the low pg/ml levels resulting in 
these assays being much more sensitive than the assays developed in our lab The 
suitability o f our assay for sample analysis is still possible, as the assays range is 
suitable for the confirmatory cut-off concentrations for opiate abuse (l e morphine and 
codeine- 2000 ng/ml, 6-M A M -10 ng/ml)
The final step in the analysis o f the E3 scFv antibody clone was to determine the 
solution phase steady state affinity constant The method employed as described in 
section 5 2 7 used the same principle as that employed in the method of Fnguet et a l 
(1985) However, the method employed in this chapter holds a number o f advantages 
over the Friguet method The mam advantage is the short contact time of equilibrated 
mixtures in the flow cell and continuous flow o f equilibrated mixtures resulting in a 
decrease in the possibility o f re-equilibration and underestimation of the affinity 
constant The method on BIAcore also does not require labels which may affect the 
calculated constant The solution phase steady state affinity constant was calculated 
using equation 5 1 and determined to be KD = 2 13 x 108 M The data obtained from 
the analysis fits the monovalent model particularly well and describes the interaction 
between the antibody and the conjugate coated surface accurately
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Production and Application of Polyclonal Antibodies
to Parathion
Chapter 6
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6 1 Introduction
6 11  O rganophosphates
Organophosphates (OPs) are the most commonly used insecticides (Table 6 1 ) 
Although they were developed in the early 19th century, it was not until the early 
1930’s that their toxicity to insects was discovered resulting in neurological diseases 
(O’Brien et a l , 1967) Structurally, organophosphates possess a central phosphorus 
atom and numerous side chains The generic structure o f the organophosphate 
compounds is shown in Figure 6 1 where X is a leaving group of variable structure 
and Ri and R2 are alkoxy, amino, thioalkyl, phenyl or other substituent groups (Storm 
et a l , 2000) OPs are categorised based on the nature o f the atoms immediately 
surrounding the central phosphorus atom (Chambers, 1992)
Ri
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R 2
Figure 61  Generic organophosphate structure
One characteristic of the OPs which has led to their wide usage in agriculture is that 
they are much less persistent in the environment compared to other insecticides OPs 
have been extensively used to control pests in agriculture for many years resulting in 
the accumulation of these pesticides over this period of time within the environment
O
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to such an extent that OPs are now considered environmental pollutants Public 
health authorities are thus extremely concerned with the levels o f OPs within the food 
chain This has prompted health authorities to set up acceptable Maximum Residue 
Levels (MRLs) which are stringently adhered to
In recent years, OPs are bemg replaced m some uses with the carbamate insecticides 
which possess lower toxic properties towards humans and wildlife
Table 6 1 Organophosphates
Acephate Formothion
Azinphos-methyl Isofenphos
Bensuhde Malathion
Carbophenothion Methidathion
Chloropyrifos Methyl-parathion
Coumaphos Mevinphos
Demeton-S-methyl Monocrotophos
Diazinon Naled
Dichlorvos/DDVP Parathion
Dicrotophos Phorate
Dimethoate Phosalone
Disulfoton Phosmet
Endothion Phosphamidan
Ethion Phoxim
Fenamiphos Propetamphos
Femtrothion Temephos
Fenthion Terbufos
Fonofos
1
Tnchlorfon
6.1.11 Mechanism of action and toxicity
Organophosphate pesticides (OPs) have the same toxic mechanism for both insects 
and mammals Cytochrome P45O-dependent monooxygenases have the ability to 
activate phosphorothionate insecticides to toxic anti-cholmesterases (Davison et a l , 
1955, Gage et a l , 1953, Wagner et a l , 1989) The organophosphate pesticides are 
converted mto their oxon analogs (Figure 6 3) by oxidative désulfuration (Levi and 
Hodgson, 1985) This reaction requires reduced NADP and O2 and is inhibited by
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CO (Kulkami and Hodgson, 1984) The majority o f the oxon active metabolites are 
assumed to be produced in the liver, from where it gains entry into the circulatory 
system to find its target molecule, the enzyme acetylcholinesterase (AChE)
OP compounds cause the enzyme acetylcholinesterase to become inactive (Mileson et 
a l , 1998) The function o f this enzyme is to increase the rate o f breakdown of 
acetylcholine (ACh) ACh is produced in the nerve cells and allows the transfer of 
nerve impulses from one nerve cell to a receptor cell (1 e muscle cell)
AChE’s fUnction is as a negative feedback control enzyme, breaking down ACh by 
chemical inactivation thus regulating the transfer of nerve impulses Without the 
breakdown of ACh by the enzyme AChE nerve impulses will carry on continuously 
High levels o f ACh results in a number o f effects in mammals such as weakness or 
paralysis o f the muscle (Gallo et a l , 1991) Death may occur when AChE’s activity 
falls to about 10-20 % of normal levels o f activity and this causes respiratory failure 
or cardiac arrest
Individual OPs possess different mechanisms of action Some function as contact 
poisons while others are stomach poisons Humans may come in contact with OPs in 
a number o f ways, which include absorption through the skin, inhalation and direct 
ingestion However, OPs are toxic through all routes of entry Inhalation of OPs 
initially affects the respiratory system, and may cause bloody and runny nose, chest 
discomfort, coughing and wheezing Contact with skin causes sweating and 
involuntary muscle contractions Contact with eyes can cause effects such as pain, 
tears, bleeding, and blurred vision Symptoms may appear within a time period of a 
few minutes to twelve hours Other symptoms include nausea, vomiting, diarrhoea, 
headache, dizziness and confusion In severe cases the central nervous (spinal cord, 
brain) and the peripheral nervous systems (nerve and fibres) can be greatly affected 
(Smith, 1993) Symptoms include defecation, psychosis, unconsciousness, 
convulsions, coma and irregular hearts beats OPs do not affect reproduction with 
respect to normal exposure levels (Gallo et a l , 1991, Storm et a l , 2000) However, 
some organophosphates (i e malathion) have been found to affect pregnancies of 
women exposed to high levels
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OPs have the ability to stay active for months after their application However, they 
are much less persistent than other pesticides This feature causes no great threat to 
water pollution over the long term The mam organophosphate of interest in this 
chapter is parathion and its mode of action is descnbed in section 6 12  1
6.1 1 2 Detection of organophosphate pesticides
Many o f the detection methods for organophosphate pesticide analysis have been 
based on conventional chromatographic (HPLC, GLC) and colourimetnc procedures 
For example, Ding and Krull, (1984) used high-performance liquid chromatography 
(HPLC) with on-line photolysis (hv), followed by electrochemical detection of 20 
different organophosphates Minimum quantities o f malathion and parathion 
detectable by this method were 50 ppb and 20 ppb, respectively (enabling this method 
to be applied to crop extracts)
Bottomley et a l (1984) developed a multi-residue method for determination of 
organophosphate pesticides in gram by GLC Following extraction using acetone- 
methanol, pesticides were separated from co-extractives by a partition process with 
dichloromethane and chromatography on an acidic aluminium oxide column Packed 
column gas-liquid chromatography with flame-photometric detection was used with 
minimal limits of detection o f 0 1 mg Kg 1
Further methods of detection of pesticides are continuously being developed as 
described by Sng et a l (1997) This paper describes the development o f a solid- 
phase microextraction (SPME) method for the analysis o f pesticides in water The 
advantage of this system is the ability o f the system to directly analyse chemical 
species in aqueous systems avoiding sample clean-up The samples are then analysed 
by gas chromatography
A method for the detection of seventeen pesticides by gas chromatography was 
developed by Soleas et a l (2000) Solid-phase extraction of a 0 5 ml sample of wine 
was followed by direct injection o f 1 jul o f the eluent onto a DB-5 MS gas 
chromatographic column This was followed by mass-selective detection using one 
target and two qualifier ions for each pesticide Recovery rates for all compounds
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were found to be higher than 80% and the detection and quantitation limits were 2 
|ig/l and 10 |ag/l, respectively
Tuovinen et a l (2000) have developed a system for the detection o f pesticides from 
liquid matrices by aspiration of ion mobility spectrometry This technology is based 
on ion mobility which is proportional to the molecular weight and charge and has the 
ability to measure changes in the product ion as well as mobility changes o f reactant 
ions The detection method is based on differences m the gas phase profiles of the 
different compounds and results have shown the ability o f this system to analyse 
pesticides with limits of detection ranging from ng to (ig levels However, most of 
these methods require many clean-up steps and are quite labour intensive 
Development o f immunoassays have become a favourable alternative to these 
methods in relation to the cost involved, the ease of use of the method and the lack of 
clean-up steps required For low molecular weight analytes such as pesticides in 
solution, competitive tests have been employed using limiting antibody 
concentrations There are two main formats used in such assays The first allows the 
antibody to be directly immobilised onto the surface of the plate and competition 
occurs as labelled and unlabelled analyte compete with each other for the binding 
sites on the antibody The second method employs a system where a hapten-carrier 
conjugate is immobilised onto the surface of a plate and free and bound analyte 
compete for the binding site on the antibody The amount o f antibody bound to the 
surface of the plate is directly proportional to the amount of free analyte in solution 
Deschamps et a l (1990) also employed polyclonal and monoclonal antibodies for the 
detection of the pesticide picloram The assay developed using polyclonal antibodies 
had a linear range of detection from 5 to 5,000 ng/ml Using a monoclonal antibody 
the range of detection was from 1 to 200 ng/ml The results indicated that the 
monoclonal antibody was more sensitive, accurate and precise compared to the 
polyclonal antibody and only the monoclonal antibody assay was suitable for 
quantitative determination o f picloram
An immunoassay was developed by McAdam et a l (1992) Initially femtrothion 
(FN) was coupled to a carrier-protein for the production o f monoclonal and 
polyclonal antibodies These antibodies were used in the development o f an ELISA
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assay for femtrothion Assay formats using either immobilised antibody or the 
immobilised hapten-protein conjugate were used to determine concentrations of 
femtrothion in solution resulting in assays with detection limits as low as 1 ng 
Skerntt et a l (1992) developed simple competitive ELISA’s for three 
organophosphates, femtrothion (FN), chloropynfos (CPM) and pirimiphos-methyl 
(PLRM) These assays had sensitivities o f low parts per million ranges No clean-up 
of samples was required and gram, flour and wheat were analysed for these 
compounds The assays used polyclonal antibodies to PIRM and monoclonal 
antibodies to FN and CPM Minimum detection limits for the pesticides were 2 
ng/ml for PIRM, 30 ng/ml of FN and 10 ng/ml for CPM
In general, anti-OP antibodies developed for detection assays are very specific 
towards a single analyte Although antibody specificity is an advantageous 
characteristic for low level detection o f trace amounts o f individual OPs, there are 
applications in which broad-specificity antibody recognition o f groups o f analytes 
would be desirable Such antibodies may be applied m cost effective screening 
programmes and for assays with the purpose of providing a positive or negative result 
for the presence of the analytes Alcocer et a l (2000) produced broad-specificity 
antibodies against a group of organophosphate pesticides by using phosphomc acid 
(TPB) as a generic hapten Results showed that detection o f a number o f pesticides 
had a poor limit of detection using this antibody It was possible to lower the limits 
of detection 20 fold by coating the OP of lower affinity (diethyl-parathion-BSA) onto 
the surface of the plate
Progress is also being made in detection o f  pesticides in the field o f immunosensors 
Some of these sensors use optical systems such as surface plasmon resonance or 
grating couplers Minunni and Mascini, (1993) used the BIAcore biosensor in the 
development o f a detection method for atrazine while Bier and Schmid, (1994) 
developed a grating coupler immunosensor for determination o f terbutryn, a tnazine 
herbicide with detection limits o f 5 05 |ag/l and 3 6 (ig/1, respectively 
The future in pesticide detection may lie in the new strategies in antibody production 
being developed Genetically engineering antibodies with the required affinity and 
stability for use in specific assays is now possible as these antibodies may be tailored
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for a specific characteristic One example o f the use o f this technology is described 
m a paper by Garrett et a l (1997) where anti-parathion scFv antibodies were 
produced and applied to an assay system for the detection o f parathion
6 1.2 Parathion
Parathion was discovered by Schrader in 1946 and since then has become one of the 
most widely used of all the organophosphate pesticides Parathion is a yellow to dark 
brown liquid with a phenol like odour It is used in a wide variety of crops l e 
cereals, fruit, vines, vegetables and field crops The structure of parathion is shown 
in Figure 6 2 and contains the characteristic phosphorus group attached to oxygen, 
which is common to the majority of organophosphate pesticides Sulphur, nitro, two 
ethyl groups, and a ring structure are also present in this molecule
Figure 6 2 Structure o f parathion
Parathion is considered to be a very toxic chemical Exposure can occur through 
inhalation or through contact with the skin Death may occur from contact with the 
skin even thought no discomfort or irritation may be felt Symptoms associated with 
exposure to this organophosphate are similar to those produced by all 
organophosphates and are sweating, nausea, headaches, diarrhoea, vomiting and loss 
of coordination (Kamrin, 1997)
S
n o 2
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6 1 2  1 Mechanism of action
Parathion is a non-systemic insecticide and acaracide with contact action, through the 
stomach and also possesses some respiratory action Parathion itself is a poor 
inhibitor o f acetylcholinesterase, whereas its oxon analogue is a very active 
anticholinesterase agent The toxicity o f parathion is therefore due to its in vivo 
metabolism Upon exposure the mammalian system metabolises parathion (Figure 
6 3) to it toxic oxygen analogue, paraoxon, and to its non-toxic analogs p-mtrophenol 
and diethyl phosphate or diethyl thiophosphate by the cytochrome P45O-dependent 
monooxygenase pathway (Neal et a l , 1967, Nakatsugawa et a l , 1968)
Most instances o f death in mammals exposed to parathion are due to failure of the 
respiratory system Once parathion has been metabolised into paraoxon, it begins to 
inhibit the activity o f the acetylcholinesterase Paraoxon is then transferred to the 
lungs and brain by the circulatory system Respiratory failure occurs as AChE is 
inhibited as discussed in section 6 1 1 1
6 1 2  2 Detection of parathion
In the past, residues of parathion have been detected by gas-liquid chromatography 
(GLC), spectrophotometry and polarographic methods However, over the past few 
decades, antibody-based methods have been developed as favourable alternatives for 
either the identification or quantification of pesticides Ercegovich et a l (1981) 
developed a radioimmunoassay (RIA) which provides a simpler procedure that 
required less clean-up steps than conventional methods as real samples may be used 
without the need for purification Parathion-specific polyclonal antibodies were 
produced and used in the development o f an RIA method by using either 3H- or 14C- 
labelled parathion as a tracer The lowest detection levels were found to be 4 ng of 
parathion in model solutions and between 10-20 ng in blood plasma and lettuce 
without any cleanup of the sample However, this method also has its disadvantages 
as it requires expensive equipment and highly trained personnel and also possesses 
radiation risk with long analysis times
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Figure 6 3 Proposed metabolic scheme for cytochrome P450-dependent 
biotransformation o f parathion (A) Represents reaction catalysed by cytochrome P450, 
while all others occur nonenzymatically (C) Represents reaction o f activation to paraoxon 
and S  (B) Detoxification to p-mtrophenol and diethyl phosphate. (D) Detoxification to p- 
nitrophenol and diethyl thiophosphate.
Bnmfield et a l (1985) developed a competitive enzyme immunoassay for paraoxon, 
which is the principal metabolite of parathion Monoclonal antibodies were produced 
to paraoxon Significant cross reactivity was found with parathion and paraoxon with 
respect to these antibodies Results from the CIEIA showed a detection linear range 
from 10 to 100 |ig/ml with a minimum detectable concentration o f 1 jug/ml for 
paraoxon
Garrett et a l (1997) described a method for the production o f recombinant scFv anti- 
parathion antibodies The scFv was produced from a hybridoma cell line secreting 
anti-parathion antibodies In this paper the feasibility o f such an antibody was tested 
by comparing the scFv to a monoclonal antibody Results showed the scFv possessed 
similar charactensties to the monoclonal antibody when tested against parathion in 
food extract analysis Both antibodies were found to be stable in the presence o f 10% 
(v/v) methanol and the minimum limits of detection were 16 ng/ml and 23 ng/ml for 
the monoclonal and scFv fragment, respectively These findings indicate the 
potential for the use o f recombinant scFv antibodies for the detection of 
organophosphate compounds in food samples
A method of analysis for detection of paraoxon, was developed by Campanella et al 
(1996) using biosensors The study involved the comparison of two new solid state 
biosensors which used a graphite electrode, coated with an ion-selective polymeric 
membrane sensitive to pH The principle o f both combined the inhibiting action of 
paraoxon with the enzyme butrylchohnesterase The first biosensor used the enzyme 
butrycolinesterase immobilised on a functional nylon membrane The second 
biosensor format used butrycholinesterase coated on a polymeric membrane by a 
polyazetidine prepolymer Results from the first biosensor analysis which used the 
enzyme butrycolinesterase immobilised on a functional nylon membrane, showed a 
minimum detection limit o f 10 ng/ml for paraoxon while the second format showed a 
detection limit o f 30 ng/ml When also comparing analysis times the second 
biosensor proved a more promising format for paraoxon analysis 
Horacek et a l (1998) used recombinant anti-parathion single chain Fv antibody 
(scFv) fragments to charactense antibody-parathion interactions using a piezoelectric
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biosensor Parathion was chemically linked to a layer o f aminothiophenol using 
either bovine serum albumin or dextran as spacer molecules Dissociation (Kd) and 
association (Ka) rate constant studies were then carried out Regeneration of 
parathion-BSA coated surfaces was not successful However, parathion-dextran 
surfaces were successfully regenerated Comparisons were then carried out between 
the anti-parathion monoclonal antibody and the scFv antibody Results showed a 50 
x lower affinity o f the scFv antibodies for parathion compared to the monoclonal 
antibodies
The development o f ELISA-based immunoassays for the detection of parathion as a 
model system in PBS is investigated in this chapter Polyclonal antibodies were 
generated and used for the development of a competitive ELISA for parathion The 
ability o f the model assays to measure free drug concentrations was studied and the 
results obtained were assessed in relation to the accuracy and the precision of the 
assays Further studies were carried out on the applicability o f this anti-parathion 
antibody to biosensor analysis
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6 2 Results
Conjugates to parathion were prepared according to the method of Ercegovich et al 
(1981) This required the reduction o f parathion to amino-parathion as described in 
section 2 3 2 2 1 Parathion and amino-parathion were analysed by infra red 
spectrophotometric scans for identification purposes The IR spectrum of the 
parathion (Figure 6 4) molecule was found to possess stretches at 1350 and 1526 cm 1 
corresponding to the symmetrical and asymmetrical stretches associated with an - 
NO2 The IR spectrum for the amino-parathion (Figure 6 5) molecule was found to 
possess stretches at 3322 and 3402 cm 1 corresponding to the NH2 asymmetrical and 
symmetrical stretches However, the bands at 1350 and 1526 c m 1 were not present 
in the amino-parathion molecule confirming that the -NO2 group has been exchanged 
for an -NH2 group
A number of amino-parathion-protein conjugates were generated for the production 
of polyclonal antibodies and also for the affinity purification o f antibodies for assay 
development Amino-parathion was coupled to various proteins (Ercegovich et a l , 
1981) using diazo-couphng chemistries as described in section 2 3 2 2 2  The 
conjugates produced were dialysed extensively against H2O over five days to remove 
any unconjugated amino-parathion In all cases, a characteristic orange colour 
appeared indicating the formation of a diazomum bond Charactensation of a 
parathion-OVA conjugate was carried out and is shown in Figure 6 6 
Spectrophotometric scans were carried out on OVA before and after conjugation to 
parathion Figure 6 6(A) shows the OVA molecule with characteristic peaks at 260 
and 280 nm However, after conjugation to parathion a third peak is present at 320 
nm (Figure 6 6(B)) representing the attached parathion The resultant conjugate was 
used for the production o f anti-parathion polyclonal antibodies
6 2 1 Production and characterisation of parathion protein conjugates
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Figure 6.4 Infrared spectrum for parathion from 600 to 4000 cm1 The two strong bands 
7 at ~ 1526 cm1 and 1350 cm1 correspond to the NO2 asymmetric and symmetric stretches, 
respectively which is present on the parathion molecule.
Figure 6.5 Infrared spectrum for anuno-parathion from 600 to 4000 cm1 The two strong 
bands at ~3322 and 3402 cm1 correspond to the N-H2 asymmetric and symmetric stretches
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AB
Figure 6 6. Spectrophotometric scans o f ovalbumin (OVA) (A) and parathion-OVA (B) 
from 200 to 400 nnt A comparison o f the parathion-OVA conjugate and OVA shows a 
distinct difference in the shoulder between 300 and 400 nm on the parathion-OVA sample, 
which was not present on the OVA sample This was explained by the presence o f 
parathion in the parathion-OVA sample, which was indicative o f the linkage of parathion 
to OVA
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For the production of anti-parathion polyclonal antibodies, rabbits were immunised 
mtradermally with the characterised parathion-OVA conjugate as described in section 
2 3 5 2 The resultant serum was purified by saturated ammonium sulphate
precipitation and affinity chromatography using a parathion-BSA-sepharose column 
The antibody purity was assessed by SDS-PAGE gel electrophoresis, and the working 
dilution of the anti-parathion antibody for competitive assay analysis was determined
Analysis of the antibody titre to parathion in serum was carried out using the ELISA 
as described in section 2 3 8 1 The results o f the titre are shown m Figure 6 7 and 
indicate that there is a specific titre to parathion present o f greater than 1/400,000 
(Figure 6 7) This titre was sufficiently high to justify the sacrifice and harvesting of 
blood The serum was then prepared as described in section 2 3 6 1 Initial partial 
purification was carried out on the rabbit serum by saturated ammonium sulphate 
precipitation, as described in section 2 3 7 2 A parathion-BSA-sepharose 
lmmunoaffimty matrix was constructed for the purification of the antibodies as 
described in section 2 3 4 1 Partially purified polyclonal antibody from the 
ammonium sulphate precipitation was passed through the column resulting in the 
binding of specific parathion antibodies After extensive washing o f the column to 
remove non-specifically bound antibodies, the anti-parathion antibodies were eluted 
with 0 1 M glycine/HCl, pH 2 2 (Figure 6 8) Eluted fractions were collected and 
protein concentration monitored by absorbance readings at 280 nm (Figure 6 8) The 
results indicated that the majority of specific antibody eluted between fractions five 
and fifteen These fractions were pooled and dialysed into PBS buffer
The purity of the antibody was analysed by sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) as described in section 2 3 7 6 and the gel is shown 
in Figure 6 9 SDS-PAGE is a technique which separates proteins on the basis of 
their molecular weight The samples and molecular weight markers were boiled with
6 2 2 Production, purification and characterisation of polyclonal anti-parathion
antibodies
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mercaptoethanol causing the polypeptide chains of the immunoglobulin to separate, 
producing bands at 25 and 50 kDa. The gel picture shows the affinity-purified anti- 
parathion antibody (lane 4) with a molecular weight band at approximately 50 kDa 
which represents the heavy chain of the immunoglobulin.
1 /Antibody Dilution
Figure 6.7. Overlay plot showing the fin a l titre o f anti-parathion antibody in serum before 
sacrifice. Serial dilutions o f serum from  1/200 to 1/400,000 were prepared in diluent with 
and without OVA and added to wells coated with parathion-OVA and OVA. Results show 
that OVA in diluent binds to OVA antibodies present in the sample effectively inhibiting 
their ability to bind to OVA coated on the wells o f the plate. The antibody response titres 
out at approximately 1/400,000 indicating a high titre o f specific antibodies present to 
parathion.
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Figure 6.8. A typical elution profile fo r polyclonal anti-parathion antibody from  a 
parathion-BSA-sepharose column. Saturated ammonium sulphate-partially-purified 
antibody was applied to the column. The column was washed and the bound antibody 
eluted with 0.1 M  glycine/HCl, pH  2.2. 0.5 ml fractions were collected, and the protein 
concentration was measured by absorbance at 280 nm. A s can be seen the majority o f 
antibody eluted between fraction 5 and 15.
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Figure 6.9. SDS-PAGE gel o f affinity purified anti-parathion antibody on a parathion- 
BSA-sepharose column. Lanes 1 and 5 contain molecular weight markers ranging from  
26.6 to 180 kDa. Lane 2 represents unpurified anti-parathion antibody rabbit serum  
Lane 3 represents rabbit antiserum purified by saturated ammonium sulphate 
precipitation. Lane 4 represents the antibody fraction following affinity-purification on a 
parathion-BSA-sepharose column.
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6 2 3 Development of a competitive enzyme-linked immunosorbent assay 
(E L IS A ) for parathion 
6 2 3 1 Checkerboard E L IS A  for determination of optimal loading ratio of 
conjugate and optimal anti-parathion antibody dilution
The working dilution of these antibodies was determined using the format already 
described in section 2 3 8 1 Parathion-BSA was coated on the wells o f a microtitre 
plate at varying concentrations from 1 56 to 100 ng/ml, and blocked with 2% (w/v) 
marvel Dilutions o f affinity-purified anti-parathion antibody were prepared at ranges 
from approximately 1/12 to 1/128,000 and each dilution of antibody was added to 
each concentration o f conjugate on the microtitre plate The results were plotted for 
the anti-parathion antibody as shown in Figure 6 10 The optimal conjugate loading 
ratio was found to be 50 jig/ml with the optimal antibody dilution determined to be 
1/500
6 2 3 2 Intra- and inter-day assay variability studies of anti-parathion antibody
To carry out intra-day assay variability studies, five sets o f standards were prepared 
for the antibody and assayed on the same day and the means plotted The intra-day 
assay variability study for the anti-parathion antibody shown in Figure 6 11 had a 
linear range o f detection between 6 10 and 781 ng/ml The R2 value for this range 
was 0 99 The coefficients o f variation (CV’s) were determined to assess the 
precision of the analytical method, expressing standard deviation as a percent 
function of the mean These ranged from 0 20% to 2 55% as shown in Table 6 2 The 
inter-day assay variability study for the anti-parathion antibody also had a linear 
range of detection between 6 10 and 781 ng/ml as shown in Figure 6 12 The R2 
value for this range was 0 99 The CV’s were determined and ranged from 3 72% to 
6 09%, as shown in Table 6 3 The percentage accuracy values obtained for both the 
intra- and inter-day assay variation were typically o f a low nature demonstrating the 
accuracy and reproducibility o f the method (Tables 6 2 and 6 3)
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Figure 6.10. Checkerboard ELISA carried out to determine the optimal dilution o f 
antibody and concentration o f coating conjugate (parathion-BSA) fo r anti-parathion 
polyclonal antibody. The optimal conjugate loading density was determined as 50 jig/nd 
and the optimal dilution o f antibody fo r  use in a competitive assay was 1/500.
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Table 62 Intra-day assay variation for parathion ELISA assay Five sets of eight
standards ranging from 6.10 to 781 ng/ml were analysed on the same day
Parathion
Concentration,
(ng/ml)
Calculated mean ± 
S D , Abs
Coefficients of 
variation (CV’s), 
%
%  Accuracy
781 0 1 0 2 1 0  0017 1 70 9 45
390 0 1 3 0 1 0  0025 1 93 6 05
195 0 1 5 9 1 0  0005 0 36 2169
97 5 0 2 0 5 1 0  0030 1 49 0 82
48 8 0 243 1 0  0320 1 32 2 72
24 4 0 2 8 7 1 0  0005 0 20 16 27
12 2 0 3 1 7 1 0  0080 2 55 5 72
6 10 0 3 4 2 1 0  0040 1 18 16 78
Log of parathion concentrator! (ng/ml)
Figure 611 Intra-day competitive ELISA assay of anti-parathion antibody for 
determination of the optimal range of detection of free parathion using an antibody 
dilution of 1/500 Parathion-BSA was coated at a concentration of 50 /Jg/ml The 
absorbance at 405 nm is inversely proportional to the amount of free drug in solution. The 
linear range of detection was found to be between 610 and 781 ng/ml
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Table 6.3 Inter-day assay variation for parathion ELISA assay Five sets of eight
standards ranging from 6.10 to 781 ng/ml were analysed over three different days
Parathion
Concentration,
(ng/ml)
Calculated mean 
1  S D , A/Ao
Coefficients of 
variation (C V ’s), 
%
%  Accuracy
781 0 276 ± 0  011 4 25 3 17
390 0 3 5 6 1 0  017 4 82 7 85
195 0 444 ± 0 027 6 09 13 15
97 5 0 5 5 8 1 0  029 5 34 1 88
48 8 0 6 5 7 1 0  032 4 88 5 13
24 4 0 7 7 6 1 0  028 3 72 20 70
12 2 0 8 3 7 1 0  031 3 77 1 39
6 10 0 911 1 0 0 4 7 5 23 17 86
Log of parathion concentration (ng/ml)
Figure 6.12 Inter-day competitive ELISA assay o f anti-parathion antibody for  
determination o f the optimal range o f detection o f free parathion using an antibody 
dilution o f 1/500 Parathion-BSA was coated at a concentration o f 50 /ig/mL The 
linear range o f detection was found to be between 610  and 781 ng/ml
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IThe specificity o f the polyclonal antibodies to parathion is critical for the 
performance of the immunoassay Cross reactivity studies were carried out with a 
number o f available drugs for this purpose using the ELISA developed as described 
in section 2 3 8 2 Standards of parathion, methyl-parathion, carbophenothion, 
fenitrothion, etnmfos, mevinphos and dichlorvos were prepared and added to a 
microtitre plate coated with parathion-BSA at a 1 1 ratio with antibody at a dilution 
of 1/500 Table 6 4 shows the percentage inhibition of each compound
Table 6 4 Cross reactivity studies o f the anti-parathion polyclonal antibody with 
structurally related molecules
6 2 4 Cross reactivity studies of the anti-parathion polyclonal antibody
Compound Inhibition expressed as a percentage of 
slope of parathion antibody
Parathion 100%
Methyl-Parathion 0 8%
Carbophenothion 0 015%
Fenitrothion 0 5%
Etnmfos No cross reactivity
Mevinphos No cross reactivity
Dichlorvos No cross reactivity
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6 2 5 1 Preconcentration and immobilisation of parathion-BSA conjugate
The first step in the development o f a model inhibition BIAcore assay to parathion 
was the immobilisation o f parathion-BSA onto the surface of a CM5 sensor chip 
The immobilisation chemistry used was EDC-mediated NHS estenfication as 
discussed in section 2 3 112 To achieve maximum binding, a preconcentration 
study of parathion-BSA was carried out as described in section 2 3 11 1 100 pig/ml of 
parathion-BSA was prepared in 10 mM sodium acetate buffer at a range of pH’s from 
3 7 to 4 7 These solutions were then injected over an underivatised chip surface and 
the optimal pH determined for immobilisation of parathion-BSA was 4 1 Parathion- 
BSA was subsequently prepared in this solution for all immobilisations
An inhibition BIAcore assay to parathion was then developed using the affinity- 
punfied anti-parathion polyclonal antibody For this purpose a number o f parameters 
were optimised including the conditions required for the regeneration of the antibody 
and also for the removal o f non-specific interactions
Non-specific interactions between the anti-parathion polyclonal antibody and for both 
the earner protein used to prepare the conjugate and the dextran matnx on the surface 
o f the sensor chip were analysed The anti-parathion antibody was passed over 
immobilised parathion-BSA, BSA and dextran surfaces at a dilution of 1/5 Binding 
of the antibody to both control surfaces was negligible (Figure 6 13) compared with 
approximately 350 RU binding to the conjugate immobilised surface
Regeneration conditions for the anti-parathion antibody required a 1 mm pulse of 40 
mM NaOH with 5% (v/v) acetomtnle The antibody solution was repeatedly injected 
and the surface regenerated in order to conduct regeneration studies These studies 
demonstrated that for the anti-parathion antibody, it was possible to regenerate the
6 2 5 Development of a model BIAcore inhibition assay for parathion in PBS
using the anti-parathion polyclonal antibody
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surface up to approximately 65 times (Figure 6 14) After 65 cycles o f binding and 
regeneration, the response after the injection of the last binding pulse was 253 1 RU 
compared with the first binding pulse o f 256 9 RU resulting in a decrease o f 1 4% in 
binding capacity over the course of the regenerations
The binding capacity o f surfaces directly immobilised with parathion (section 
2 3 1 1 3 )  were also assessed using the anti-parathion antibody Again a 1/5 antibody 
dilution was used resulting in approximately 300 RU binding to the surface, however, 
to regenerate the surface a 1 mm pulse o f 40 mM NaOH with 20% (v/v) acetomtnle 
was required This surface displayed a 12% decrease in binding capacity over 40 
regenerations (Figure 6 15) which is well within acceptable parameters of 20% 
(Wong e ta l ,  1997)
A BIAcore inhibition assay was then set up on surfaces immobilised with parathion- 
BSA and parathion Standards of parathion were prepared in PBS with 1% (v/v) 
methanol ranging from 100,000 to 781 ng/ml and mixed with a 1/5 dilution of anti- 
parathion antibody The samples were then passed in random order over two 
individual surfaces, one immobilised with parathion-BSA and the other with 
parathion directly immobilised This was followed by regeneration of the parathion- 
BSA surface with a 1 min pulse o f 40 mM NaOH with 5% (v/v) acetomtnle and the 
parathion surface with a 1 min pulse o f 40 mM NaOH with 20% (v/v) acetomtnle A 
calibration curve was constructed for both surfaces by plotting the change in response 
for each standard of free drug against the concentration o f parathion in solution 
Results from the surface immobilised with parathion-BSA (Figure 6 16), showed no 
inhibition o f the anti-parathion antibody However, results from the surface with 
directly immobilised parathion (Figure 6 17) showed inhibition o f antibody binding 
to the surface when mixed with the higher concentrations o f free parathion
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Figure 613 Overlay plot demonstrating the binding of affinity-purified anti-parathion 
polyclonal antibody to immobilised parathion-BSA (— ) and BSA (—) surfaces and also 
over a blank dextran surface (—). There was negligible binding to the control BSA and 
dextran surfaces However, approximately 350 response units of anti-parathion antibody 
bound to the immobilised parathion-BSA surface indicating the antibody is specific to the 
parathion portion of the conjugate.
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Figure 614 Typical regeneration profile for approximately 65 cycles of a 5 nun binding 
pulse of affinity-purified anti-parathion polyclonal antibody to the surface of a chip 
immobilised with parathion-BSA Polyclonal antibody at a 1/5 dilution was used and the 
surface regenerated with a 1 nun pulse of 40 mM NaOH with 5% (v/v) acetonitrile, After 
65 cycles of binding and regeneration, the response after the injection of the last binding 
pulse was 253 9 RU compared with the first binding pulse of256,9 RU The ligand binding 
capacity was shown to decrease by approximately 1,4% over the course of the regeneration 
cycles
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Figure 6.15. Typical regeneration profile fo r  approximately 40 cycles o f a 5 min binding 
pulse o f affinity purified anti-parathion polyclonal antibody to the surface o f a chip 
directly immobilised with parathion. Polyclonal antibody at a 1/5 dilution was used and 
the surface regenerated with a 1 min pulse o f 40 mM NaOH with 20% (v/v) acetonitrile. 
After 40 cycles o f binding and regeneration, the response after the injection o f the last 
binding pulse was 289.7 RU compared with the first binding pulse o f329.6 RU. The ligand 
binding capacity was shown to decrease by approximately 12% over the course o f the 
regeneration cycles.
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Figure 6.16» Assay curve for parathwn using the affinity-purified anti-parathion 
polyclonal antibody on a parathion-BSA immobilised chip surface. The calibration curve 
was constructed using BIAevaluation 31 software package. The result shows the absence 
of inhibition using a surface immobilised with parathion-BSA conjugate.
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Figure 6.17 Assay curve for parathion using the affinity-purified anti-parathion 
polyclonal antibody on a chip surface directly immobilised with parathion. The result 
shows inhibition of antibody binding to the surface of the chip at the higher concentrations 
of free parathion.
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The broad specificity polyclonal antibody was supplied by the Institute o f Food 
Research, Norwick, UK for the development o f a BIAcore inhibition assay 
For the development of such an assay, parathion-BSA was immobilised onto the 
surface of the chip using already optimised parameters as described in section 6 2 5 1 
Non-specific interactions between the broad specificity polyclonal antibody and for 
both the carrier protein (BSA) used to prepare the conjugate and the dextran matnx 
on the surface o f the sensor chip were analysed Binding of the antibody (1/5 
dilution) to both control surfaces was negligible (Figure 6 18) compared with 
approximately 220 RU binding to the conjugate immobilised surface
Regeneration conditions for the broad specificity antibody required two 1 min pulses 
in the order o f 20 mM NaOH followed by 20 mM HC1 The antibody solution was 
repeatedly injected and the surface regenerated in order to conduct regeneration 
studies Results demonstrated that it was possible to regenerate the surface up to 
approximately 20 times (Figure 6 19) After 20 cycles o f binding and regeneration, 
results show that over the first five regeneration cycles there is a slight increase in 
binding of antibody However, after the first five binding regeneration cycles, 
binding of antibody to the surface of the chip stabilises and is found to be very 
reproducible
6 2 6 Development of a model BIAcore inhibition assay for parathion in PBS
using the broad specificity antibody
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Figure 618. Shows overlay plot demonstrating the binding of the affinity purified broad 
specific polyclonal antibody to immobilised parathion-BSA (— ) and BSA (—) surfaces 
and also over a blank dextran surface (—) There was negligible binding to the control 
BSA and dextran surfaces However, approximately 220 response units of broad specific 
anti-organophosphate polyclonal antibody bound to the immobilised parathion-BSA 
surface indicating the antibody is specific to the parathion portion of the conjugate
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Figure 6.19. Typical regeneration profile fo r approximately 20 cycles o f a 5 min binding 
pulse o f affinity-purified broad specific polyclonal antibody to the surface o f a chip 
immobilised with parathion-BSA. Polyclonal antibody at a 1/5 dilution was used and the 
surface regenerated with two 1 min pulses in the order o f 20 mM NaOH followed by 20 
mM HCL After 20 cycles o f binding and regeneration, results show that there is a slight 
increase in binding o f antibody over the first five regeneration cycles, resulting in the first 
five regenerations in any future work being disregarded However, after the first five , 
binding o f antibody to the surface o f the chip stabilises and is found to be reproducible.
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For the determination o f the range o f detection o f parathion for a BIAcore inhibition 
assay, a range of standards o f parathion were prepared in PBS with 1% (v/v) 
methanol ranging from 0 78 to 100 fig/ml for the broad specificity antibody The 
antibody, prepared at a dilution o f 1/5 in PBS was mixed with the corresponding 
concentration o f free parathion Each mixture was allowed to incubate at room 
temperature for ten min and then passed over the surface o f a sensor chip 
immobilised with parathion-BSA in random order This was followed by 
regeneration of the surface with two 1 min pulses in the order of 20 mM NaOH 
followed by 20 mM HCl Figure 6 20 illustrates a typical antibody binding response 
for each concentration o f parathion From the calibration curve constructed the range 
of detection for the broad specificity antibody for parathion was found to be between 
3 12 and 100 |ig/ml (Figure 6 21)
6 2 6 2 Intra- and inter-day assay variability studies of broad specificity 
polyclonal antibody
Three sets o f standards were prepared for the broad specificity antibody to study the 
intra-day variability o f the assay and assayed on the same day and their means 
plotted The range of detection was found to be between 3 12 and 100 |ag/ml (Figure 
6 21) Table 6 5 shows the CV’s which ranged from 1 85% to 12 24% The inter-day 
assay variability study carried out over three separate days for the broad specificity 
polyclonal antibody, had a range of detection between 3 12 and 100 (ig/ml as shown 
in Figure 6 22 and the CV’s ranged from 2 51% to 23 99% as shown in Table 6 6
6 2 6 1 Determination of the range of detection of parathion in PBS in a
BIAcore inhibition assay using the broad specific polyclonal antibody
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Figure 6.20. An overlay plot for a typical set of binding curves in a parathion inhibition 
assay. Parathion standards ranging from 3.12 to 100 jig/ml o f free organophosphate were 
mixed with the broad specific polyclonal antibody and passed over a parathion-BSA 
immobilised surface. The measured binding response was used to construct the calibration 
curves for the intra-day assay variability studies. This result was normalised and used in 
conjunction with 2 other normalised binding response curves for the inter-day assay 
variability studies.
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Table 6 5 Intra-day assay CV*s for broad specificity antibody BIAcore inhibition assay
Three sets of six standards ranging from 312 to 100 fJg/ml were analysed on the same day
and the CV*s calculated
Parathion Concentration, Calculated mean ± S D , 
R U
Coefficients o f variation
(CV’s), %
100 29 06 ± 3 55 12 24
50 49 75 ± 0 91 1 85
25 63 53 ± 3 58 5 64
12 5 79 63 ± 5 52 6 94
6 25 89 30 ± 5 95 6 67
3 12 104 73 ± 2  95 2 82
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F igure 6 21. In tra -day assay curve fo r  para th ion  u sin g  th e  broad specificity po lyclona l 
antibody on a parath ion-B SA  im m obilised  chip  su rfa ce  T he residua l p lo t show s th e  
excellen t correlation o f  th e  data se t to  th e  fo u r-p a ra m eter m odel f i t  The calibration curve  
was constructed  using  B IA eva lua tion  3 1  softw are package* The assay was carried o u t in  
trip lica te a n d  the m ean response ca lcu la ted  fo r  each concentra tion  o f  fr e e  
organophosphate. The range o f  detection o f  fre e  para th ion  was fo u n d  to  be betw een 3 1 2  
and  100 fig /m l
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Table 6 6. Inter-day assay CV’s for broad specificity antibody BIAcore inhibition assay
Three sets of six standards ranging from 312 to 100 ¿ig/ml were analysed over three
different days and the CV*s calculated
Parathion Concentration, 
(Ug/ml)
Calculated mean ± S D , 
R /R o
Coefficients o f variation
(CV’s), %
100 0 207 ± 0 032 15 81
50 0 3 1 9 1 0  076 23 99
25 0 449 ± 0 082 18 45
12 5 0 603 ± 0 041 6 87
6 25 0 708 ± 0  017 2 51
3 12 0 830 ± 0 020 2 48
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F igure 6,22 In ter-day assay curve fo r  para th ion  using  th e  broad specificity po lyclona l 
antibody on a para th ion-B SA  im m obilised  chip  surface. The residua l p lo t show s the  
excellen t correlation o f  th e  data se t to  th e  fo u r-p a ra m eter m odel f i t  The assays were 
carried  o u t in  trip lica te over three days a n d  norm alised  a n d  th e  m ean ca lcu la ted  fo r  each  
concentra tion  o f  fr e e  organophosphate The range o f  detection o f  fr e e  para th ion  was 
fo u n d  to  be betw een 3 12 a n d  100 fjg /m l
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6 3 Discussion
As discussed in chapter three, the production of a polyclonal antibody initially 
requires the preparation of a suitable antigen Small haptens such as parathion, the 
hapten of interest in this chapter, are not immunogenic and so require conjugation to 
a larger molecule such as a protein As described by Ercegovich ei al (1981), the 
coupling technology for parathion to these proteins was via diazo linkage between the 
amino group present on the hapten and the nitrogen on imidazole and phenolic ring 
structures found on the protein As parathion does not possess an amine group, the 
amine group was synthesised by reducing the nitro group present on the molecule to 
an amine group This was carried out as described in section 2 3 2 2 1 
Characterisation of this amine group and the purity o f the compound was analysed by 
use of infra-red (ER) studies The infra-red spectrum of a compound is the 
superposition of absorbance bands of specific functional groups Thus, IR analysis of 
compounds may be used to confirm the presence of specific functional groups on a 
compound The IR spectrum of parathion and reduced-parathion are shown in 
Figures 6 4 and 6 5, respectively, for comparison As can be seen from Figure 6 5, 
the two strong bands at -3322 and 3402 cm 1 correspond to the -NH2 asymmetric and 
symmetric stretches confirming the presence of an amino group on the reduced form 
of parathion
The resultant amino-parathion product was ready for linking to proteins by diazomum 
coupling chemistry The aromatic amine present on the parathion molecule is 
converted to a highly reactive and unstable diazomum under acidic conditions at 0°C 
with sodium nitrite This diazomum ion is now ready to attack aromatic rings on 
residues present in proteins The resultant diazomum bond bound amino-parathion to 
protein and is characterised by the formation of coloured compounds The conjugate 
was charactensed by spectrophotometric analysis Figure 6 6 shows the spectra of 
unconjugated protein and conjugated protein for comparison between 200 and 400 
nm The presence of bands in both spectra at 260 and 280 nm represent the 
characteristic peaks present on proteins However, the peak at 320 nm on the
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conjugated protein represents the presence of parathion in the sample confirming the 
production of a parathion-protein conjugate
Polyclonal antibodies to parathion were then produced by using these conjugates for 
immunisation Once an antibody titre o f over 1/400,000 from serum was obtained 
(Figure 6 7), the host animal (rabbit) was sacrificed and the serum removed
Initial purification of the antibodies from both animals was carried out by saturated 
ammonium sulphate precipitation A parathion-BSA-sepharose column was 
produced and used to affinity purify specific parathion antibodies The elution profile 
is shown in Figure 6 8 Checking the purity o f the eluted antibody fraction was 
carried out by SDS-PAGE gel (Figure 6 9) This gel shows the process of 
purification of antibodies, starting with samples o f serum followed by saturated 
ammonium sulphate precipitation and finally the affinity purified antibody The 
affinity-purified antibody fraction was found to be pure as there were no 
contaminating bands present on the gel
The purified polyclonal anti-parathion antibody was produced for the detection of the 
pesticide parathion in a competitive immunoassay format, in which the antibody 
would compete for the free analyte in solution and the surface bound parathion-BSA 
conjugate
The limits o f detection in competitive ELISA7 s are a function o f the antibody affinity, 
and the equilibrium between both the free and immobilised conjugate As a result, 
the coating conjugate concentration must be optimised as too high a concentration 
will shift the binding equilibrium in favour of binding to the immunoplate and cause 
reduced sensitivity to free antigen in solution Similarly, the concentration of 
antibody used must be optimised allowing the antibody to be the limiting factor in the 
assay If this were not the case, antibody would be capable o f binding to free drug 
and bound conjugate in excess The optimal antibody concentration was determined 
by taking a dilution of antibody producing a signal between 50-70% of maximum
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binding from a titre of the antibody Antibody dilutions chosen from the asymptotes 
of the antibody dilution curve would show minimal changes in response to small 
changes in antibody concentration Therefore, it is essential to optimise both the 
loading concentration of solid-phase conjugate and the optimal dilution of antibody 
Results from the checkerboard ELISA (Figure 6 10) for the anti-parathion antibody 
gave an optimal concentration of loading conjugate o f 50 |ig/ml and optimum dilution 
of antibody of 1/500 At this dilution of antibody, minimal changes in antibody 
concentration give maximum changes in absorbance readings
A competitive assay was developed for parathion in PBS using the affinity-purified 
antibody and optimised parameters determined from the checkerboard ELISA 
Standards of parathion ranging from 0 38 to 25,000 ng/ml were prepared and mixed 
with purified polyclonal antibody at a dilution of 1/500 The assay showed a range of 
detection between 6 10 to 781 ng/ml (Figure 6 11) and displayed excellent linearity 
with low limits of detection Intra-day and inter-day assay coefficients of variation 
(CV’s) for the anti-parathion antibody were found to be between 0 20 to 2 55% and 
3 72 to 6 09% respectively for 5 replicates (Tables 6 2 and 6 3) The percentage 
accuracy values obtained for both the intra- and inter-day assay variation were 
typically o f a low nature demonstrating the accuracy and reproducibility of the 
method (Tables 6 2 and 6 3) When analysing the results produced from the assay, it is 
clearly evident that the antibody produces an accurate, specific and reproducible assay
Cross reactivity is defined as a measure of the antibody response to structurally 
similar molecules One of the initial steps in designing an immunoassay is the 
assessment of reactivity towards structurally similar molecules (Wild, 1994) Serial 
dilutions o f the cross reactive analytes o f interest are prepared with similar dilutions 
of the specific antigen and a competitive ELISA carried out as described in section 
2 3 8 1 Table 6 4 shows the percentage inhibition of each compound using the 
slope of the line as a comparison 100% inhibition equals the slope of the line for the 
parathion immunoassay and the slope of the line of each analyte studied is 
determined as a percentage o f this slope Results showed minimal cross reactivity of
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the antibody with the analytes tested The antibody mixture is clearly specific for 
parathion This may be mainly due to its purification using the parathion-BSA- 
sepharose column
Having shown that the anti-parathion polyclonal antibody was suitable for use in a 
competitive ELISA assay, the aim was to develop an inhibition assay using the 
BIAcore biosensor
The first step in setting up such an immunoassay was the immobilisation of 
parathion-BSA and parathion onto the surface o f a CMS sensor chip It is essential to 
maximise the interaction between the dextran surface o f the chip and the conjugate of  
interest in order to immobilise as much conjugate as possible onto the surface of the 
chip This was achieved by preparing the parathion-BSA conjugate in sodium acetate 
buffer pH 4 1 Parathion was directly immobilised onto the chip as described in 
section 2 3 113
Non-specific analysis o f the anti-parathion polyclonal antibody was carried out by 
passing the antibody over a BSA immobilised surface and an underivatised dextran 
surface For the anti-parathion polyclonal antibody the non-specific interactions were 
found to be negligible (Figure 6 13)
For the successful development o f an inhibition BIAcore assay, an important aspect 
of the biosensor assay, that must be optimised (as discussed in chapter 4), is the 
binding capacity o f the immobilised ligand This is not necessary in ELISA 
Multiple regenerations are desirable on a single chip surface without a decrease in 
binding capacity o f more than 20% (Wong et a l , 1997) to allow adequate routine 
sample analysis
In this chapter, the binding capacity of surfaces immobilised with parathion-BSA and 
parathion were analysed This was achieved by carrying out a series o f binding and 
surface regenerations to assess the binding capacity deviation over these 
regenerations Regeneration conditions were initially optimised for the anti-parathion
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antibody and found that conjugate surfaces required a 1 min pulse o f 40 mM NaOH 
with 5% (v/v) acetomtrile for regeneration while directly immobilised surfaces 
required a 1 min pulse o f 40 mM NaOH with 20% (v/v) acetomtrile Results showed 
that the binding capacity o f the conjugate immobilised surface decreases by only 
1 4% over the course of approximately 70 binding-regeneration cycles However, 
results from regeneration studies from the directly immobilised surface showed a 
decrease in binding capacity o f 12% over 40 binding-regeneration cycles This result 
implies that the conjugate surface is more applicable for such an assay system than 
the directly immobilised surface However, previous results (Fitzpatrick, 2001) have 
shown that directly immobilised surfaces are more applicable to the BIAcore 
biosensor In this case, surface regeneration studies conducted demonstrated that the 
sensor chip surfaces with directly immobilised 4'-aminowarfarin were essentially in­
exhaustible with respect to antibody-binding capacity, and were regenerated up to 
1000 times This is because directly immobilised surfaces may be regenerated with 
harsher solutions than that used for regeneration of conjugate immobilised surfaces 
without resulting in denaturation o f the hapten on the surface Harsh solutions 
denature proteins resulting in antibody-antigen binding interactions being disrupted 
when using a conjugate immobilised surface
The regeneration conditions required for the dissociation of the antibody-antigen 
complex on the surface of a parathion-conjugate surface were not quite as harsh as 
those required for regeneration of the surfaces with parathion directly immobilised 
This may explain the excellent stability of the conjugate surfaces compared to the 
directly immobilised surfaces Leaching of directly immobilised parathion from the 
surface of the chip may be occurring as a result o f the harsher regeneration solutions 
Leaching would cause antibody binding to decrease over a number of regenerations 
as the surface is slowly losing ligand, reducing the availability o f  binding sites on the 
surface Results also show a slightly more variable binding response o f antibody to 
the directly immobilised surface, calling into question the accuracy of the 
regeneration profile (Figure 6 15) for further analysis The results demonstrate the 
use of hapten-protein conjugates is applicable to the development o f an inhibition
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immunoassay as the antibody binding capacity o f the surface is extremely stable 
(Figure 6 14)
A BIAcore inhibition assay was then set up on surfaces immobilised with parathion- 
BSA and parathion Standards of parathion were prepared in PBS/methanol ranging 
from 781 to 100,000 ng/ml and mixed with a 1/5 dilution of anti-parathion antibody 
However, no inhibition of antibody binding to the conjugate immobilised surface was 
detected and inhibition of binding of antibody to the directly immobilised surface was 
present only at the higher concentrations o f antibody However, as shown in Figure 
6 15 the antibody possesses a variable binding response to the surface and thus 
inhibition of antibody at the higher concentrations of parathion is not accurate and 
cannot be considered as a true result due to these variable binding responses 
The absence of inhibition with the use of conjugate immobilised surfaces is an 
interesting result Using the same antibody in ELISA, competition occurs proving the 
antibodies affinity for free parathion However, the result on BIAcore would suggest 
differently At closer inspection of both techniques, there are many differences 
ELISA is based on the antibody-antigen interaction reaching a state of equilibrium 
which allows binding o f a range of antibodies with different affinities The antibody- 
antigen interaction is also given a relatively long time to occur (i e 1 5 h) The 
BIAcore biosensor on the other hand is based on inhibition, the antibody-antigen 
complex is premixed for a period of time followed by injection over the surface o f a 
chip immobilised with the appropriate antigen The unbound excess antibody binds 
to the surface allowing the generation of a standard curve for different concentrations 
of free analyte In the BIAcore system the antibody-antigen mixture does not reach 
equilibrium and bound antigen and free antigen do not compete with one another for 
binding to the antibody, so the assay is referred to as an antigen inhibition assay 
rather than a competitive assay
The minimal inhibition seen in the BIAcore assay may be explained by the range of 
detection of free parathion using the polyclonal antibody differing from the range 
detected on ELISA The detection of parathion may be of a higher range than the 
concentrations set up in the assay Higher ranges o f parathion were not analysed as 
parathion was found to precipitate out of solution at higher concentrations An
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increase in methanol concentration to combat this precipitation resulted in loss of 
antibody activity
The conjugate concentration on the surface of the chip may also be too high resulting 
in a shift in the binding equilibrium in favour of antibody binding to the surface of the 
chip, reducing sensitivity to free antigen in solution To test this theory a reduction in 
the conjugate concentration on the surface of the chip is required, which would result 
in an increase in the concentration of antibody required However, with respect to the 
amount of antibody available, this experiment was not feasible 
Due to the fact that the surface of the sensor chip is a hydrogel and is not the same 
solid state surface as in the case of the ELISA Stenc hindrance with a high 
dissociation rate of antibody may be a cause for the lack of displacement in the 
BIAcore assay (Kusterbeck et a l , 1990) The short half-life o f an antibody-antigen 
interaction may be characterised by a continuous association-dissociation process of 
the antibody-antigen complex If the parathion antibody has a high dissociation 
constant, this would result in the antibody becoming free to bind to the surface o f the 
chip with parathion-BSA immobilised, resulting in a non-measurable displacement 
response
Schofield et al (1996) carried out a study on the affinities o f antibodies produced to 
the influenza A virions in both ELISA and using surface plasmon resonance No 
kinetic results from the SPR system for mAB HC58 were obtained although it had 
one of the highest affinities using the ELISA format, and was 28-fold higher than 
another mAB (HC10) which gave good data by SPR With regards to this assay, the 
orientation o f the analyte on the surface o f the chip made it difficult for the antibody 
to access its epitope in the flow cell resulting in the lack of antibody binding This 
may be indirectly applied to the anti-parathion antibody If the opposite were the 
case in the anti-parathion displacement assay and the epitope present on the conjugate 
was placed on the surface o f the chip allowing easy access for the antibody This in 
conjunction with a high dissociation rate would allow the antibody to bind more 
freely to the immobilised antigen instead of the free antigen in solution resulting in an 
assay with no displacement
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A broad specificity polyclonal antibody was supplied by the Institute o f Food 
Research, Norwick, UK with the ability to bind to a number of organophosphate 
pesticides including parathion (Alcocer et a l , 2000) This antibody was used in the 
development of a BIAcore inhibition assay for parathion Controls were initially 
carried out and the antibody showed negligible binding to BSA and dextran 
Regeneration of the surface was achieved with two 1 min pulses in the order o f 20 
mM NaOH followed by 20 mM HC1 20 cycles o f binding and regeneration were 
carried out and results showed there to be is a slight increase in binding of antibody 
over the first five regeneration cycles However, after the first five, binding of 
antibody to the surface of the chip stabilised and was found to be very reproducible 
An inhibition assay was then set up and the range o f detection of parathion was found 
to be between 3 12 and 100 |ag/ml The assay displayed low limits o f detection 
Intra-day and inter-day assay variability statistics were then analysed in an attempt to 
look at the reproducibility o f the assay The intra-assay CV’s were found to be quite 
low However, the CV’s for the inter-day assay were not found to be very 
reproducible with results as high as 20%
When comparing the results from the anti-parathion polyclonal and the broad 
specificity polyclonal antibody inhibition assays, it was found that all the parameters 
used were the same for both assays except for the antibody and the regeneration 
conditions The conjugate immobilised on the surface and the free pesticide 
concentrations were prepared in the same manner This proves that the lack of 
inhibition seen in the anti-parathion polyclonal antibody assays was not as a result of 
some flaw in the assay protocol or design Instead, some characteristic of the 
polyclonal antibody is responsible for the lack of inhibition
The toxicity o f OPs is well known, nevertheless, OPs have been extensively used in 
the control of pests in the agricultural industry for many years This usage has 
resulted in the accumulation of these toxic compounds in the environment to such an 
extent that they are now considered an environmental pollutant Evidence would 
suggest that these compounds have entered the food chain, resulting in the need for
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detection systems As many traditional analytical systems have been used in the past 
for detection of parathion (section 6 12  2), recent methods have concentrated on the 
production of methods which are rapid, accurate, relatively inexpensive and capable 
of screening large numbers of samples This need for detection systems is the main 
factor behind the ELISA method developed in this chapter for the analysis of 
parathion The ELISA competition assay developed in this chapter for parathion 
illustrates the potential o f using the ELISA technique compared to other detection 
techniques for the quantification of parathion This assay compares favourably with 
various traditional analytical based detection methods for organophosphates as 
discussed in section 6 1 1 2  Various immunoassays developed by Ercegovich et al 
(1981) and Garrett et a l (1997) have detection limits in the low ng levels while 
Bnmfield et a l (1985) possesses detection limits o f low |ig levels for parathion 
When comparing these assays to the assay developed in this chapter we find that our 
assay has detection limits which are also in low ng levels
Biosensors have also become very prominent in the detection of various analytes 
The BIAcore biosensor was used in the development o f an assay to parathion as this 
biosensor possesses many advantages such as ‘real-time5 monitoring o f interactions, 
label free detection, reusable chip surface and the ability for rapid analysis With all 
these in mind, an inhibition assay for parathion was developed using a broad 
specificity polyclonal antibody to organophosphates
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7 1 Overall Conclusions
The research work described in this thesis is mainly concerned with the development 
of polyclonal antibodies to two compounds, morphine-3-glucuromde and parathion 
Following characterisation, they were applied to antibody-based immunoassay 
systems for the detection of these compounds Genetic techniques were also 
developed for the production of single chain Fv (scFv) antibodies to morphine-3 - 
glucuromde for development of antibody-based immunoassays 
The initial work earned out in this thesis was the production and charactensation of 
drug-protein conjugates o f morphine-3-glucuromde Conjugation of this hapten to 
the earner protein was carried out by coupling the amine group present on the protein 
to a carboxyl group present on morphine-3-glucuromde A variety of drug-protein 
conjugates were produced and used in the production and characterisation of 
polyclonal antibodies Two polyclonal antibodies were produced and purified and 
used in the development of competitive ELISA immunoassays for morphine-3- 
glucuromde These antibodies displayed the ability for use at high dilution factors 
and the ability to detect low concentrations o f morphine-3-glucuromde in both model 
systems developed in PBS and urine
Chapter 4 has outlined the development o f BIAcore-based inhibition immunoassays 
for morphine-3-glucuromde Both R1 and R2 polyclonal antibodies described in 
chapter 3 were used in the development of BIAcore inhibition immunoassays A 
model immunoassay for detection of M3G in buffer was initially developed followed 
by the development o f an immunoassay in urine The biosensor-based assay used a 
surface with drug-protein conjugate immobilised Studies were carried out on the 
binding/regeneration reproducibility of the antibodies Both antibodies exhibited 
excellent binding and regeneration characteristics (Wong et a l , 1997) allowing the 
development o f inhibition assays The assays developed displayed good intra- and 
inter-day coefficients o f variation while also exhibiting very low levels o f detection 
for morphine-3-glucuromde The low degree of sample preparation for BIAcore 
analysis highlights some of the advantages o f BIAcore over some traditional 
detection techniques such as HPLC and GC-MS which require extensive sample
277
clean-up steps before analysis As a result of this, the sample throughput of BIAcore 
assays is comparatively better than traditional techniques
Results obtained from chapter 5 show the production of recombinant scFv antibodies 
with antigen specific characteristics using the Krebber system Libraries produced 
from pre-immumsed spleen mRNA do not necessarily requires high transformant 
numbers in order to isolate positive clones Instead, as results have shown in this 
chapter, the high titres o f immunised mice and the resultant specific mRNA 
produced, allowed the screening of specific clones to M3G from a small library 
Once specific clones were isolated, the scFv antibodies produced by these clones 
were studied for their application in an assay format The ELISA results show that 
the scFv antibody produced is applicable to this assay format but large quantities of 
scFv antibody is required The characterisation o f the scFv antibody on the BIAcore 
biosensor produced very different results With the ability o f the BIAcore to carry 
out assays with minimal use of samples, an assay was developed for M3G Results 
showed that the assays produced were repeatable and reliable, confirming the ability 
of the scFv antibody to be used in such an assay format both in a model system and 
for sample analysis
In chapter 6, parathion was used for the production of parathion-protein conjugates 
These conjugates were subsequently characterised by spectrophotometnc analysis and 
used in the production of rabbit polyclonal antibodies Antibodies from rabbit serum 
were purified and used in the development o f a competitive ELISA for parathion 
analysis Studies clearly demonstrated the accuracy and reproducibility of the assay 
However, when the anti-parathion antibody was used in the BIAcore biosensor format, 
it was found not to be applicable to such a system Inhibition assays were developed 
for parathion using a broad specificity antibody, indicating the possibility of 
development o f a BIAcore parathion assay with antibodies with the required 
characteristics for use in this system
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To summarise, the BIAcore biosensor possesses strengths and weaknesses The 
instrument was used to perform accurate and reproducible assays for morphine-3- 
glucuromde using both polyclonal and single chain Fv antibodies However, the fact 
that the anti-parathion polyclonal antibody produced showed no inhibition on BIAcore 
while exhibiting competition on the ELISA format indicates that not all antibodies are 
applicable to such an assay format
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Appendix A
Glossary of terms and definitions commonly employed m Bioanalytical 
Validation procedures
The terms listed below are commonly referred to in bioanalytical validation 
procedures and the criteria which they can be defined under have been extensively 
reviewed (Karnes et a l , 1991, Shah et a l , 1991, Braggio et a l , 1996, Hubert et a l , 
1999, Curne, 1999 and Findlay et a l , 2000)
Mean
Describes the average of replicate (x) measurements (i e nj+n2+ nx/x)
Standard Curve
This describes the relationship between the measured analyte response (i e 
absorbance, response units) and the analyte concentration
Non-specific binding
This describes matrix effects which affect the degree o f binding o f the 
antibody antigen interaction, and can occur as a result o f increased protein 
concentration and sample viscosity in the sample matrix (e g plasma ), and also as 
result of altered ionic composition (e g unne) of the sample matrix The assay 
design should therefore be robust enough to be able to withstand such variations in 
sample composition, and the degree of non-specific binding minimised prior to 
sample analysis (e g use o f detergents and/or surface treatment with non-specific 
protein prior to sample analysis)
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Coefficient of Variation (% C V )
A quantitative measure of the precision of an analytical measurement expressed as a 
percent function of the mean value, also referred to as the Relative Standard 
Deviation (% R S D )
% C V = [S D /Mean value] x 100 
Limit of Detection (LOD)
Lowest concentration of analyte for which the response can be reliably distinguished 
from background noise
Normalised Response Values
The response recorded in response units (RU) at each particular antigen concentration 
divided by the response recorded in the presence o f zero antigen 
1 e
Normalised Response = Response measured at particular antigen concentration
Response measured at zero antigen concentration
Normalised Absorbance Values
The absorbance recorded (AU) at each particular antigen concentration divided by the 
absorbance recorded in the presence of zero antigen 
1 e
Normalised Absorbance = Absorbance measured at particular antigen concentration
Absorbance measured at zero antigen concentration
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